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General Protocol 
 
 
 
1. 1H NMR spectra were recorded on Bruker avance II 400 MHz NMR 
spectrometer using TMS as an internal reference.  
 
2. Mass spectra were recorded on GC-MS QP-2010 spectrometer. 
 
3. IR spectra were recorded on Schimadzu FR-IR-8400 spectrometer using 
KBr pellet method.  
 
4. Elemental analysis was carried out on Vario EL III Carlo Erba 1108. 
 
5. Thin layer chromatography was performed on Silica Gel (Merck 60 F254). 
 
6. The chemicals used for the synthesis of compounds were purchased from 
Spectrochem, Merck, Thomas-baker and SD fine chemical. 
 
7. MPs were taken in open capillary and are uncorrected. 
 
8. Microwave assisted reaction were carried out in QPro-M microwave 
synthesizer.  
 
 
 
Chapter 1 
 
 
 
 
 
 
1.1 Biginelli Reaction     01 
1.2 Mechanistic Studies of Biginelli Reaction 02 
1.3 Alternative synthetic routes   03 
1.4 Biologically active dihydropyrimidones   13 
1.5 Current work       18 
1.6 Reaction Schemes      19 
1.7 Experimental      22 
1.8 Physical data      23 
1.9 Spectral discussion     26 
1.10 References      39 
Synthesis and characterization of 
N-aryl substituted DHPM 
derivatives by Biginelli reaction 
 1
 
 
 
 
 
 
 
 
 
1.1 Biginelli Reaction 
 
P. Biginelli reported the synthesis of functionalized 3,4-dihydropyrimidin-(1H)-ones 
(DHPMs) via three-component condensation reaction of an aromatic aldehyde, urea, and 
ethyl acetoacetate. In the past decade, this long-neglected multicomponent reaction has 
experienced a remarkable revival, mainly due to the interesting pharmacological 
properties associated with this dihydropyrimidine scaffold1.  
 
 
  
 
 
 
 
 
Biginelli Dihydropyrimidine Synthesis 
 
The reaction was carried out by simply heating a mixture of the three components 
dissolved in ethanol with a catalytic amount of HCl at reflux temperature. The product of 
this novel one-pot, three-component synthesis that precipitated on cooling of the reaction 
mixture was identified correctly by Biginelli as 3,4-dihydropyrimidin-2(1H)-one. Apart 
from a series of publications by the late Karl Folkers in the mid 1930s, the “Biginelli 
reaction” or “Biginelli condensation” as it was henceforth called was largely ignored in 
the early part of the 20th century. The synthetic potential of this new heterocycle synthesis 
therefore remained unexplored for quite some time. In the 1970s and 1980s, interest 
slowly increased, and the scope of the original cyclocondensation reaction was gradually 
Chapter 1 
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DHPM derivatives by Biginelli reaction   
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extended by variation of all three building blocks, allowing access to a large number of 
multifunctionalized dihydropyrimidines.2-4  
 
1.2 Mechanistic Studies of Biginelli Reaction 5-9 
 
The mechanism of the Biginelli reaction has been the subject of some debate over the past 
decades. Early work by Folkers and Johnson3 suggested that bisureide, i.e. the primary 
bimolecular condensation product of benzaldehyde and urea, is the first  
 
 
 
 
 
 
 
 
 
 
 
 
 
intermediate in this reaction. In 1973, Sweet and Fissekis5 proposed a different pathway 
and suggested that carbenium ion, produced by an acid-catalyzed aldol reaction of 
benzaldehyde  with ethyl acetoacetate, is formed in the first and limiting step of the 
Biginelli condensation. Kappe et al6 reinvestigated the mechanism in 1997 using 1H/13C 
NMR spectroscopy and trapping experiments and have established that the key step in 
this sequence involves the acid-catalyzed formation of an N-acyliminium ion intermediate 
from the aldehyde and urea precursors. Interception of the iminium ion by ethyl 
acetoacetate, presumably through its enol tautomer, produces an open-chain ureide  which 
subsequently cyclizes to hexahydropyrimidine. Acid-catalyzed elimination of water 
ultimately leads to the final DHPM product. The reaction mechansim can therefore be 
classified as an α-amidoalkylation, or more specifically as an α-ureidoalkylation. The 
alternative “carbenium ion mechanism” does not constitute a major pathway; however, 
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small amounts of enone are sometimes observed as byproduct. Although the highly 
reactive N-acyliminium ion species could not be isolated or directly observed, further 
evidence for the proposed mechanism was obtained by isolation of intermediates, 
employing sterically bulky or electron-deficient acetoacetates respectively. The relative 
stereochemistry in hexahydropyrimidine was established by an X-ray analysis. In fact, a 
number of hexahydropyrimidines could be synthesized by using perfluorinated 1,3-
dicarbonyl compounds or α-keto esters as building blocks in the Biginelli condensation. 
 
1.3 Alternative synthetic routes for better yield, shorter 
reaction time and to synthesize new analogs  
 
Various modifications have been applied to Biginelli reaction to get better yield and to 
synthesize biologically active analogs. Different catalysts have been reported to increase 
the yield of the reaction. Microwave synthesis strategies are also applied to shorten the 
reaction time. Solid phase synthesis and combinatorial chemistry has made possible to 
generate library of DHPM analogs.  
 
1.3.1 Catalysts  
 
Essa H. Hu et al10 reported Biginelli reaction catalyzed with trifluoroborane etherate, 
transition metal salt, and proton source to yield 80-90% Biginelli product. They proposed 
a mechanism similar to that of Folkers and Johnson3 and to that of Kappe5 for the 
Biginelli reaction wherein formation of acyl imine intermediate  formed by reaction of the 
aldehyde with urea and stabilized by either trifluoroborane or the transition metal, is the 
key, rate limiting step. Subsequent addition of the α-keto ester enolate, followed by 
cyclization and dehydration, would afford the dihydropyrimidinone.  
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Brindaban C. Ranu et al11reported Indium (III) Chloride as an efficient catalyst for 
Biginelli reaction. A wide range of structurally varied α-dicarbonyl compound, aldehyde 
and urea were coupled together by this procedure to produce the corresponding 
dihydropyrimidinones. A variety of substituted aromatic, aliphatic, and heterocyclic 
aldehydes have been subjected to this condensation very efficiently. Thiourea has been 
used with similar success to provide the corresponding dihydropyrimidin-2(1H)-thiones. 
R1 R2
O O
R3 CHO
H2N NH2
O/S InCl3
THF
N
H
NH
R3
R1 O/S
R2
O
 
 
Bose et al12used cerium(III) chloride as a catalyst and reported solvent free synthesis of 
Biginelli compounds using this new catalyst. This procedure provides higher yield, 
shorter reaction time and simple work up methods. Solvent free reactions using this 
catalyst gave about 70% yield and reaction time was about 10 hrs. If ethanol is used as 
solvent, 90% yield was obtained with this catalyst. 25 mol % amount of cerium(III) 
chloride heptahydrate was found to be sufficient to push the reaction forward. The 
increased amount did not build further advantage. 
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Enantioselective one pot synthesis of Biginelli reaction is reported with use of lanthanide 
triflates/ytterbium triflates.  These catalyst leads to highly enantioselectivity and up to 
99% enantioselective Biginelli reaction can be carried out.13 
 5
 
 
 
 
Me OEt
O O
H2N NH2
O
Ln(OTf)3
RT
N
H
NH
O
EtO
O
CHO
 
 6
Very recently, chiral phosphoric acid is reported as highly enantioselective catalyst for 
Biginelli reaction. Reaction is reported in presence of 10 mol % of chiral phosphoric acid 
to produce desired enantioselective product. This is the first organocatalytic asymmetric 
Biginelli reaction. The optimal chiral phosphoric acid afforded the reaction in high yields 
with excellent enantioselectivities of up to 97% ee. A wide variety of substrates, 
including aldehydes and α-keto esters, could be tolerated. This reaction has an advantage 
of avoiding the contamination of transition metals in the manufacture of the medicinally 
relevant chiral 3,4-dihydropyrimidin-2-(1H)-ones.14 
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Recently Jiang and Chen15reported Yb(III)-Resin catalyzed Biginelli reaction under 
solvent-free conditions. 
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Heravi et al16 recently reported synthesis of dihydropyrimidones using 12-
molybdophosphoric acid in refluxing acetic acid to catalyze this three-component 
condensation reaction to afford the corresponding pyrimidinones in good yields. 
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An improved approach has been found to carry out the Biginelli reaction for the synthesis 
of 3,4- dihydropyrimidin- 2(1H)-one derivatives. This synthesis was performed in the 
presence of hydrochloric acid and β-cyclodextrin in ethanol solution. Compared with the 
classical Biginelli reaction conditions, this new approach has the advantage of excellent 
yields and short reaction time.17   
 
An efficient synthesis of 3,4-dihydropyrimidinones from the aldehyde, β-keto ester and 
urea in ethanol, using ferric chloride hexahydrate or nickel chloride hexahydrate as the 
catalyst, is described18. Compared with the classical Biginelli reaction conditions, this 
new method has the advantage of excellent yields (53-97%) and short reaction time (4-5 
hours).  
 
5-Alkoxycarbonyl-4-aryl-3,4-dihydropyrimidin-2-ones are synthesised by the one-pot 
reactions of aldehydes, β-ketoesters and urea using a catalytic amount of phosphotungstic 
acid (PTA) in ethanol. The modified Biginelli cyclocondensation not only shortens the 
reaction period and simplifies the operation, but also improves the yields.19 
Ruthenium(III) chloride efficiently catalyzes the three-component Biginelli reaction of an 
aldehyde, a β-keto ester, and urea or thiourea under solvent-free conditions to afford the 
corresponding 3,4-dihydropyrimidine-2-(1H)-ones in excellent yields.20 
The Biginelli reaction, a one-pot condensation of aldehydes, urea or thiourea, and -
dicarbonyl compounds, is efficiently catalyzed by samarium diiodide. The biologically 
active dihydropyrimidinones are easily synthesized in moderate to excellent yields under 
solvent-free conditions.21 
Hydroxyapatite doped with ZnCl2, CuCl2, NiCl2 and CoCl2 efficiently catalyses the three 
components Biginelli reaction between an aldehyde, ethyl acetoacetate and urea in 
refluxing toluene to afford the corresponding dihydropyrimidinones in high yields.22 
Scandium (III)triflate efficiently catalyzes the three-component condensation reaction of 
an aldehyde, a β-ketoester, and urea in refluxing acetonitrile to afford the corresponding 
3,4-dihydropyrimidin-2(1H)-ones in excellent yields. The catalyst can be recovered and 
reused, making this method friendly and environmentally acceptable.23 
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Shailaja et al24 have demonstrated experimentally a simple and straightforward protocol 
(combination system of SnCl2–LiCl) which provides dihydropyrimidin-2-one system in 
high yield and high purity while retaining the simplicity of the Biginelli concept. 
 
Magnesium bromide efficiently catalyzes the three-component condensation reaction of 
aldehyde, β-diketone and urea/thiourea under solvent free conditions to afford the 
corresponding dihydropyrimidinones in high yields and short reaction time.25  
R1
O O
R2 CHO
H2N NH
O/S
N
NH
R2
O/S
R1
O
MgBr2
45 to 90 min
R3
100 C
R3  
Bismuth nitrate pentahydrate catalyzes the three component condensation reaction of an 
aromatic aldehyde, urea and a β-ketoester or a β-diketone under solvent-free conditions to 
afford the corresponding dihydropyrimidinones (DHPMs) in high yields. The method is 
also effective for the selective condensation of aryl aldehydes in the presence of aliphatic 
aldehydes.26 
NO2
CHO
CHO
Bi(NO3)3 5 H2O(0.1 mmol)
urea, ethylacetoacetate, reflux, 35 min
N
H
NH
O
EtO
O
NO2
N
H
NH
O
EtO
O
78% 0%  
Sharma et al27 reported a simple, efficient, mild and green method has been developed for 
the synthesis of 3,4-dihydropyrimidin-2-ones employing dodecyl sulfonic acid as an 
excellent surfactant-type Bronsted acid catalyst in aqueous media at room temperature.  
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Yadav et al28 reported that Ceric ammonium nitrate efficiently catalyzes the three 
component Biginelli reaction in methanol to afford the corresponding 
dihydropyrimidinones in excellent yields under sonication. 
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1.3.2 Solid Phase Synthesis  
 
 
In recent years, various methods have been examined for the synthesis of DHPM on solid 
phase. Li and Lam29 describe a convenient traceless solid-phase approach to 
synthesize3,4-dihydropyrimidine-2-ones. Key steps in the synthesis are (i) sulfinate 
acidification, (ii) condensation of urea or thiourea with aldehydes and sulfinic acid, and 
(iii) traceless product release by a one-pot cyclization-dehydration process. Since a 
variety of reagents can be used in steps (ii) and (iii), the overall strategy appears to be 
applicable to library generation. 
SO2Na SO2H
H2N NH2
X
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NH
R1 NH2
X
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R3
O
R2HN
N
H
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Very recently, Gross et al30 developed a protocol based on immobilized α-ketoamides to 
increase the diversity of DHPM. The resulting synthetic protocol proved to be suitable for 
the preparation of a small library using different building blocks. They found that the 
expected DHPM derivatives were formed in high purity and yield if aromatic aldehyde- 
and α-ketoamide building blocks were used. The usage of an aliphatic aldehyde leads to 
an isomeric DHPM mixture. Purities and yields were not affected if thiourea was used 
instead of urea. 
Polymer O
O HN
R
O
O
Polymer O
O HN
R
O
O
R1
H2N S
NH2Cl
N
NH
SR
OR
O
O
Polymer
 
Lusch and Tallarico31 reported a direct, Lewis acid-catalyzed Biginelli synthesis of 3,4-
dihydropyrimidinones on high-capacity polystyrene macrobeads with a polymer O-silyl-
attached N-(3-hydroxypropyl)urea. Resin-urea was first reacted separately with either 4-
bromo- or 4-chlorobenzaldehyde or lithium trifluoromethanesulfonate in acetonitrile at 80 
°C. After washing, the beads were pooled and reacted with ethyl acetoacetate and lithium 
trifluoromethanesulfonate in acetonitrile at 80 °C. Formation of only one kind of Biginelli 
product per bead demonstrated the feasibility of a solid-phase non-Atwal two-step split-
and-pool synthesis of 3,4-dihydropyrimidinones.  
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1.3.3 Microwave assisted synthesis  
 
 
In general, the standard procedure for the Biginelli condensation involves one-pot 
condensation of the three building blocks in a solvent such as ethanol using a strongly 
acidic catalyst, that is, hydrochloric acid. One major drawback of this procedure, apart 
from the long reaction times involving reflux temperatures, are the moderate yields 
frequently observed when using more complex building blocks. Kappe et al32 recently 
described a high yielding and rapid microwave-assisted protocol that allows the synthesis 
of gram quantities of DHPMs utilizing controlled single-mode microwave irradiation. As 
the first model reaction for our scale-up experiments, they selected the standard Biginelli 
cyclocondensation, where in a one-pot process equimolar amounts of benzaldehyde, ethyl 
acetoacetate, and urea react under Lewis acid (FeCl3) catalysis to the corresponding 
dihydropyrimidine. Utilizing single-mode microwave irradiation, the reaction can be 
carried out on a 4.0 mmol scale in AcOH/EtOH 3:1 at 120 °C within 10 min, compared to 
3-4 h using conventional thermal heating, providing DHPM in 88% isolated yield and 
high purity (>98%).  
O H
ROOC
O
NH2
H2N
O NH
NH
O
ROOC
EtOH
X
/HCl
AcOH/EtOH 3:1, FeCl3
MW, 10-20 min
X
 
Dihydropyrimidines were synthesised in high yields by one-pot cyclocondensation 
reaction of aldehydes, acetoacetates and urea using various acid catalysts like Amberlyst-
15, Nafion-H, KSF clay and dry acetic acid under microwave irradiation.33 
 
The antimony(III) chloride impregnated on alumina efficiently catalyses a one-pot, three-
component condensation reaction among an aldehyde, a β-ketoester, and urea or thiourea 
to afford the corresponding dihydropyrimidinones in good to excellent yields. The 
reactions are probed in microwave (MW), ultrasonic, and thermal conditions and the best 
results are found using MW under solvent-free conditions.34 
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Cupric chloride dihydrate catalyzes the three-component Biginelli condensation between 
an aldehyde, a β-ketoester and urea or thiourea under microwave irradiation in the 
absence of solvent to yield various substituted 3,4-dihydropyrimidin-2(1H)-ones. The 
reaction is also effective when performed at room temperature in acetonitrile or at 100 °C 
in a solvent free approach, without any side reactions as observed by Biginelli and 
others.35  
The publications by Gupta36 and Dandia37 describe 26 examples of microwave-enhanced 
solution-phase Biginelli reactions employing ethyl acetoacetate, (thio) ureas, and a wide 
variety of aromatic aldehydes as building blocks. Upon irradiation of the individual 
reaction mixtures (ethanol, catalytic HCl) in an open glass beaker inside the cavity of a 
domestic microwave oven the reaction times were reduced from 2–24 hours of 
conventional heating (80 ºC, reflux) to 3–11 minutes under microwave activation (ca. 
200–300 W). At the same time the yields of DHPMs obtained by the authors were 
markedly improved compared to those reported earlier using conventional conditions.  
 
Kappe38 reinvestigated above reactions using a purpose-built commercial microwave 
reactor with on-line temperature, pressure, and microwave power control. 
Transformations carried out under microwave heating at atmospheric pressure in ethanol 
solution show no rate or yield increase when the temperature is identical to conventional 
thermal heating. In the case of superheating by microwave irradiation at atmospheric 
pressure the observed yield and rate increase phenomenon are rationalized as a 
consequence of a thermal (kinetic) effect. Under sealed vessel conditions (20 bar, 180 ºC) 
the yield of products is decreased and formation of various byproducts observed. The 
only significant rate and yield enhancements are found when the reaction is performed 
under “open system” conditions where the solvent is allowed to rapidly evaporate during 
microwave irradiation. However, the observed rate and yield enhancements in these 
experiments are a consequence of the solvent-free conditions rather than caused 
specifically by microwave irradiation. This was confirmed by control experiments of the 
solvent less Biginelli reaction under microwave and thermal heating. 
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1.3.4 Ionic liquid  
Wang et al39 reported the Biginelli reaction between an aromatic aldehyde, ethyl 
acetoacetate, and urea - catalyzed by polymer-supported, re-usable, room-temperature 
ionic liquids (RTIL) - was shown to efficiently proceed in glacial AcOH at 100° to afford 
the corresponding pyrimidine-5-carboxylates in yields up to 99% within 2 h. The 
catalyst(s) could be reused at least five times, basically without loss of activity, which 
makes this transformation not only straight-forward, but also considerably less expensive 
compared to methods involving classical RTIL catalysts. 
1.4 Biologically active dihydropyrimidones  
4-Aryl-1,4-dihydropyridines (DHPs, e.g nifedipine, ) are the most studied class of organic 
calcium channel modulators. More than 30 years after the introduction of nifedipine, 
many DHP analogs have now been synthesized and numerous second-generation 
commercial products have appeared on the market.40, 41  
 
In recent years, interest has also focused on aza-analogs such as dihydropyrimidines 
(DHPMs) which show a very similar pharmacological profile to classical dihydropyridine 
calcium channel modulators.42-49 Over the past few years several lead-compounds were 
developed that are superior in potency and duration of antihypertensive activity to 
classical DHP drugs, and compare favorable with second-generation analogs such as 
amlodipine and nicardipine.50 
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Barrow et al55 reported in vitro and in vivo evaluation of dihydropyrimidinone C-5 amides 
as potent and selective α1a Receptor Antagonists for the treatment of benign prostatic 
hyperplasia. 
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α1 adrenergic receptors mediate both vascular and lower urinary tract tone, and α1 
receptor antagonists such as terazosin are used to treat both hypertension and benign 
prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been 
identified, with the α1a receptor being most prevalent in lower urinary tract tissue. 4-
aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-5 amide as 
selective α1a receptor subtype antagonists. In receptor binding assays, these types of 
compounds generally display Ki values for the α1A receptor subtype <1 nM while being 
greater than 100-fold selective versus the α1b and α1d receptor subtypes. Many of these 
compounds were also evaluated in vivo and found to be more potent than terazosin in 
both a rat model of prostate tone and a dog model of intra-urethral pressure without 
significantly affecting blood pressure. While many of the compounds tested displayed 
poor pharmacokinetics, one compound was found to have adequate bioavailability 
(>20%) and half-life (>6 h) in both rats and dogs. Due to its selectivity for the α1a over the 
α1b and α1d receptors as well as its favorable pharmacokinetic profile, it has the potential 
to relieve the symptoms of BPH without eliciting effects on the cardiovascular system.51-
55 
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The 4-aryldihydropyrimidinone heterocycle attached to an aminopropyl-4-arylpiperidine 
via a C-5 amide has proved to be an excellent template for selective α1a receptor subtype 
antagonists. These types of compounds are exceptionally potent in both cloned receptor 
binding studies as well as in in vivo pharmacodynamic models of prostatic tone. 
 
Compounds exhibited high binding affinity and subtype selectivity for the cloned human 
α1A receptor. Systematic modifications led to identification of highly potent and subtype-
selective compounds with high binding affinity (Ki =0.2 nM) for α1a receptor and greater 
than 1500-fold selectivity over α1b and α1d adrenoceptors. The compounds were found to 
be functional antagonists in human, rat, and dog prostate tissues. They exhibited excellent 
selectively to inhibit intraurethral pressure (IUP) as compared to lowering diastolic blood 
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pressure (DBP) in mongrel dogs (Kb(DBP)/Kb(IUP))suggesting uroselectivity for α1a-
selective compounds.56 
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Cho et al57 reported 3-N-substituted-3,4-dihydropyrimidine and 3-N-substituted-
dihydropyrimidin-2(1H)-ones  as calcium channel antagonist. Compounds [especially  
[R1=(CH2)2N(benzyl)(2-naphthylmethyl),R2=i-Pr,X=2-N02] and [R'= (CH2)2N(benzyl) 
(3,4-dichlorobenzyl),R2=i-Pr, X=2-NO2]] exhibited not only more potent and longer 
lasting vasodilative action but also a hypertensive activity with slow onset as compared 
with dihydropyridines. Moreover, some dihydropyrimidines [R'=(CH2)2N(benzyl)(3-
phenylpropyl),R2=CH2(cyclopropyl),X=2-NO2] were weaker in blocking atrioventricular 
conduction in anesthetized open-chest dogs and less toxic than the dihydropyridines. 
N
N
R1OOC
Y
COOR2
X
 
Atwal et al58 examined a series of novel dihydropyrimidine calcium channel blockers that 
contain a basic group attached to either C5 or N3 of the heterocyclic ring. Structure-
activity studies show that l-(phenylmethyl)-4-piperidinyl carbamate moiety at N3 and 
sulfur at C2 are optimal for vmrelaxant activity in vitro and impart potent and long-acting 
antihypertensive activity in vivo. One of the compounds was identified as a lead, and the 
individual enantiomers were synthesized. Two key steps of the synthesis were (1) the 
efficient separation of the diastereomeric ureido derivatives and (2) the high-yield 
transformation of 2-methoxy intermediate to the (p-methoxybenzy1)thio intermediates. 
Chirality was demonstrated to be a significant determinant of biological activity, with the 
dihydropyridine receptor recognizing the enamino ester moiety but not the carbamate 
moiety. Dihydropyrimidine is equipotent to nifidepine and amlodipine in vitro. In the 
spontaneously hypertensive rat, dihydropyrimidine is both more potent and longer acting 
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than nifidepine and compares most favorably with the long-acting dihydropyridine 
derivative amlodipine. Dihydropyrimidine has the potential advantage of being a single 
enantiomer. 
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In order to explain the potent antihypertensive activity of the modestly active (ICw = 3.2 
pM) dihydropyrimidine calcium channel blocker, Atwal et al59 carried out drug 
metabolism studies in the rat and found it is metabolized. Two of the metabolites (ICw = 
16 nM) and (ICw = 12 nM), were found to be responsible for the antihypertensive activity 
of compound. Potential metabolism in vivo precluded interest in pursuing compounds 
related to it. Structure-activity studies aimed at identifying additional aryl-substituted 
analogues led to comparable potential in vivo, though these compounds were less potent 
in vitro. To investigate the effects of absolute stereochemistry on potency, authors 
resolved via diastereomeric ureas, prepared by treatment with (R)-α-methylbenzylamine. 
The results demonstrate that the active R-(-)-enantiomer is both more potent and longer 
acting than nifedipine as an antihypertensive agent in the SHR. The in vivo potency and 
duration is comparable to the long-acting dihydropyridine amlodipine. The superior oral 
antihypertensive activity compared to that of previously described carbamates could be 
explained by its improved oral bioavailability, possibly resulting from increased stability 
of the urea functionality. 
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Atwal et al60 modified the structure of previously described dihydropyrimidine i.e. 3-
substituted 1,4-dihydropyrimidines. Structure- activity studies using potassium-
depolarized rabbit aorta show that ortho,meta-disubstituted aryl derivatives are more 
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potent than either ortho- or meta-monosubstituted compounds. While vasorelaxant 
activity was critically dependent on the size of the C5 ester group, isopropyl ester being 
the best, a variety of substituents (carbamate, acyl, sulfonyl, alkyl) were tolerated at N3. 
The results show dihydropyrimidines are significantly more potent than corresponding 2- 
heteroalkyl-l,4-dihydropyrimidines and only slightly less potent than similarly substituted 
2-heteroalkyl-1-4-dihydropyridines. Where as dihydropyridine enantiomen usually show 
10-15-fold difference in activity, the enantiomers of dihydropyrimidine show more than a 
1000-fold difference in activity. These results strengthen the requirement of an enamino 
ester for binding to the dihydropyridine receptor and indicate a nonspecific role for the 
N3-substituent. 
N
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2-Heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5-pyrimidinecarboaxcyildicesters, which 
lack the potential symmetry of dihydropyridine calcium channel blockers, were prepared 
and evaluated for biological activity. Biological assays using potassium-depolarized 
rabbit aorta and radio ligand binding techniques showed that some of these compounds 
are potent mimics of dihydropyridine calcium channel blockers.60 
N
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1.5 Current work   
 
 
Our group is involved in the synthesis of modified 1,4-dihydropyridine and 
dihydropyrimidine skeleton derivatives for last few years. Introduction of phenyl 
carbamoyl moiety at C-3 and/or C-5 position in dihydropyridine skeleton has showed 
diversed activity profile. Very promising results obtained with these modifications to 
dihydropyridine skeleton. N-phenyl substituted dihydropyridines were also synthesized 
and it also showed interesting biological profile. Result obtained in dihydropyridine 
modification, inspired to introduce phenyl carbamoyl moiety at C-5 position of 
dihydropyrimidine skeleton. This modification to dihydropyrimidine skeleton exhibited 
moderate biological profile. Moderate anti tubercular activity was observed for these 
derivatives against Mycobacterium H37Rv.  
 
Current work describes the synthesis of derivatives with phenyl ring at N1 of 
dihydropyrimidine skeleton and phenyl carbamoyl moiety at C-5 position. Reaction 
schemes are illustrated in Section 1.6. Scheme 1 and 2 displays the synthesis of N-phenyl 
urea and acetoacetanilides, two building blocks of Biginelli reaction. Different N-phenyl 
ureas with methyl substations (-Phenyl, -3-methylphenyl, 2,4-dimethylphenyl) were 
synthesized. Acetoacetanilides were synthesized with different halogen substitutions (4-
chloro, 4-flouro, 3-chloro-4-flouro). Scheme 3 is synthesis of N-phenyl substituted 
DHPM derivatives by reacting N-(phenyl/3-methylphenyl/2,4-dimethyl) urea, (4-chloro, 
4-flouro, 3-chloro-4-flouro)acetoacetanilide and aromatic aldehyde. The reaction time 
was observed 8-12 hours depending on the substitution on substitutions on 4-phenyl and 
N-phenyl ring. The synthesized compounds are characterized by IR, NMR and Mass 
spectral analysis and are under screening against Mycobacterium H37Rv for anti 
tubercular activity. Physical data of synthesized compounds is reported in Section 1.8 and 
spectral data is discussed in Section 1.9. 
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1.6 Reaction Schemes  
 
1.6.1 Scheme 1.  
 
 
 
 
 
 
 
 
 
Scheme 1. Reagents and conditions: a = water, glacial acetic acid, con. HCl, reflux.   
 
 
 
1.6.2 Scheme 2.  
 
 
 
 
 
 
 
 
 
Scheme 2. Reagents and conditions: b = KOH/NaOH, toluene, 115° C. 
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 1.6.3 Scheme 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Reagents and conditions: c = MeOH, con. HCl, reflux.  
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Reaction Mechanism  
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1.7 Experimental  
 
 
1.7.1   N-substitutedphenylurea:  
It was prepared according to literature methoda. Aniline (3-methyl/2,4-dimethylaniline) 
hydrochloride (0.2M) and urea (0.2M) were dissolved in 100 ml of water. 2 ml of glacial 
acetic acid and 2 ml of conc. HCl was added to this solution. The reaction mixture was 
refluxed and white crystals appeared after 30-40 minutes. It was further refluxed for 
another 30 minutes. The reaction mixture was cooled and filtered. The solid product was 
taken into 300 ml of water and boiled. It was filtered, and the filtrate was concentrated 
and allowed to cool. The crystal of phenyl urea was filtered and dried. Similarly, N-(3-
methylphenyl)urea and N-(2,4-dimethylphenyl) urea were synthesized. (Physical data is 
given in Table 1.8.2) 
1.7.2  Substituted acetoacetanilide:  
It was prepared according to literature methodb. Substituted aniline (0.1M) and ethyl 
aceto acetate was refluxed at 110° C in 40 ml of toluene and catalytic amount of 
KOH/NaOH. The completion of reaction was monitored with thin layer chromatography. 
After completion of reaction, toluene was distilled out. The residue was cooled at room 
temperature and was treated with ether. The solid was filtrated and dried. (Physical data is 
given in Table 1.8.1) 
1.7.3 4-(substitutedphenyl)-N-(substitutedphenyl)-1,2,3,4-tetrahydro-6-
methyl-2-oxo-1-(substituted phenyl)lpyrimidine-5-carboxamide:  
Acetoacetanilide (0.01M), aldehyde (0.01M) and N-phenyl urea (0.015M) were dissolved 
in methanol and refluxed until clear solution is obtained. Few drops of con HCl was 
added to reaction mixture and was refluxed for 8-12 hrs. The reaction was monitored with 
thin layer chromatography and after completion; the reaction mixture was allowed to 
cool. The solid separated was filtered, washed with hot methanol and dried. The 
compounds were recrystallized from dimethylformamide. (Physical data is given in Table 
1.8.3) 
a Vogel’s text book of practical organic chemistry, 5th Edition, Page no. 965.  
b [1] Desai, B.; Sureja, D.; Naliapra, Y.; Shah, A.; Saxena, A.; Bioorg. Med. Chem. 2001 9, 1993-98. [2] 
Kharkar, P.; Desai, B.; Gaveria, H.; Varu, B.; Loriya, R.; Naliapara, Y.; Shah, A.; Kulkarni, V.; J. Med. 
Chem. 2002 45, 4858-67.  
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1.8 Physical data tables  
 
1.8.1 Physical data of N-(substituted phenyl)-3-oxobutanamide [compounds 1a-c]. 
 
 
 
 
 
Compound  R1 MF MW MP ºC Yield Rf 
1a 4-Cl C10H10ClNO2 211.64 134-35 58 0.64 
1b 4-F C10H10FNO2 195.19 91-92 52 0.69 
1c 3-Cl,4-F C10H9ClFNO2 229.64 122-24 45 *0.51 
1d H C10H11NO2 177.20 82-83 64 0.53 
1e 2-Cl C10H10ClNO2 211.64 104-106 57 0.59 
1f 2-Me C11H13NO2 191.22 106-08 58 0.52 
1g 2,4-di-Me C12H15NO2 205.23 92-93 62 0.57 
1h 3-Me C11H13NO2 191.22 112-14 60 0.48 
 
1.8.2 Physical data of N-(substituted phenyl) urea [compounds 2a-c].  
 
Compound  R1 MF MW MP ºC Yield Rf 
2a H C7H8N2O 136.15 149-50 55 0.41 
2b 3-CH3 C8H10N2O 150.18  172-73 65 0.37 
2c 2,4-di-CH3 C9H12N2O 164.20  156-59 60 0.30 
H
N
O O
R1
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1.8.3 Physical data of 4-(substitutedphenyl)-N-(substitutedphenyl)-1,2,3,4-tetrahydro-6-methyl-2-
oxo-1-(substituted phenyl)lpyrimidine-5-carboxamide [compounds 3a-t]. 
 
 
 
 
 
 
 
 
 
 
 
Compound  Code  R R1 R2 MF MW MP Yield  Rf 
3a AKS-121 H 4-Cl Ph C24H20ClN3O2 417.89 208-10 52 0.48 
3b AKS-122 H 4-Cl 4-OH-Ph C24H19ClN4O4 462.89 176-77 48 0.53 
3c AKS-123 H 4-Cl 4-Cl-Ph C24H19Cl2N3O2 452.33 188-89 50 0.61 
3d AKS-124 3-CH3 4-Cl 2-Cl-Ph C25H21Cl2N3O2 466.36 213-14 54 0.45 
3e AKS-125 3-CH3 4-Cl 2-OH-Ph C25H22ClN3O3 447.91 199-201 50 0.49 
3f AKS-126 H 4-Cl 2-OCH3-Ph C26H24ClN3O3 461.94 191-92 50 0.67 
3g AKS-127 3-CH3 4-Cl 3-NO2 C25H21ClN4O4 476.91 214-17 42 0.55 
N
NH
R2
O
O
N
H
R1
R
 25 
3h AKS-128 2,4-CH3 4-Cl 2-Cl-Ph C26H23Cl2N3O2 480.39 168-70 46 0.39 
3i AKS-129 2,4-CH3 4-Cl 4-Cl-Ph C26H23Cl2N3O2 480.39 195-96 45 0.41 
3j AKS-130 2,4-CH3 4-Cl 4-NO2-Ph C26H23ClN4O4 490.94 182-83 50 0.56 
3k AKS-131 H 4-F Ph C24H20FN3O2 401.15 218-220 54 0.63 
3l AKS-132 3-CH3 4-F 2-Cl-Ph C25H21ClFN3O2 449.90 204-05 46 0.59 
3m AKS-133 3-CH3 4-F 4-NO2-Ph C25H21FN4O4 460.46 213-14 42 0.40 
3n AKS-134 2,4-CH3 4-F 2-Cl-Ph C26H23ClFN3O2 463.93 196-98 47 0.58 
3o AKS-135 2,4-CH3 4-F 4-NO2-Ph C26H23FN4O4 474.48 221-24 40 0.37 
3p AKS-136 3-CH3 3-Cl, 4-F 2-Cl-Ph C25H20Cl2FN3O2 484.35 172-74 44 0.54 
3q AKS-137 3-CH3 3-Cl, 4-F 4-NO2-Ph C25H20ClFN4O4 494.90 176-77 42 0.62 
3r AKS-138 2,4-CH3 3-Cl, 4-F 4-NO2-Ph C26H22ClFN4O4 508.93 185-86 38 0.46 
3s AKS-139 H 3-Cl, 4-F 4-Cl-Ph C26H22Cl2FN3O2 471.24 211-14 43 0.55 
3t AKS-140 H 4-Cl 3-NO2-Ph C26H23ClN4O4 462.77 199-01 50 0.42 
 
 
TLC solvent system:  Compound 1a-c (EA:Hexane )  2:8,  *1:9   MPs were taken in open capillary and are not corrected 
   Compound 2a-c (CHCl3:MeOH ) 0.5:9.5   
   Compound 3a-t  (EA:Hexane ) 3:7 
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1.9 Spectral discussion  
 
 
1.9.1  Mass spectral study 
 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection 
Probe technique. The molecular ion peak was found in agreement with molecular weight 
of the respective compound. Characteristic M+2 ion peaks with one-third intensity of 
molecular ion peak were observed in case of compounds having chlorine atom. The 
DHPMs having chlorine atom showed this characteristic peak. Fragmentation pattern can 
be observed to be particular for this kind of compounds and the characteristic peaks 
obtained for each compound. Various characteristic peaks obtained for each compound in 
this series can be discussed as below.  
 
1. Cleavage of bond adjacent to carbonyl group expected to give peak in mass 
spectrum. Cleave of C-N bond (adjacent bond to C=O bond at carbamoyl side 
chain at C-5 position) gave intense peak in each spectrum [1].  
2. Cleavage of another bond adjacent to C=O group of carbamoyl moiety gives 
another characteristic peak which is observed in each spectrum of this series [2].  
3.  Cleavage of –Me group at C-6 position from above fragment gave characteristic 
peak at m/e value less than 15 [3].  
4. Cleavage to both α-bonds to C=O bond of DHPM ring, gives another 
characteristic peak for this series of compounds [4].  
5. Another characteristic peak was observed at 153 m/e [5].  
 
 
 
 
 
 
 
 
 
 
   [1]         [2]            [3]   [4]    [5]   
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1.9.2   IR spectral study  
 
Various functional groups present in molecule were identified by characteristic frequency 
obtained for them. Presence of two carbonyl groups can be confirmed by IR spectra 
because two carbonyl stretching frequencies were observed for two carbonyl groups 
present in the moiety. Cyclic C=O group peak was observed between 1690-1720 cm-1 
while another C=O group (NH-CO-) was observed between 1655-1680 cm-1. Two N-H 
groups gave peaks between 3210-3380 cm-1. Peaks were identified for aromatic and alkyl 
group as per their characteristics. In case of compounds having different substations on 
aromatic ring, characteristic frequencies were observed depending on the functional 
group present i.e. nitro, hydroxyl, chloro, methoxy etc.   
 
1.9.3  1H NMR spectral study 
 
Numbers of proton identified from NMR spectrum and their chemical shift (δ ppm) were 
in agreement of structure of molecule. Methyl protons were observed at 1.3-1.9 δ ppm. 
Proton on C-4 carbon atom gave singlet at 5.12-5.80 δ ppm. Aromatic protons were 
observed between 7.2-7.9 δ ppm. J values were calculated to identify ortho and meta 
coupling. In some cases, aromatic protons were obtained as multiplet.   
 
In spectrum of compound AKS-123, singlet was obtained at 1.81 δ ppm for methyl 
protons. Proton on C4 gave singlet in downfield at 5.48 δ ppm. A doublet with J value of 
8.52 and 1.96 for two aromatic protons for ortho and meta coupling were observed. 
Another doublet for two protons was also observed for ortho and meta coupling J values. 
Doublet for one proton with J value for ortho coupling was obtained. Other aromatic 
protons were obtained as multiplet.  
 
In spectrum of AKS-122, methyl protons gave singlet at 1.68 δ ppm and C4 proton singlet 
was observed at 5.48 δ ppm. Aromatic protons were observed as a doublet for one proton 
with J value of ortho coupling (8.8), a triplet for three protons with J value of ortho 
coupling (8.32, 9.87), a doublet for two protons with J value of ortho coupling (8.80) and 
two multiplet for three and five protons.  
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In case of compound AKS-139, singlets were observed at 1.71 and 5.38 for methyl and C4 
proton respectively. A doublet with J value of 8.42 for two protons, a triplet with J value 
of 2.04 for one proton, a doublet with J value of 1.57 for one proton, a doublet with J 
value of 10.16 for one proton and two multiplets for four protons each were observed.    
 
1.9.4  Elemental analysis  
 
Elemental analysis showed calculated and found percentage values of carbon, hydrogen 
and nitrogen in support of structure of synthesized compounds. The spectral and 
elemental analysis data are given below for individual compounds.  
 
Spectral data of synthesized compounds (AKS 121-140) 
 
N-(4-chlorophenyl)-6-methyl-2-oxo-1,4-diphenyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-121) – IR (cm-1): 3375, 3288 (-NH-), 3055 (Ar-H), 2988, 2918, 
2866 (-Me), 1716 (C=O), 1666 (C=O), 1596, 1491, 1473, 1096 (C-O), 883, 775 (OOP); 
Anal cacld for C24H20ClN3O2: C 68.98, H 4.82, N 10.06, found: C 69.01, H 4.85, N 
10.14. 
 
N-(4-chlorophenyl)-4-(4-hydroxyphenyl)-6-methyl-2-oxo-1-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-122) – IR (cm-1): 3396, 3247 (-NH-), 
3085 (Ar-H), 2945, 2903, 2818 (-Me), 1707 (C=O), 1660 (C=O), 1585, 1428, 1447, 1124 
(C-O), 894, 754 (OOP); 1H NMR (δ ppm): 1.68 (3H, s), 5.48 (1H, s), 6.53 (1H, d, J=8.8), 
6.87 (3H, m), 7.18 (5H, m), 7.32 (3H, t, J=8.32, 9.87), 7.64 (2H, d, J=8.80), 8.35 (1H, s), 
9.59 (1H, s); Anal cacld for C24H19ClN4O4: C 66.44, H 4.65, N 9.68, found: C 66.48, H 
4.70, N 9.75. 
 
N-(4-chlorophenyl)-4-(4-chlorophenyl)-6-methyl-2-oxo-1-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-123) – IR (cm-1): 3412, 3310 (-NH-), 
3019 (Ar-H), 2971, 2911, 2853 (-Me), 1702 (C=O), 1674 (C=O), 1555, 1446, 1085 (C-
O), 824, 741 (OOP); 1H NMR (δ ppm): 1.81 (3H, s), 5.48 (1H, s), 7.21 (4H, m), 7.34 (2H, 
d, J=8.52, 1.96), 7.38 (1H, d, J=7.20), 7.43 (4H, m), 7.57 (2H, d, J=8.88, 2.08); Anal 
cacld for C24H19Cl2N3O2: C 63.73, H 4.23, N 9.29, found: C 63.78, H 4.27, N 9.35. 
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N-(4-chlorophenyl)-4-(2-chlorophenyl)-6-methyl-1-(3-methylphenyl)-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-124) – IR (cm-1): 3347, 3217 (-NH-), 
3079 (Ar-H), 2917, 2841 (-Me), 1694 (C=O), 1654 (C=O), 1519, 1460, 1447, 1184 (C-
O), 704 (OOP); Mass (m/e): 466 (Molecular ion peak), 339 (base peak), 311, 296, 269, 
153, 122, 91, 77;  Anal cacld for C25H21Cl2N3O2: C 64.39, H 4.54, N 9.01, found: C 
64.36, H 4.51, N 9.06. 
 
N-(4-chlorophenyl)-4-(2-hydroxyphenyl)-6-methyl-1-(3-methylphenyl)-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-125) – IR (cm-1): 3481, 3222 (-NH-), 
3061 (Ar-H), 2973, 2945, 2811 (-Me), 1701 (C=O), 1678 (C=O), 1503, 1441, 1408, 1056 
(C-O), 770 (OOP); Anal cacld for C25H22ClN3O3: C 67.04, H 4.95, N 9.38, found: C 
67.08, H 4.91, N 9.45. 
 
N-(4-chlorophenyl)-4-(2-methoxyphenyl)-6-methyl-2-oxo-1-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-126) – IR (cm-1): 3334, 3217 (-NH-), 
3107 (Ar-H), 2991, 2957, 2831 (-Me), 1692 (C=O), 1674 (C=O), 1509, 1427, 1128 (C-
O), 717(OOP); Mass (m/e): 462 (Molecular ion peak), 336, 308, 294, 265, 153, 127, 118 
(base peak), 91, 77; Anal cacld for C26H24ClN3O3: C 67.04, H 4.95, N 9.38, found: C 
67.09, H 4.96, N 9.44. 
 
N-(4-chlorophenyl)-4-(3-nitrophenyl)-6-methyl-1-(3-methylphenyl)-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-127) - IR (cm-1): 3292, 3248 (-NH-), 
3101 (Ar-H), 2924, 2870 (-Me), 1701 (C=O), 1658 (C=O), 1525, 1510, 1492 (C=C), 
1089, 1010 (C-O), 812, 775 (OOP); Anal cacld for C25H21ClN4O4: C 62.96, H 4.44, N 
11.75, found: C 62.89, H 4.49, N 11.82. 
 
N-(4-chlorophenyl)-4-(2-chlorophenyl)-1-(2,4-dimethylphenyl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-128) – IR (cm-1): 3412, 3345 (-
NH-), 3120 (Ar-H), 3008, 2922, 2856 (-Me), 1721 (C=O), 1658 (C=O), 1544, 1477, 1055 
(C-O), 878, 657 (OOP); Anal cacld for C26H23Cl2N3O2: C 65.01, H 4.83, N 8.75, found: 
C 64.97, H 4.85, N 8.81. 
 
N-(4-chlorophenyl)-4-(4-chlorophenyl)-1-(2,4-dimethylphenyl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-129) – IR (cm-1): 3440, 3207 (-
NH-), 3117 (Ar-H), 2944, 2903, 2818(-Me), 1700 (C=O), 1654 (C=O), 1550, 1448, 1427, 
 30
1184 (C-O), 647 (OOP); Anal cacld for C26H23Cl2N3O2: C 65.01, H 4.83, N 8.75, found: 
C 65.07, H 4.81, N 8.83. 
 
N-(4-chlorophenyl)-4-(4-nitrophenyl)-1-(2,4-dimethylphenyl)-6-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-130) – IR (cm-1): 3314, 3185 (-NH-), 
3104 (Ar-H), 2917, 2924, 2854 (-Me), 1721 (C=O), 1651 (C=O), 1547, 1440, 1418, 1117 
(C-O), 841, 681 (OOP); Anal cacld for C26H23ClN4O4: C 63.61, H 4.72, N 11.41, found: 
C 63.65, H 4.73, N 11.45. 
 
N-(4-fluorophenyl)-6-methyl-2-oxo-1,4-diphenyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-131) – IR (cm-1): 3425, 3177 (-NH-), 3021 (Ar-H), 2991, 2955, 
2853 (-Me), 1710 (C=O), 1657 (C=O), 1541, 1452, 1407, 1163 (C-O), 942, 752 (OOP); 
Anal cacld for C24H20FN3O2: C 71.81, H 5.02, N 10.47, found: C 71.75, H 5.06, N 10.54. 
 
N-(4-fluorophenyl)-4-(2-chlorophenyl)-6-methyl-1-(3-methylphenyl)-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-132) - IR (cm-1): 3319, 3290 (-NH-), 
3037 (Ar-H), 2953, 2916, 2854 (-Me), 1724 (C=O), 1654 (C=O), 1531, 1514, 1491 
(C=C), 1095, 1043 (C-O), 767 (OOP); Anal cacld for C25H21ClFN3O2: C 66.74, H 4.70, 
N 9.34, found: C 66.79, H 4.74, N 9.39. 
 
N-(4-fluorophenyl)-4-(4-nitrophenyl)-6-methyl-1-(3-methylphenyl)-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-133) – IR (cm-1): 3318, 3223 (-NH-), 
3018 (Ar-H), 2943, 2817 (-Me), 1685 (C=O), 1671 (C=O), 1558, 1433, 1407, 1142 (C-
O), 682 (OOP); Anal cacld for C25H21FN4O4: C 65.21, H 4.60, N 12.17, found: C 65.23, 
H 4.57, N 12.22. 
 
N-(4-fluorophenyl)-4-(2-chlorophenyl)-1-(2,4-dimethylphenyl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-134) – IR (cm-1): 3387, 3247 (-
NH-), 3112 (Ar-H), 2954, 2815, 2780 (-Me), 1717 (C=O), 1652 (C=O), 1547, 1441, 
1405, 1185 (C-O), 773 (OOP); Mass (m/e): 464 (Molecular ion peak), 353 (base peak), 
325, 310, 295, 280, 220, 138, 110, 77;  Anal cacld for C26H23ClFN3O2: C 67.31, H 5.00, 
N 9.06, found: C 67.28, H 5.04, N 9.14. 
 
N-(4-fluorophenyl)-4-(4-nitrophenyl)-1-(2,4-dimethylphenyl)-6-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-135) – IR (cm-1): 3419, 3219 (-NH-), 
 31
3077 (Ar-H), 2916, 2851, 2768 (-Me), 1711 (C=O), 1657 (C=O), 1547, 1417, 1107 (C-
O), 748 (OOP); Anal cacld for C26H23FN4O4: C 65.81, H 4.89, N 11.81, found: C 65.85, 
H 4.94, N 11.88. 
 
N-(3-chloro-4-fluorophenyl)-4-(2-chlorophenyl)-6-methyl-1-(3-methylphenyl)-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-136) – IR (cm-1): 3337, 3217 (-
NH-), 3124(Ar-H), 2951, 2884 (-Me), 1696 (C=O), 1654 (C=O), 1556, 1430, 1411, 1073 
(C-O), 814 (OOP); Anal cacld for C25H20Cl2FN3O2: C 61.99, H 4.16, N 8.68, found: C 
62.02, H 4.17, N 8.72. 
 
N-(3-chloro-4-fluorophenyl)-4-(4-nitrophenyl)-6-methyl-1-(3-methylphenyl)-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-137) – IR (cm-1): 3423, 3258 (-
NH-), 3076 (Ar-H), 2951, 2827, 2780 (-Me), 1714 (C=O), 1665 (C=O), 1552, 1481, 1116 
(C-O), 756 (OOP); Anal cacld for C25H20ClFN4O4: C 60.67, H 4.07, N 11.32, found: C 
60.68, H 4.05, N 11.37. 
 
N-(3-chloro-4-fluorophenyl)-4-(4-nitrophenyl)-1-(2,4-dimethylphenyl)-6-methyl-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-138) – IR (cm-1): 3413, 3285 
(-NH-), 3009 (Ar-H), 2912, 2857 (-Me), 1697 (C=O), 1651 (C=O), 1542, 1433, 1410, 
1076 (C-O), 648 (OOP); Anal cacld for C26H22ClFN4O4: C 61.36, H 4.36, N 11.01, 
found: C 61.38, H 4.35, N 11.05. 
 
N-(3-chloro-4-fluorophenyl)-4-(4-chlorophenyl)-6-methyl-2-oxo-1-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-139) - IR (cm-1): 3377, 3286 (-NH-), 
3055 (Ar-H), 2949, 2916 (-Me), 1716 (C=O), 1666 (C=O), 1525, 1467 (C=C), 1122, 
1093 (C-O), 887, 776 (OOP) 1H NMR (δ ppm): 1.71 (3H, s), 5.38 (1H, s), 6.87 (2H, d, 
J=8.42), 7.19 (4H, m), 7.28 (4H, m), 7.35 (1H, t, J=2.04), 7.60 (1H, d, J=1.57), 8.05 (1H, 
d, J=10.16); Anal cacld for C26H22Cl2FN3O2: C 62.66, H 4.45, N 8.43, found: C 62.65, H 
4.47, N 8.48. 
 
N-(4-chlorophenyl)-4-(3-nitrophenyl)-6-methyl-2-oxo-1-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-140) – IR (cm-1): 3336, 3251 (-NH-), 
3094 (Ar-H), 2991, 2843 (-Me), 1708 (C=O), 1662 (C=O), 1547, 1420, 1404, 1163 (C-
O), 722 (OOP); Mass (m/e): 447 (Molecular ion peak), 321 (base peak), 293, 278, 250, 
 32
187, 153, 91, 77; Anal cacld for C26H23ClN4O4: C 63.61, H 4.72, N 11.41, found: C 
63.64, H 4.73, N 11.46. 
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1.9.5.1  1H NMR spectrum of AKS-123 
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1.9.5.2  1H NMR spectrum of AKS-122 
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1.9.5.3  1H NMR spectrum of AKS-139 
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1.9.5.4 Mass Spectrum of AKS - 126  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.9.5.5  Mass spectrum of AKS - 140 
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1.9.5.6  IR spectrum of AKS-121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.9.5.7  IR spectrum of AKS-127 
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1.9.5.8 IR spectrum of AKS-132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.9.5.9 IR spectrum of AKS-139 
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2.1 Scaffold decoration of DHPM ring, methods of synthesis 
and their biological profile  
 
Importance of DHPM moiety and various modifications applied to Biginelli reaction for 
better yield, shorter reaction time and synthesis of various analogs is surveyed in detail in 
Chapter 1. The biological profile of this heterocyclic moiety is briefly reported in the 
same Chapter.  
Biginelli reaction is not only important to synthesize analogs of DHPM ring using 
different building block as potent bioactive heterocycles, but diversed fused and non-
fused heterocycles can be synthesized by careful applications.  
 
2.1.1 Various scaffolds derived from DHPMs 
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As displayed in above figure, it can be understood that a number of new moieties can be 
generated from DHPM ring.  
 
2.1.2 N3-Acylated and C5-substituted DHPMs and their biological 
importance  
 
Kappe et al2 reported that N3-acylated DHPMs can be rapidly synthesized in a 
highthroughput fashion by combining microwave-assisted acylations with microwave-
assisted scavenging techniques. Scavenging experiments can be carried out employing 
either supported nucleophilic amine sequestration reagents or water. N-acylated DHPMs 
are pharmacologically important N-acylation of DHPM can be performed as shown 
below.  
N
NH
R4
E
R6
R1
X
(R3CO)2O, TEA, DMAP
MW, 5-20 min, 100-180 C
scavenging reagent
MW, 5 min, 80-100 C
SPE
N
N
R4
E
R6
R1
X
R3
O
 
N3-substituted DHPMs have been identified to possess potent pharmacological profiles, 
e.g. following compound exhibited high binding affinity and subtype selectivity for the 
cloned human α1a receptor3.  
N
H
N
O
N
H
O
O
O
N
R
Ph
NO2
 
 
Systematic modifications of above compounds led to identification of highly potent and 
subtype-selective compounds with high binding affinity (Ki = 0.2 nM) for α1a receptor 
and greater than 1500-fold selectivity over α1b and α1d adrenoceptors. The compounds 
were found to be functional antagonists in human, rat, and dog prostate tissues. 
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Modifications to the C5 position also play important role in potency of DHPM ring. 4-
aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-5 amide as 
selective α1a receptor subtype antagonists. In receptor binding assays, these types of 
compounds generally display Ki values for the α1a receptor subtype <1 nM while being 
greater than 100-fold selective versus the α1b and α1d receptor subtypes. Many of these 
compounds were also evaluated in vivo and found to be more potent than terazosin in 
both a rat model of prostate tone and a dog model of intra-urethral pressure without 
significantly affecting blood pressure4.  
N
H
NH
R O
N
H
O
F
R1R2
F
 
 
2.1.3 Intramolecular Heck cyclization of DHPMs 
 
The intramolecular Heck reaction can be observed in DHPM skeleton. The starting 
material for the intramolecular Heck reaction was prepared by selective N3-acylation of 4-
(o-bromophenyl)-dihydropyrimidone with acryloyl chloride5 
 
N
H
NHO
O
O
Br
Cl
O
Et3N, MeCN
MW, 180 C, 20 min
N
H
NO
O
O
Br
O
 
 
N
H
N
R O
N
H
O
R1
O
N
CO2Me
Ph
NO2
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Applying intramolecular Heck reaction, tricyclic ring system can be obtained as shown 
below.6 
Pd2(OAc)2[P(o-tolyl)3]2
MW, 150 C, 15 min
N
H
NO
O
O
Br
O
N
H
NO
O
O
O
 
The computational experiments reveal that the formation of a tricyclic ring system did not 
flatten out the overall geometry. On the contrary, the aryl ring was still locked in a 
pseudoaxial position, resembling other nonfused 4-aryl-dihydropyrimidines.7,8 In fact, 
here, the intramolecular Heck strategy allows locking of the aryl ring in the proposed 
bioactive, that is, the pseudoaxial orientation.9 
 
 
 
 
 
 
 
 
2.1.4 N3-Arylation of DHPMs 
 
N3-arylated DHPM analogues cannot be obtained by classical Biginelli condensation 
strategies involving N-arylureas. Here, the corresponding N1-substituted derivates will be 
formed exclusively10,11.  
Wannberg et al11 reported protocol using concentrated mixture of 20 mol % of cuprous 
iodide as catalyst, 1.5 equiv of cesium carbonate as base, and 5 mol equiv of 
dimethylformamide as solvent. The reactions were conducted at 180 °C for 40 min with a 
set of eight differently substituted aryl iodides. 
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Ar-I, CuI, Cs2CO3, DMF
MW, 180 C, 40 min
N
NHO
O
O N
NO
O
O
R1
Ar
R1  
 
2.1.5 Fused bicyclic systems derived from DHPMs  
 
Many bicyclic fused systems can be synthesized from DHPM scaffold. Pyrazolo[4,3-
d]pyrimidine derivatives synthesized by reacting sodium azide with N-Methyl, 6-
Bromomethyl DHPM. The possible mechanism of this transformation is shown below 
and involves decomposition of the diazide to vinyl diazo derivative, which undergoes 
spontaneous 1,5-electrocyclization to 3H-pyrazole. Subsequent migration of the ester 
substituent from the tetrahedral carbon to N2 (thermal van Alphen-Hüttel rearrangement) 
yields pyrazolo[4,3-d]pyrimidine. The structure confirming the position of the ester group 
at N2 was established by an X-ray analysis55.  
 DMF
N
NH
Ph
EtO2C
(N3)2HC O N
NH
Ph
O
N
NEtO2C
-2 N2
N
NH
Ph
EtO2C
ON2 N
NH
Ph
O
N
N
EtO2C
 
Use of the 4-chloroacetoacetate building block in a Biginelli-type condensation is very 
useful to get variety of bicyclic systems. The resulting functionalized DHPM appeared to 
be an ideal common chemical template for the generation of a variety of interesting 
bicyclic scaffolds such as furo[3,4-d]- pyrimidines, pyrrolo[3,4-d]pyrimidines, and 
pyrimido-[4,5-d]pyridazines. 
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Solid-phase and solution-phase protocols for the synthesis of furo[3,4-d]pyrimidines, 
pyrrolo[3,4-d]-pyrimidines, and pyrimido[4,5-d]pyridazines are reported. The multistep 
solid-phase sequence involves the initial high-speed, microwave-promoted 
acetoacetylation of hydroxymethylpolystyrene resin with methyl 4-chloroacetoacetate. 
The immobilized 4-chloroacetoacetate precursor was subsequently subjected to three 
component Biginelli-type condensations employing urea and a variety of aromatic 
aldehydes. The resulting 6-chloromethyl-functionalized resin-bound dihydropyrimidones 
served as common chemical platforms for the generation of the desired heterobicyclic 
scaffolds using three different traceless cyclative cleavage strategies. The corresponding 
furo[3,4-d]pyrimidines were obtained by microwave flash heating in a rapid, thermally 
triggered, cyclative release. Treatment of the chloromethyl dihydropyrimidone 
intermediates with a variety of primary amines followed by high-temperature microwave 
heating furnished the anticipated pyrrolo[3,4-d]pyrimidine scaffolds via nucleophilic 
cyclative cleavage. In a similar way, reaction with monosubstituted hydrazines resulted in 
the formation of pyrimido[4,5-d]pyridazines. All compounds were obtained in moderate 
to good overall yields and purities56.  
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2.1.6 Chemistry and biological importance of thaizolo[3,2-a]pyrimidine 
and pyrimido[2,1-b][1,3]thiazines scaffolds 
 
Preparation of thiazolo[3,2-a]pyrimidine derivatives is very well reported in literature. 
Two approaches is generally employed for synthesis.  
1. Azole approach 
Literature survey on synthetic methodology for thiazolo[3,2-a]pyrimidine derivatives can 
be summarized in Chart 1 & 2 where various methods are illustrated for synthesis of this 
class of compounds.  
 
Chart 1: Thiazolo[3,2-a]pyrimidine 2 was prepared in 30% yield by the reaction of 2-
aminothiazole 1 with ethyl cyanoacetate  in a sodium ethoxide/ethanol mixture or using 
polyphosphoric acid or acetic acid. However, oxothiazolopyrimidine 3 was obtained upon 
treatment with phosphorous pentoxide and methanesulfonic acid. 
 
The reaction of 1 with ethyl acetoactate at 140-150°C resulted in the formation of 
compound that was then converted to the Z-isomer upon heating at 250°C and cyclized to 
give 4. 2-Aminothiazole 5 cyclized with acetylacetone at 100°C, in the presence of 
methanesulfonic acid-phosphorus pentoxide or formic acid-phosphorus pentoxide, 
followed by treatment with 70% perchloric acid, to give the thiazolopyrimidin-4-ium salt 
5. The ester 6 was obtained from 2-aminothiazole 1 with an excess of methyl 
methanetricarboxylate in 61 % yield. Cyclocondensation of 1 with diethyl 
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ethoxymethylene malonate in acetic acid followed by hydrolysis of the ester gave 7. 
Similarly, 2-aminothiazole 1 reacted with benzylidine in ethanol to give 8. Stanovink et al 
reported the synthesis of a series of thiazolopyrimidine derivatives upon reacting 2-
aminothiazole with a variety of different reagents. Thus, dimethylaminobut- 2-enoate (or 
pentenoate), reacted with 1 to give thiazolopyrimidines.12-25 
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Chart 1 
Chart 2: The reaction of 2-aminothiazole 1 with 2-hydropolyfluoroalk-2-enoate in basic 
medium gave two isomers, 7-oxo 2 and its isomeric 5-0x0 3. The structure of both 2 and 
3 was established through 1H NMR, 19F NMR and mass spectra26. 2-Aminothiazole 
derivatives , (R' = H, C02Et; R2 = Ph, aryl, Me), reacted with the acetylenic derivative  
and ester derivative in ethanol and polyphosphoric acid, respectively, to give the isomeric 
oxothiazolopyrimidine derivatives 4 and 5, in 5-32% and 8-97 % yield, respectively27. 
Condensation of 2-aminothiazole 1 in absolute ethanol with the sodium salt of ethyl 
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oximinocyanoacetate gave after acidification (pH 6) with diluted hydrochloric acid, the 
nitroso derivative 6 in 92% yield28. Treatment of the 2-aminothiazaole derivatives 5 with 
the hydrazone derivatives gave the oxothiazolo [3,2-a] pyrimidine derivatives 7.29 
N
S
NH2
R2
R1
N
NS
R1
R2
R3
O
R3
COOEt
F
N
N SO
Cl
R2
R1
Cl
O
OEt
O
1
2
Cl
COOMe
4
N
N S
R2
R1
5
Cl
O
N
NS
R2
R1
O
NO
NH2
6
N
HO
COOEt
NC
N
N
S
O
N
N
Ar
R2
COOEt
7
NHArEtOOC
COMe
 
Chart 2 
2-Amino-2-thiazoline reacted with 2-acylamino-3-dimethylamino-propenoates in acetic 
acid to yield 6-acylamino-5-oxo-2,3-dihydro-5-thiazolo[3,2-a]pyrimidines in 73 and 12% 
yields, respectively30.  
 
N
S
NH2
Me2N
H CO2Me
NHCOR
N
NS
O
NHCOR
 
 
Moreover, 2-amino-2-thiazoline reacted with an aromatic aldehyde and diethyl malonate, 
to give a mixture of thiazolidino[3,2-a]pyrimidines. Furthermore, malononitrile reacted to 
give following product.31-32  
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NH2  
2-Amino-thiazoline reacted with potassium 2-ethoxycarbonyl-2-fluorovinyl alcoholate in 
a sodium methoxide/methanol mixture to give 6-fluoro-2,3-dihydro-5-oxothiazolo[3,2-
a]pyrimidine33.  
N
S
NH2
N
N SH
F
O
OKH
F CO2Et
 
2-(Methylthio)-24hiazoline reacted with /3-alanine to give a 5-oxothiazolo[3,2-a]-
pyrimidine derivative  in 23% yield34. 
N
S
MeS
H2N
COOH
N
N
S
O
 
 
2. Azine approach 
 
Pyrmidinethione derivatives were alkylated with monochloroacetic acid or chloroacetyl 
chloride and then cyclized to give thiazolopyrimidine derivatives.35-48 Thus, 
pyrimidinethione reacted in dimethylformamide35 or in an acetic anhydride/pyridine 
mixture37 to give thiazolo-pyrimidines. Alkylation in the presence of an aromatic 
aldehyde gave the ylidene. Similarly, pyrimidinethione derivatives reacted with 
monochloroacetic acid in acetic acid/acetic anhydride/sodium acetate mixture or with 
chloroacetyl chloride in dry dioxane to give the corresponding thiazolopyrimidines39,40.  
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Treatment of mercaptopyrimidine derivative with 2-chloroethanol in dimethylformamide 
gave the asymmetrical thioether which underwent cyclization on refluxing with a mixture 
of acetic anhydride-pyridine, to give the oxothiazolopyrimidine49.  
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1,3-Dibromopropan-2-ol reacted with mercaptopyrimidine derivative to give product 
through the non isolated intermediates. The same reaction product was obtained by 
reacting with I-bromomethyloxirane.50 
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Several derivatives of 4,5-disubstituted imidazole, 2,4,5-trisubstituted pyrimidine, 2-
substituted purine, thiazolo[3,2-a]purine, [1,3]thiazino[3,2-a]purine, thiazolo[2,3-
i]purine, [1,3]thiazino-[2,3-i]purine, and 6-substituted pyrazolo[3,4-d]pyrimidine were 
synthesized and tested as inhibitors of the xanthine oxidase enzyme51. 
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Dihydropyrimidines are now known for calcium channel blockers property. According to 
the literature, analogous derivatives are anti-inflammatory. Bo´szing and co-workers52 
reported the synthesis of the pyrimidothiazines and assay these compounds for the same 
profile. Acute anti-inflammatory activity was tested by inhibition of the carrageenan-
induced paw edema in rats. 
S
N
N
R
COX
R1  
Adam et al53 filed US patent for phenyl substituted thiazolo pyrimidine derivatives 
synthesized from DHPM. These compounds and their slats are novel and are 
distinguished by valuable therapeutic properties. Specifically, it has been found that the 
compounds of general formula given below are metabotropic glutamate receptor 
antagonists. These compounds are capable of high affinity binding to group II mGluα 
receptors.  
N
NS
R1 O
R2
R8
R12
R11 R10
R9
R3
R4
R5
R6
R7
 
Compounds displayed by general formulae given below exhibit excellent adenosine α3 
receptor antagonism where A is an optionally substituted benzene ring. B may be 
substituted and R1 is optionally substituted cyclic group54.  
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2.2 Current work   
 
 
Importance of dihydropyrimidine ring to develop variety of bicyclic systems is briefly 
surveyed in Section 2.1. N3-substitution in dihydropyrimidine ring is reported to enhance 
activity profile. Similarly, substitutions at C5 position also plays key role in activity 
profile. Earlier in our lab, phenyl carbomoyl side chain is introduced at C5 position of 
dihydropyrimidine ring, but this substitution does not enhance activity profile of 
dihydropyrimidine ring. Moderate result obtained for this kind of derivatives. To get 
better activity profile, N-phenyl derivatives with phenyl carbamoyl moiety at C5 position 
are synthesized and characterized in Chapter 1. 
 
Thiazolo pyrimidine and pyrimido thiazine are very important bicyclic system in 
medicinal chemistry. Various synthetic routes have been reported in literature to 
synthesize these bicyclic systems. Utility of dihydropyrimidine ring to synthesize such 
bicyclic system can be used to obtain derivatives with phenyl carbamoyl as side chain on 
pyrimidine ring of bicyclic system. 
 
Dihydropyrimidine ring, substituted with phenyl carbamoyl side chain at C5 position, was 
synthesized by reacting acetoacetanilide, thiourea and aldehyde. This dihydropyrimidine 
ring was reacted with dihalo alkane to get fused bicyclic systems. In synthesis of thiazolo 
pyrimidine system, 1,2-dibromo ethane was reacted with 2-thiodihydropyrimidine 
derivatives. Pyrimido-thiazine systems can be synthesized using 1,3-dibromo propane in 
place of 1,2-dibromo ethane with shorter reaction time and better yields as compared with 
synthesis of thiazolo pyrimidine systems. Reaction schemes for synthesis of these bicyclic 
systems are given in Section 2.3. Physical data of synthesized compounds are given in 
Section 2.5 and spectral data are discussed in Section 2.6.  
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2.3 Reaction Schemes  
 
2.3.1 Scheme 1 
 
 
 
 
 
 
 
 Scheme 1. Reagents and conditions: a = KOH/NaOH, toluene, 115° C. 
 
 
2.3.2  Scheme 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Reagents and conditions: b = MeOH, con. HCl, reflux. 
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Reaction Mechanism  
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 2.3.3 Scheme 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Reagents and conditions: c = DMF/CH3CN, 140 ° C, n = 1-2 
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2.4 Experimental  
 
 
2.4.1 4-chloro/flouro acetoacetanilide 
4-chloro/flouro aniline (0.1M) and ethyl aceto acetate was refluxed at 110° C in 40 ml of 
toluene and catalytic amount of KOH/NaOH. The completion of reaction was monitored 
with TLC. After completion of reaction, toluene was distilled out. The residue was cooled 
at room temperature and was treated with ether. The solid was filtrated and dried. 
(Physical data is given in Chapter 1) 
 
2.4.2 N-(substitutedphenyl)-1,2,3,4-tetrahydro-6-methyl-4-
(substitutedphenyl)-2-thioxopyrimidine-5-carboxamide 
Acetoacetanilide (0.01M), aldehyde (0.01M) and thiourea (0.015M) were dissolved in 
minimum quantity of methanol. It was heated for 5-10 minutes to get the clear solution. 
Few drops of con. HCl were added to the reaction mixture as a catalyst. The reaction 
mixture was then refluxed in water bath for 6-12 hrs. The progress of reaction was 
monitored by thin layer chromatography. The reaction mixture was allowed to cool at 
room temperature. The solid separated upon cooling was filtered, washed with hot 
methanol and dried. Compounds were recrystallized from dimethylformamide. (Physical 
data are given in Table 2.5.1) 
 
2.4.3 N-(4-chlorophenyl)-3,5,8,8a-tetrahydro-7-methyl-5-phenyl-2H-
thiazolo[3,2-a]pyrimidine-6-carboxamide 
N-(substitutedphenyl)-1,2,3,4-tetrahydro-6-methyl-4-(substitutedphenyl)-2-
thioxopyrimidine-5-carboxamide (2a-p) (0.01M) and dibromo propane (or ethane) 
(0.015M) were dissolved in DMF and the reaction mixture was refluxed at 140° C for 2-
2.5 hrs. The reaction mixture was poured on crushed ice and was extracted with 
chloroform. The chloroform was removed in vacuum. The residue was dried and 
recrystallized from dimethylformamide. (Physical data is given in Table 2.5.2)  
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2.5 Physical data  
 
 
2.5.1 Physical data of N-(substitutedphenyl)-1,2,3,4-tetrahydro-6-methyl-4-(substitutedphenyl)-2-
thioxopyrimidine-5-carboxamide (compounds 2a-p) 
 
 
 
 
 
 
 
 
 
 
 
Compound Code  R1 R2 MF MW MP° C Yield Rf 
2a AKS- 201 4-Cl Ph C18H16ClN3OS 357.89 211-13 55 0.44 
2b AKS- 202 4-Cl 3,4-OCH3-Ph C20H20ClN3O3S 417.95 163-66 49 0.56 
2c AKS- 203 4-Cl 4-NO2-Ph C18H15ClN4O3S 402.89 253-55 52 0.49 
2d AKS- 204 4-Cl 3,4-OH-Ph C18H16ClN3O3S 392.89 268-69 46 0.36 
2e AKS- 205 4-Cl 2-OCH3-Ph C19H18ClN3O2S 387.92 189-90 50 0.47 
N
H
NH
R2
S
O
N
H
R1
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2f AKS- 206 4-Cl 2-Cl-Ph C18H15Cl2N3OS 392.34 204-06 56 0.54 
2g AKS- 207 4-Cl 3-NO2-Ph C18H15ClN4O3S 402.89 244-45 58 0.54 
2h AKS- 208 4-Cl 2-NO2-Ph C18H15ClN4O3S 402.89 201-04 55 0.57 
2i AKS- 209 4-F 2-OH-Ph C18H16FN3O2S 357.44 175-78 59 *0.40 
2j AKS- 210 4-F 4-N(CH3)2-Ph C20H21FN4OS 387.51 166-67 48 *0.52 
2k AKS- 211 4-F 2-Cl-Ph C18H15ClFN3OS 375.88 158-59 53 *0.46 
2l AKS- 212 4-F 4-OCH3-Ph C19H18FN3O2S 371.47 196-97 50 *0.48 
2m AKS- 213 3,4-benzo 2-OCH3-Ph C23H21N3O2S 403.53 184-86 56 **0.55 
2n AKS- 214 3,4-benzo 4-N(CH3)2-Ph C24H24N4OS 416.58 198-99 48 **0.61 
2o AKS- 215 3,4-benzo 2-Cl-Ph C22H18ClN3OS 407.95 152-53 59 **0.58 
2p AKS- 216 3,4-benzo 2-OH-Ph C22H19N3O2S 389.51 221-22 62 **0.46 
 
TLC solvent system:  EA:Hexane  3.5:6.5      MPs were taken in open capillary and are not corrected 
   *EA:Hexane     3:7 
   **CH2Cl2:MeOH 9.5:0.5  
 
.  
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2.5.2 Physical data of N-(4-chlorophenyl)-3,5,8,8a-tetrahydro-7-methyl-5-phenyl-2H-thiazolo[3,2-
a]pyrimidine-6-carboxamide (compounds 3a-r) 
  
 
 
 
 
 
 
 
 
 
 
 
Compound Code R1 R2 MF MW MP° C Yield  Rf 
3a AKS-231 4-Cl Ph C20H18ClN3OS 383.89 153-54 68 0.48 
3b AKS-232 4-Cl 3,4-OCH3-Ph C22H22ClN3O3S 443.95 174 66 0.41 
3c AKS-233 4-Cl 4-NO2-Ph C20H17ClN4O3S 428.89 182-85 72 0.54 
3d AKS-234 4-Cl 4-OH-Ph C20H18ClN3O2S 399.89 190-91 69 0.49 
3e AKS-235 4-Cl 4-OCH3-Ph C21H20ClN3O2S 413.92 160-62 66 0.62 
3f AKS-236 4-Cl 2-Cl-Ph C20H17Cl2N3OS 418.34 177-78 60 0.56 
N
N
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n
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#3g AKS-237 4-Cl 3-NO2-Ph C21H19ClN4O3S 442.92 214-17 59 0.58 
#3h AKS-238 4-Cl 2-Cl-Ph C21H19Cl2N3OS 432.37 168-70 72 0.55 
#3i AKS-239 4-Cl 2-NO2-Ph C21H19ClN4O3S 442.92 190-92 68 0.44 
#3j AKS-240 4-Cl Ph C21H20ClN3OS 397.92 144-45 74 0.52 
3k AKS-241 4-F 2-OH-Ph C20H18FN3O2S 383.44 183-84 63 0.66 
3l AKS-242 4-F 4-N(CH3)2-Ph C22H23FN4OS 410.51 212-14 65 0.43 
3m AKS-243 4-F 2-Cl-Ph C20H17ClFN3OS 401.88 196-97 62 0.52 
3n AKS-244 4-F 4-NO2-Ph C21H20FN3O2S 397.47 175 69 0.61 
3o AKS-245 3,4-benzo 2-OCH3-Ph C25H23N3O2S 429.53 181 72 *0.48 
3p AKS-246 3,4-benzo 4-N(CH3)2-Ph C26H26N4OS 442.58 193-95 74 *0.52 
3q AKS-247 3,4-benzo 2-Cl-Ph C24H20ClN3OS 433.95 162-63 70 *0.43 
3r AKS-248 3,4-benzo 2-OH-Ph C24H21N3O2S 415.51 186-88 72 *0.56 
 
 
TLC solvent system: EA:Hexane – 4:6, * CH2Cl2:MeOH - 9:1     MPs were taken in open capillary and are not corrected 
 
# n = 2 
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2.6 Spectral discussion  
 
 
2.6.1  Mass spectral study 
 
Systematic fragmentation pattern was observed in mass spectral analysis. Peaks for 
specific fragments were identified in each mass spectrum. Molecular ion peaks observed 
were in agreement with molecular weight of compounds. Fragmentation pattern can be 
described as below.  
 
[1] A base peak in each spectrum was obtained because of specific fragmentation in 
each molecule. Fragment obtained due to cleavage of bond adjacent to carbonyl 
double bond in the phenyl carbamoyl side chain at C5 position gave base peak in 
each spectrum. Base peak obtained at 271, 317, 273, 302 and 300 m/e values in 
mass spectrum of compound AKS-240, AKS-232, AKS-234, AKS-244 and AKS-
242 were due to specific fragmentation pattern for this observed for this series. 
[2] The second characteristic peak observed in each spectrum was due to cleave bond 
adjacent to carbonyl double bond at the other side. Peaks were observed at 243, 
289, 245, 274 and 272 m/e values in respective spectrum for these fragments.  
[3] Cleavage of methyl group from peak [1] gave another characteristic peak. Peaks 
were observed at 256, 303, 258 and 285 m/e values for compounds AKS-240, 
AKS-232, AKS-234 and AKS-242. 
[4] Cleavage of bonds adjacent to both N atoms, gives characteristic peaks with 
respect to ring size (peak at 99 and 115 respectively for n = 1 and 2).  
[5] Removal of one N atom from above fragment gave peak at 14 less m/e value.  
[6] Peaks were also observed for fragment shown as [6] in figure 1. 
[7] Cleavage of bond adjacent to carbonyl double bond gave fragment [7].  
 
Above fragments are shown in the Figure 1 given below.  
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 Figure 1. Characteristic fragments observed in mass spectrums  
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2.6.2   IR spectral study  
In IR spectrums, characteristic frequencies were observed for functional group present in 
the molecule.  -NH stretching vibration was observed between 3420-3112 cm-1. Methyl 
and methylene group gave characteristic peaks between 2980-2815 cm-1. Carbonyl 
frequency was characterized between 1680-1645 cm-1 because of amide carbonyl group. 
Aromatic ring gave characteristic frequencies for Ar-H, ring –C=C- and out of plane 
vibration. IR frequencies for each compound are given in spectral data of the compounds.  
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2.6.3 1H NMR spectral study 
N
NCH3
O
NH
S
a
b
c
d
e
 
Number of protons and their chemical shifts were found to support the structure of the 
synthesized compounds. Signal (a) of methyl proton was observed between 2.1-2.4 δ 
ppm. Protons (-CH2-) of thiazol and thiazine ring gave double doublet between 3.0-3.8 δ 
ppm. Signal (c) was observed between 5.2-5.8 δ ppm. Aromatic protons (d, e) were 
observed between 7-8 δ ppm and J values were found to be according to substitution on 
phenyl ring.  
 
In spectrum of AKS-231, singlet for methyl protons was obtained at 2.23 δ ppm. Four 
protons of two cyclic –CH2- of thiazolo ring were observed as multiplet for each proton at 
3.11, 3.22, 3.42 and 3.61 δ ppm. C4 proton gave singlet at 5.48 δ ppm. Aromatic protons 
were obtained as multiplet.  
 
In case of AKS-235, C6 methyl proton singlet was observed at 2.25, while methoxy 
proton singlet was obtained at 3.46 δ ppm. Four multiplets were obtained for four cyclic 
thiazolo protons. C4 proton was identified at 5.39 δ ppm. A triplet for a proton with J 
value of 7.96 and another triplet for a proton with 2.11 J value were obtained. A doublet 
with 7.76 J value for a proton and a double doublet with 8.12 and 2.16 J values were 
obtained. Other aromatic protons were obtained as multiplet.  
 
In spectrum of AKS-247, a singlet (2.36 δ ppm) for methyl protons, four multiplets for 
four cyclic thiazolo protons and a singlet (6.13 δ ppm) for C4 proton were observed. The 
NMR data along with chemical shifts and respective J values are given in spectral data of 
compounds.  
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2.6.4  13C NMR Spectral study 
13C NMR spectrum data for compound AKS-235 is given below. δ ppm values is listed 
along with corresponding carbon atom number given in bracket and displayed in the 
structure.  
N
NN
H
O
O
Cl
S
C1
C2
C3
C4
C5
C6
C7
C8
C9 C10
C11
C12 C13 C14
C15
C16
C17
C18
C19
C20
C21
 
13C δ ppm:  14.73 (C1), 21.25 (C2), 25.08 (C3), 50.39 (C4), 55.93 (C5), 107.86 (C6), 
114.39 (C7), 114.61 (C8), 121.17 (C9), 121.24 (C10), 127.56 (C11), 128.97 (C12), 
129.36 (C13), 130.06 (C14), 131.88 (C15), 134.26 (C16), 145.00 (C17), 157.02 (C18), 
159.43 (C19), 163.79 (C20), 165.78 (C21) 
 
2.6.5  Elemental Analysis  
Elemental analysis of the synthesized compounds was found in agreement of calculated 
% of elements for respective compounds. The spectral and elemental analysis data are 
given below for individual compound.  
 
Spectral data of synthesized compounds (AKS 231-248) 
 
N-(4-chlorophenyl)-7-methyl-5-phenyl-2,3-dihydro-5H-[1,3]thiazolo[3,2-a] 
pyrimidine-6-carboxamide (AKS-231) - IR (cm-1): 3256 (N-H), 3089 (Ar-H), 2914 (-
CH3), 2818 (-CH2), 1673 (C=O), 1614 (C=C), 1126 (C-O); 1H NMR (DMSO d6) (δ ppm): 
2.23 (3H, s), 3.11 (1H, m), 3.22 (1H, m), 3.42 (1H, m), 3.61 (1H, m), 5.48 (1H, s), 7.14 
(1H, s), 7.16-7.40 (9H, m); Anal cacld for C20H18ClN3OS: C 62.57, H 4.73, N 10.95, 
found: C 62.61, H 4.72, N 10.97.  
 
N-(4-chlorophenyl)-7-methyl-5-(3,4-dimethoxyphenyl)-2,3-dihydro-5H-[1,3] 
thiazolo[3,2-a]pyrimidine-6-carboxamide (AKS-232) - IR (cm-1): 3318 (N-H), 3077 
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(Ar-H), 2922 (-CH3), 2835 (-CH2), 1658 (C=O), 1622 (C=C), 1169 (C-O); Mass (m/e): 
443 (molecular ion peak), 428, 317 (base peak), 303, 289, 215, 127, 99; Anal cacld for 
C22H22ClN3O3S: C 59.52, H 4.99, N 9.47, found: C 59.50, H 4.98, N 9.49.  
 
N-(4-chlorophenyl)-7-methyl-5-(4-nitrophenyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-
a]pyrimidine-6-carboxamide (AKS-233) - IR (cm-1): 3346 (N-H), 3114 (Ar-H), 2988 (-
CH3), 2857 (-CH2), 1662 (C=O), 1608 (C=C), 1078 (C-O); Anal cacld for 
C20H17ClN4O3S: C 56.01, H 4.00, N 13.06, found: C 56.03, H 4.02, N 13.09.  
 
N-(4-chlorophenyl)-7-methyl-5-(4-hydroxyphenyl)-2,3-dihydro-5H-[1,3]thiazolo [3,2-
a]pyrimidine-6-carboxamide (AKS-234) - IR (cm-1): 3341 (N-H), 3056 (Ar-H), 2907 (-
CH3), 2823 (-CH2), 1681 (C=O), 1606 (C=C), 1142 (C-O); Mass (m/e): 399 (molecular 
ion peak), 384, 273 (base peak), 245, 127, 99; Anal cacld for C20H18ClN3O2S: C 60.07, H 
4.54, N 10.51, found: C 60.08, H 4.53, N 10.53.  
 
N-(4-chlorophenyl)-7-methyl-5-(4-methoxyphenyl)-2,3-dihydro-5H-[1,3]thiazolo 
[3,2-a]pyrimidine-6-carboxamide (AKS-235) - IR (cm-1): 3273 (N-H), 3051 (Ar-H), 
2924 (-CH3), 2868 (-CH2), 1662 (C=O), 1639 (C=C), 1107 (C-O); 1H NMR (DMSO d6) 
(δ ppm): 2.25 (3H, s), 2.93 (1H, m), 3.01 (1H, m), 3.23 (1H, m), 3.41 (1H, m), 3.46 (3H, 
s), 5.39 (1H, s), 7.23 (2H, m), 7.37 (3H, m), 7.53 (1H, t) (J=7.96), 7.76 (1H, d) (J=7.76), 
8.15 (1H, dd)(J=8.12, 2.16), 8.20 (1H, t) (J=2.11); 13C NMR (δ ppm):  14.73, 21.25, 
25.08, 50.39, 55.93, 107.86, 114.39, 114.61, 121.17, 121.24, 127.56, 128.97, 129.36, 
130.06, 131.88, 134.26, 145.00, 157.02, 159.43, 163.79, 165.78; Anal cacld for 
C21H20ClN3O2S: C 60.94, H 4.87, N 10.15, found: C 60.96, H 4.88, N 10.17.  
 
N-(4-chlorophenyl)-7-methyl-5-(2-chlorophenyl)-2,3-dihydro-5H-[1,3]thiazolo [3,2-
a]pyrimidine-6-carboxamide (AKS-236) - IR (cm-1): 3284 (N-H), 3012 (Ar-H), 2926 (-
CH3), 2878 (-CH2), 1674 (C=O), 1637 (C=C), 1112 (C-O); 1H NMR (DMSO d6) (δ ppm): 
2.21 (3H, s), 3.14 (1H, m, 3.25 (1H, m, 3.44 (1H, m, 3.61 (1H, m, 7.20-7.34 (8H, m); 
Anal cacld for C20H17Cl2N3OS: C 57.42, H 4.10, N 10.04, found: C 57.45, H 4.11, N 
10.07.  
 
N-(4-chlorophenyl)-8-methyl-6-(3-nitrophenyl)-3,4-dihydro-2H,6H-pyrimido[2,1-
b][1,3]thiazine-7-carboxamide (AKS-237) - IR (cm-1): 3230 (N-H), 3014 (Ar-H), 2988 
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(-CH3), 2816, 2719 (-CH2), 1692 (C=O), 1610 (C=C), 1179 (C-O); Anal cacld for 
C21H19ClN4O3S: C 56.95, H 4.32, N 12.65, found: C 56.98, H 4.31, N 12.67.  
 
N-(4-chlorophenyl)-8-methyl-6-(2-chlorophenyl)-3,4-dihydro-2H,6H-pyrimido [2,1-
b][1,3]thiazine-7-carboxamide (AKS-238) - IR (cm-1): 3341 (N-H), 3077 (Ar-H), 2945 
(-CH3), 2862 (-CH2), 1652 (C=O), 1616 (C=C), 1171 (C-O); Anal cacld for 
C21H19Cl2N3OS: C 58.34, H 4.43, N 9.72, found: C 58.35, H 4.45, N 9.75.  
 
N-(4-chlorophenyl)-8-methyl-6-(2-nitrophenyl)-3,4-dihydro-2H,6H-pyrimido[2,1-
b][1,3]thiazine-7-carboxamide (AKS-239) - IR (cm-1): 3292 (N-H), 3026 (Ar-H), 2941 
(-CH3), 2889, 2866 (-CH2), 1689 (C=O), 1643 (C=C), 1091 (C-O); Anal cacld for 
C21H19ClN4O3S: C 56.95, H 4.32, N 12.65, found: C 56.99, H 4.33, N 12.68.  
 
N-(4-chlorophenyl)-8-methyl-6-phenyl-3,4-dihydro-2H,6H-pyrimido[2,1-b][1,3] 
thiazine-7-carboxamide (AKS-240) - IR (cm-1): 3275 (N-H), 3020 (Ar-H), 2941 (-CH3), 
2872, 2820 (-CH2), 1678 (C=O), 1653, 1645 (C=C), 1089 (C-O); Mass (m/e): 397 
(molecular ion peak), 271 (base peak), 243, 167, 115, 100; Anal cacld for C21H20ClN3OS: 
C 63.39, H 5.07, N 10.56, found: C 63.44, H 5.10, N 10.60.  
 
N-(4-fluorophenyl)-5-(2-hydroxyphenyl)-7-methyl-2,3-dihydro-5H-[1,3]thiazolo [3,2-
a]pyrimidine-6-carboxamide (AKS-241) - IR (cm-1): 3522 (-OH), 3312 (N-H), 3079 
(Ar-H), 2935 (-CH3), 2888, 2845 (-CH2), 1659 (C=O), 1603 (C=C), 1129 (C-O); Anal 
cacld for C20H18FN3O2S: C 62.57, H 4.73, N 10.95, found: C 62.61, H 4.72, N 10.97.  
 
N-(4-fluorophenyl)-5-(4-dimethylaminophenyl)-7-methyl-2,3-dihydro-5H-[1,3] 
thiazolo[3,2-a]pyrimidine-6-carboxamide (AKS-242) - IR (cm-1): 3326 (N-H), 3055 
(Ar-H), 2947 (-CH3), 2824 (-CH2), 1680 (C=O), 1617 (C=C), 1178 (C-O); Mass (m/e): 
402 (molecular ion peak), 300, 272, 111, 86; Anal cacld for C22H23FN4OS: C 62.57, H 
4.73, N 10.95, found: C 62.61, H 4.72, N 10.97.  
 
N-(4-fluorophenyl)-5-(2-chlorophenyl)-7-methyl-2,3-dihydro-5H-[1,3]thiazolo [3,2-
a]pyrimidine-6-carboxamide (AKS-243) - IR (cm-1): 3346 (N-H), 3082 (Ar-H), 2967 (-
CH3), 2866 (-CH2), 1661 (C=O), 1650 (C=C), 1118 (C-O); Anal cacld for 
C20H17ClFN3OS: C 62.57, H 4.73, N 10.95, found: C 62.61, H 4.72, N 10.97.  
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N-(4-fluorophenyl)-5-(4-nitrophenyl)-7-methyl-2,3-dihydro-5H-[1,3]thiazolo[3,2-
a]pyrimidine-6-carboxamide (AKS-244) - IR (cm-1): 3389 (N-H), 3098 (Ar-H), 2971 (-
CH3), 2856 (-CH2), 1653 (C=O), 1602 (C=C), 1146 (C-O); Mass (m/e): 412 (molecular 
ion peak), 302 (base peak), 256, 243, 115, 86; Anal cacld for C21H20FN3O2S: C 62.57, H 
4.73, N 10.95, found: C 62.61, H 4.72, N 10.97.  
 
7-methyl-N-1-naphthyl-5-(2-methoxyphenyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-
a]pyrimidine-6-carboxamide (AKS-245) - IR (cm-1): 3146 (N-H), 3086 (Ar-H), 2924 (-
CH3), 2875 (-CH2), 1674 (C=O), 1651 (C=C), 1014 (C-O); Anal cacld for C25H23N3O2S: 
C 62.57, H 4.73, N 10.95, found: C 62.61, H 4.72, N 10.97.  
 
7-methyl-N-1-naphthyl-5-(4-dimethylaminophenyl)-2,3-dihydro-5H-[1,3]thiazolo 
[3,2-a]pyrimidine-6-carboxamide (AKS-246) - IR (cm-1): 3319 (N-H), 3056 (Ar-H), 
2918 (-CH3), 2814 (-CH2), 1670 (C=O), 1609 (C=C), 1136 (C-O); Anal cacld for 
C26H26N4OS: C 62.57, H 4.73, N 10.95, found: C 62.61, H 4.72, N 10.97.  
 
7-methyl-N-1-naphthyl-5-(2-chlorophenyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a] 
pyrimidine-6-carboxamide (AKS-247) - IR (cm-1): 3277 (N-H), 3032 (Ar-H), 2947 (-
CH3), 2877 (-CH2), 1681 (C=O), 1620 (C=C), 1116 (C-O); 1H NMR (DMSO d6) (δ ppm): 
2.36 (3H, s), 3.09 (1H, m), 3.22 (1H, m), 3.40 (1H, m), 3.72 (1H, m), 6.13 (1H, s), 7.16 
(1H, s), 7.37 (3H, m), 7.40 (4H, m), 7.64 (2H, dd, J=8.2, 2.1), 7.73 (1H, d, J=7.48), 7.80 
(1H, d, J=8.2); Anal cacld for C24H20ClN3OS: C 62.57, H 4.73, N 10.95, found: C 62.61, 
H 4.72, N 10.97.  
 
7-methyl-N-1-naphthyl-5-(2-hydroxyphenyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-
a]pyrimidine-6-carboxamide (AKS-248) - IR (cm-1): 3309 (N-H), 3055 (Ar-H), 2915 (-
CH3), 2811 (-CH2), 1668 (C=O), 1619 (C=C), 1128 (C-O); Anal cacld for C24H21N3O2S: 
C 62.57, H 4.73, N 10.95, found: C 62.61, H 4.72, N 10.97.  
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2.6.6.1   1H NMR spectrum of AKS- 231 
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2.6.6.2 1H NMR spectrum of AKS- 247 
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2.6.6.3 1H NMR spectrum of AKS-235 
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2.6.6.4 Mass spectrum of AKS- 240 
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2.6.6.5 Mass spectrum of AKS- 232 
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2.6.6.6 Mass spectrum of AKS- 234 
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2.6.6.7 Mass spectrum of AKS- 244 
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2.6.6.8 Mass spectrum of AKS- 242  
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2.6.6.9 IR spectrum of AKS-235 
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2.6.6.10 IR spectrum of AKS-236 
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2.6.6.11 IR spectrum of AKS-239 
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2.6.6.12 IR spectrum of AKS-240 
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2.6.6.13 IR spectrum of AKS-245 
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2.6.6.14 IR spectrum of AKS-247 
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2.6.6.15  13C NMR spectrum of AKS-235 
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3.1 Biginelli Reaction: problems associated with conventional 
methods  
 
First chapter deals with synthesis and characterization of DHPMs with N-phenyl 
substitution and second chapter covers synthesis of bicyclic systems derived from DHPM. 
Importance of Biginelli reaction is very well described and recent development on this 
more than hundred year old reaction is also briefly reviewed.  
 
The major limitations of Biginelli reaction are lower yield and longer reaction time. When 
thiourea is used for synthesis, yield obtained is very low and reaction completion takes 
longer time. Similar disadvantages are observed when different 1,3-diketone and 
aldehyde other than aromatic are used for the synthesis of designed molecules. Moreover, 
product separation and work up also cause problem and needed special techniques. Thus, 
three main disadvantages are lower yield, longer reaction time and work up in Biginelli 
reaction when different building blocks are used to synthesize library of compound.  
 
3.2 Microwave Assisted Organic Synthesis  
 
The use of microwave as energy source in organic synthesis for better yield and shorter 
reaction time has been extensively investigated1-6. Most of the early pioneering 
experiments in MAOS were performed in domestic, sometimes modified, kitchen 
microwave ovens; the current trend is to use dedicated instruments which have only 
become available in the last few years for chemical synthesis. The number of publications 
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related to MAOS has therefore increased dramatically since the late 1990s to a point 
where it might be assumed that, in a few years, most chemists will probably use 
microwave energy to heat chemical reactions on a laboratory scale. Not only is direct 
microwave heating able to reduce chemical reaction times from hours to minutes, but it is 
also known to reduce side reactions, increase yields, and improve reproducibility. 
Therefore, many academic and industrial research groups are already using MAOS as a 
forefront technology for rapid optimization of reactions, for the efficient synthesis of new 
chemical entities, and for discovering and probing new chemical reactivity. A large 
numbers of review articles provide extensive coverage of the subject7-12. 
 
Microwave-enhanced chemistry is based on the efficient heating of materials by 
“microwave dielectric heating” effects. This phenomenon is dependent on the ability of a 
specific material (solvent or reagent) to absorb microwave energy and convert it into heat. 
The electric component of an electromagnetic field causes heating by two main 
mechanisms: dipolar polarization and ionic conduction. Irradiation of the sample at 
microwave frequencies results in the dipoles or ions aligning in the applied electric field. 
As the applied field oscillates, the dipole or ion field attempts to realign itself with the 
alternating electric field and, in the process, energy is lost in the form of heat through 
molecular friction and dielectric loss. The amount of heat generated by this process is 
directly related to the ability of the matrix to align itself with the frequency of the applied 
field. If the dipole does not have enough time to realign, or reorients too quickly with the 
applied field, no heating occurs. The allocated frequency of 2.45 GHz used in all 
commercial systems lies between these two extremes and gives the molecular dipole time 
to align in the field, but not to follow the alternating field precisely13-14. 
 
The heating characteristics of a particular material (for example, a solvent) under 
microwave irradiation conditions are dependent on its dielectric properties. The ability of 
a specific substance to convert electromagnetic energy into heat at a given frequency and 
temperature is determined by the so-called loss factor tanδ. This loss factor is expressed 
as the quotient tanδ=e’’/e’, where e’’ is the dielectric loss, which is indicative of the 
efficiency with which electromagnetic radiation is converted into heat, and e’ is the 
dielectric constant describing the ability of molecules to be polarized by the electric field. 
A reaction medium with a high tanδ value is required for efficient absorption and, 
consequently, for rapid heating15. 
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3.2.1 Name reactions  
 
Following scheme shows an example of a standard Heck reaction involving aryl bromides 
and acrylic acid to furnish the corresponding cinnamic acids. Optimization of the reaction 
conditions under small-scale (2 mmol) single-mode microwave conditions led to a 
protocol that employed acetonitrile as the solvent, 1 mol% palladium acetae/p-tolyl 
phosphine as the catalyst system, and triethylamine as the base. The reaction time was 15 
minutes at a reaction temperature of 180ºC. 
 
NC
X
Br
COOH
NC
X
COOH
Pd(OAc)2/P(o-tolyl)3
NEt3, MeCN
MW, 180 C, 15 min
 
 
The Suzuki reaction (the palladium-catalyzed cross-coupling of aryl halides with boronic 
acids) is arguably one of the most versatile and at the same time also one of the most 
often used cross-coupling reactions in modern organic synthesis. Carrying out high-speed 
Suzuki reactions under controlled microwave conditions can be considered almost a 
routine synthetic procedure today, given the enormous literature precedent for this 
transformation. Recent examples include the use of the Suzuki protocol for the high-
speed modification of various heterocyclic scaffolds of pharmacological interest16-24.  
 
  
89
A significant advance in Suzuki chemistry has been the observation that Suzuki couplings 
can be readily carried out using water as the solvent in conjunction with microwave 
heating25-28.  
X
R1
(HO)2B
R2
Pd(OAc)2, TBAB, Na2CO3, H2O
MW, 150-175 C, 5 min
R1 R2  
General protocols for microwave-assisted Sonogashira reactions under controlled 
conditions were first reported in 2001 by ErdMlyi and Gogoll35-36. Many more examples 
can be cited for different name reaction.  
I
NH2
H SiMe3
[PdCl2(PPh3)2], CuI, DMF, Et3NH
MW, 120 C, 5 min
NH2
SMe3
KF.2H2O, MeOH, RT, 7 h
NH2
[PdCl2(PPh3)2], CuI, DMF, Et3NH
MW, 120 C, 5 min
I
COOMe
NH2
MeOOC
 
 
3.2.2  Heterocyclic systems  
 
Various heterocyclic systems can be synthesized in short time with high yield. 
Heterocyclic systems like dihydroquinolone, triazine, dihydropyridines and other bicyclic 
systems are reported in literature synthesized using microwave29-33. Few examples are 
shown below.  
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R1
NH2
O
R2
Sc(OTf)3, MeCN
MW, 140-50 C
    50-60 min
R1
N
H
R2
R2  
N
H
NH2
R1
R2 CHO
Sc(OTf)3, (bmim)Cl-AlCl3
MW, 100-20 C
    30-60 min N
H
NH
R1
R2
 
R1 O
OR2
HN R3
O
NH2
NH4OAc/AcOH
MW, 180 C, 5-10 min
N
N
NR1
R2 R3  
R1
O
H
O
COOR2
NH3, H2O
MW, 140-50 C
    10-15 min
N
H
COOR2R2OOC
R1
 
COOMeR1
R2
CN
G H2N
NH
R4
NaOMe/MeOH
MW, 100-140 C, 10 min
H
N
N
NO
R1
R2
R4
R3
G=CN, COOMe
R3=NH2, OH  
 
3.2.3  Rearrangements  
 
Ley and co-workers34 have described the microwave assisted Claisen rearrangement of 
allyl ether in their synthesis of the natural product carpanone. A 97% yield of the 
rearranged product could be obtained by three successive 15-minute irradiations at 220 
ºC. This is an example of microwave assisted reaction clubbed with ionic liquid.  
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O
O O
[bmim]PF5, toluene
MW, 220 C, 3*15 min
O
O OH
 
 
3.2.4  Cycloaddition reaction 
 
O
O H
O
O
O H
OH H
neat, MW, 165 C, 20 min
 
O
O
Ar
N R
O
O
neat, MW, 165-200 C, 30 min
O
N
O
H
Ar
H
H
O
O
R
 
Above scheme display microwave assisted diles alder reaction in neat condition without 
using any solvent. First process gave 97% yield in 20 min. in second process, 
diastereomers were obtained.37-38 
 
3.2.5 Oxidation  
 
The osmium-catalyzed dihydroxylation reaction, the addition of osmium tetroxide to 
olefins to produce a vicinal diol, is one of the most selective and reliable organic 
transformations. Recent work by Sharpless, Fokin, and coworkers39 has uncovered that 
electron-deficient olefins can be converted into the corresponding diols much more 
efficiently when the reaction medium is kept acidic. 
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F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
OH
OH
K2OsO2(OH)4, NMO, citric acid
t-BuOH/water
MW, 120 C, 150 min
 
 
3.2.6 Multicomponent Reaction  
 
The Mannich reaction has been known since the early 1900s and has since then been one 
of the most important transformations to produce β-amino ketones. Although the reaction 
is powerful, it suffers from some disadvantages, such as the need for drastic reaction 
conditions, long reaction times, and sometimes low yields of products. Luthman and 
coworkers40 have reported microwave-assisted Mannich reactions that employed 
paraformaldehyde as a source of formaldehyde, a secondary amine in the form of its 
hydrochloride salt, and a substituted acetophenone.  
H H
O
R1
N
R2
H
Ar
O
Ar
O
N
R2
R1
dioxane, MW, 180 C, 10 min
 
H R1
O
R3
N
R2
H
CuCl, dioxane, MW, 150 C, 6-10 min
R4 H
R1
R2R3
R4
N
N
PF6-
 
 
3.2.7 Nucleophilic Aromatic Substitution 
 
A number of publications report efficient nucleophilic aromatic substitutions driven by 
microwave heating involving either halogen substituted aromatic or heteroaromatic 
systems. Scheme given below summarizes some heteroaromatic systems and nucleophiles 
along with the reaction conditions that have been developed by Cherng for microwave-
assisted nucleophilic substitution reactions. In general, the microwave-driven processes 
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provide significantly higher yields of the desired products in much shorter reaction 
times41-45.  
Hetaryl - X Hetaryl - Nu
             nucleophile
neat or NMP, HMPA, DMPU
MW, 70-110 C, 1-20 min
N N N N
N
N
N
X
X
I
X Cl
N Cl N N
Br
Br
 
 
3.2.8 Solid Phase Organic Synthesis  
 
Solid-phase organic synthesis (SPOS) exhibits several advantages compared with 
classical protocols in solution. Reactions can be accelerated and driven to completion by 
using a large excess of reagents, as these can easily be removed by filtration and 
subsequent washing of the solid support. In addition, SPOS can easily be automated by 
using appropriate robotics and applied to “split-and-mix” strategies, useful for the 
synthesis of large combinatorial libraries46-47 
A study published in 2001 demonstrated that high temperature microwave heating (200 
8C) can be effectively employed to attach aromatic carboxylic acids to chloromethylated 
polystyrene resins (Merrifield and Wang) by the cesium carbonate method. Significant 
rate accelerations and higher loadings were observed when the microwave-assisted 
protocol was compared to the conventional thermal method. Reaction times were reduced 
from 12–48 hours with conventional heating at 80 ºC to 3–15 minutes with microwave 
heating at 200 ºC in NMP in open glass vessels48-49. 
O
Cl
O
O
O
R
R-COOH, Cs2CO3, NMP
MW, 200, 3-15 min
 
Kappe et al50 have reported microwave assisted synthesis of bicyclic systems derived 
from Biginelli DHPM derivatives.  
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OH
MeO
O
O
Cl
DCB
MW, 170 C, 15 min
O
O
O
Cl
R1-CHO, urea
dioxane, HCl
70 C, 18 h
N
H
NH
R1
O
O
O
ClNH
NH
R1
O
O
O
DMF, MW, 150 C, 10 min
N
H
NH
R1
O
N
O
R2
R2-NH2, DMF, 70 C, 18 h
DMF, MW, 150-200 C, 10 min
N
H
NH
R1
O
HN
N
O
R3
R3-NH-NH2, DMF, RT, 30 min DMF, MW, 150 C, 10 min
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3.3 Current work   
 
 
Work done earlier in our lab on 1,4-dihydropyridine and interesting results obtained for 
this structural class inspire to modify aza analogs of 1,4-dihydropyridine i.e. 
dihydropyrimidine. Earlier library of compounds was generated of dihydropyrimidine 
derivatives with phenyl carbamoyl moiety at C5 position. Moderate pharmacological 
profile obtained for this library. In continuation of work, it was planned to develop 
various modified compounds of this class.  
 
In earlier chapters, synthesis of dihydropyridine derivatives is reported with N-phenyl 
substitution and phenyl carbamoyl moiety at C5 position; and bicyclic systems with 
phenyl carbamoyl moiety at C5 position. In this chapter, phenyl ring at C4 position of 
classical dihydropyrimidine is replaced with aliphatic chain. The current chapter deals 
with an aliphatic aldehyde (butyraldehyde) as a substrate to obtain a dihydropyrimidine 
skeleton without phenyl or heteroaryl ring at C4. The aim of this work was to develop 
small library of novel DHPM compounds which give diversity from earlier ones. When 
the reactions carried out by conventional methods, very long reaction time (12-15 hours) 
and very low yield (10-12%) cause major problem in synthesizing series of compounds 
with 4-alkyl substitutions.  
 
To overcome these problems, microwave irradiation technique was utilized and higher 
yields (30-35%) within shorter reaction time (10-15 minutes) were obtained. Different 
solvent were used (methanol, ethanol, THF, acetonitrile, DMF) but methanol was found 
to be most suitable. The synthesized compounds were analyzed by IR, NMR and Mass 
spectral techniques. The physical data is given in Table 3.6.2.  
 
In another scheme, benzimidazole-2-thiol was reacted with dibromo alkanes under 
microwave irradiation to cyclize the ring fused to imidazole. In conventional method, the 
reaction time was observed 2.5-3 hours, while under microwave, the reaction completed 
within 4-7 minutes. The physical data of synthesized compounds are given in Table 3.6.2.   
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3.4 Reaction Schemes  
 
3.4.1 Scheme 1.  
 
 
 
 
 
 
 Scheme 1. Reagents and conditions: a = KOH/NaOH, toluene, 115° C. 
 
 
3.4.2 Scheme 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Reagents and conditions: b = MeOH, con. HCl, MW (200W), 90º C 
 
N
H
NH
O
O
N
H
R1
O
N
H
R1
O H2N
NH2
O
CHO
b
O
OC2H5
O HN
O O
NH2
R1
R1
a
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Reaction Mechanism 
O
H
H2N
NH2 H
H2O-
N
H
H2N
O
H
NH
O
O
H-
NNH
H2N
O
H
O
O
NNH
O
H
O
N
H
HO
H2O-
NNH
O
H
O
N
H
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3.4.3 Scheme 3.  
 
 
 
 
 
 
 
 
 
 
Scheme 3. Reagents and conditions: c = DMF, MW (200W), 150º C 
 
 
 
Reaction Mechanism  
 
 
N
H
N
S
Br
N
N
S
Br
H
..
N
H
N
S
Br
..
-HBr
-HBr
N
H
N
R SH
Br
Br
n N
N
R
S
n
c
  
99
 
 
3.5 Experimental  
 
 
3.5.1 Substituted acetoacetanilide: It was prepared as described in Section 1.7.2, 
Chapter 1.  
 
3.5.2 N-(substitutedphenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-4-propylpyrimidine 
-5-carboxamide: Substituted acetoacetanilide (0.01M), butyraldehye and urea were 
dissolved in methanol and few drops of HCl were added. The reaction mixture was 
irradiated with microwave (200W) at 80° C for 12-15 minutes. The completion of 
reaction was monitored by thin layer chromatography. The reaction mixture was allowed 
to stand at room temperature. The solid separated was filtered and recrystallized from 
dimethylformamide. (Physical data are given in Table 3.6.1)     
 
3.5.3 6-methoxy-2,3-dihydro[1,3]thiazolo[3,2-a]benzimidazole: 6-methoxy-1H-
benzimidazole-2-thiol and dibromo ethane were taken into dimethylformamide and 
irradiated with microwave (200W) at 150° C for 4-7 minutes. The completion of reaction 
was monitored with thin layer chromatography. It was extracted with chloroform. The 
solvent was evaporated and solid was dried and crystallized from dimethylformamide. 
(Physical data are given in Table 3.6.2)     
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3. 6  Physical data tables  
 
 
3.6.1 Physical data of N-(substitutedphenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-4-
propylpyrimidine -5-carboxamide [compounds 2a-o] 
 
 
 
N
H
NH
O
N
H
O
R
 
 
 
Compound Code  R MF MW Yield Mp Rf 
2a AKS-321 H C15H19N3O2 273.26 32 170-71 0.41 
2b AKS-322 4-Cl C15H18ClN3O2 307.77 36 185-86 0.53 
2c AKS-323 4-F C15H18FN3O2 291.24 30 210-11 0.55 
2d AKS-324 3-Cl,4-F C15H17ClFN3O2 325.76 28 168-69 0.47 
2e AKS-325 4-Me C16H21N3O2 287.35 33 177-79 0.61 
 101 
2f AKS-326 2,3-benzo C19H21N3O2 323.38 35 160-63 0.58 
2g AKS-327 2-Cl C15H18ClN3O2 307.77 36 201-03 0.44 
2h AKS-328 4-NO2 C15H18N4O4 318.32 29 213-14 0.50 
2i AKS-329 3-Me C16H21N3O2 287.35 32 188-90 0.59 
2j AKS-330 3,4-di-Me C17H23N3O2 301.45 34 196-98 0.63 
2k AKS-331 2-Me C16H21N3O2 287.35 36 205-08 0.58 
2l AKS-332 2,4-di-Me C17H23N3O2 301.45 34 175-77 0.52 
2m AKS-333 2,5-di-Me C17H23N3O2 301.45 33 182-83 0.46 
2n AKS-334 3-NO2 C15H18N4O4 318.32 26 210-12 0.40 
2o AKS-335 2-CF3 C18H18F3N3O2 341.32 32 200-02 0.61 
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3.6.2 Physical data [compounds 3a-f] 
 
 
N
N
R
S
n  
 
Compound Code  R n  MF MW Yield Mp Rf 
3a AKS-341 H 1 C9H8N2S 176.23 62 177-79 0.46 
3b AKS-342 H 2 C10H10N2S 190.26 68 182-85 0.50 
3c AKS-343 H 3 C11H12N2S 204.29 70 180-83 0.47 
3d AKS-344 6-OMe 1 C10H10N2OS 206.26 65 190-191 0.52 
3e AKS-345 6-OMe 2 C11H12N2OS 220.29 70 205-07 0.58 
3f AKS-346 6-OMe 3 C12H14N2OS 234.31 70 196-98 0.55 
 
 
TLC solvent system:  Compound 2a-o (EA:Hexane) 4:6    MPs were taken in open capillary and are not corrected 
   Compound 3a-f (CHCl3:MeOH ) 0.5:9.5 
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3.7 Spectral discussion  
 
 
 
3.7.1  Mass spectral study 
 
Molecular ion peak was obtained in agreement of molecular weight of the molecules. 
Specific fragmentation pattern was observed. For example, in mass spectrum of AKS-
322, following characteristic peaks were obtained. Similar pattern was observed in other 
Mass spectra also.  
[1] M+ 2  peak was obtained at 309 m/e because of chlorine atom.  
[2] Molecular ion peak was obtained at 307 m/e.  
[3] Cleavage of alkyl chain at C-4 position gave peak at 264 m/e. [M- (CH2-CH2-CH3)].  
[4] Cleavage of α-bond of carbonyl gave base peak at 181 m/e.  
[5] Cleavage of other α-bond of carbonyl gave peak at 153 m/e.  
 
3.7.2  IR spectral study 
 
In IR spectrums, characteristic frequencies were observed for functional group present in 
the molecule. N-H groups are present in DHPM derivatives and characteristic frequencies 
were observed at 3320-3450 cm-1. Alkyl chain gave characteristic methyl and methylene 
frequencies. Two carbonyl groups were distinctly observed. Cyclic carbonyl group gave 
peak at 1680-1710 cm-1, while amide carbonyl group gave peak at lower value (1650-
1690 cm-1). Aromatic protons were also identified in specific frequency region for 
aromatic C-H stretching, aromatic C=C and out of plane bending vibrations.  
  
3.7.3  1H NMR spectral study 
 
Number of protons and their chemical shifts were found to support the structure of the 
synthesized compounds. In NMR spectrum of AKS-245, -CH2- protons were obtained as 
multiplet between 2.45-4.14 δ ppm. Methoxy protons were identified at 3.84 δ ppm. 
Three aromatic protons gave two doublets and one double doublet and it can be 1,2,4-
trisubstituted aromatic ring signal pattern. Proton on C3 position gave doublet with J value 
for meta coupling while, proton on C6 gave doublet with J value for ortho coupling. A 
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double doublet was observed for proton on C5 and because of coupling with ortho and 
meta protons, respective J values were obtained.  
 
Similar pattern was observed in NMR spectrum of AKS-244. Four protons of two –CH2- 
group were identified to give two multiplets. Signal at 3.83 can be assigned to methoxy 
protons. Three aromatic protons, similar to 1,2,4-trisubstituted aromatic ring, gave two 
doublets and a double doublet as observed in AKS-245. 
 
In NMR spectrum of AKS-334, protons of methyl group at C6 position gave signal at 
1.98, while protons of methyl group of aliphatic chain on C4 atom observed at 1.74. 
Protons of two –CH2- groups gave two multiplets at 2.50 and 3.13 ppm. Four aromatic 
protons (similar to 1,3-substituted aromatic ring) were observed between 6.78 to 7.38 
ppm. [i] C2 proton gave doublet with J value of 2.32 (meta coupling), [ii] C4 proton 
observed as double doublet with J value of 2.44, 8.56 (ortho & meta coupling), [iii] C5 
proton gave doublet with J value of 8.72 (ortho coupling), [iv] C6 proton also gave 
doublet with J value of 8.92 (ortho coupling).      
    
3.7.4  Elemental analysis 
 
Elemental analysis of synthesized compounds was in agreement with calculated values of 
composition of carbon, hydrogen and nitrogen. Spectral data and elemental analysis data 
are given below for individual compounds.  
 
Spectral data of synthesized compounds (AKS 321-335, AKS 341-46) 
 
6-Methyl-2-oxo-N-phenyl-4-propyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide 
(AKS-321) – IR (cm-1): 3315, 3227 (N-H), 3070 (Ar-H), 3039, 2924 (alkane), 1701, 1662 
(C=O), 1529, 1492, 1475 (C=C), 1313 (C-N), 1080 (C-O), 790 (OOP); Anal cacld for 
C15H19N3O2: C 68.19, H 6.99, N 14.73, found: C 68.24, H 7.04, N 14.81. 
 
N-(4-Chlorophenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-322) - IR (cm-1): 3370, 3283 (N-H), 3065 (Ar-H), 2974, 2856 
(alkane), 1708, 1671 (C=O), 1520, 1476, 1423 (C=C), 1294 (C-N), 1123 (C-O), 807 
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(OOP); Mass (m/e):309 (M+2), 307 (molecular ion peak), 264, 181 (base peak), 153, 127, 
110, 84, 68; Anal cacld for C15H18ClN3O2: C 63.58, H 6.32, N 13.73, found: C 63.62, H 
6.35, N 13.78. 
 
N-(4-Flourophenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-323) - IR (cm-1): 3417, 3218 (N-H), 3055 (Ar-H), 2968, 2843 
(alkane), 1692, 1654 (C=O), 1553, 1447, 1417 (C=C), 1297 (C-N), 1079 (C-O), 756 
(OOP); Mass (m/e): 291 (molecular ion peak), 248, 214, 183, 170, 141, 116, 91 (base 
peak), 77, 65; Anal cacld for C15H18FN3O2: C 65.70, H 6.53, N 14.19, found: C 65.76, H 
6.55, N 14.25. 
 
N-(3-Chloro-4-flourophenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-
5-carboxamide (AKS-324) – IR (cm-1): 3408, 3316 (N-H), 3028 (Ar-H), 2966, 2811 
(alkane), 1688, 1659 (C=O), 1577, 1450, 1423 (C=C), 1278 (C-N), 1069 (C-O), 827 
(OOP); Anal cacld for C15H17ClFN3O2: C 61.42, H 5.92, N 13.26, found: C 61.48, H 
5.97, N 13.33. 
 
6-Methyl-N-(4-methylphenyl)-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-325) - IR (cm-1): 3339, 3286 (N-H), 3081 (Ar-H), 2949, 2851 
(alkane), 1711, 1663 (C=O), 1517, 1471, 1410 (C=C), 1302 (C-N), 1147 (C-O), 745 
(OOP); Anal cacld for C16H21N3O2: C 68.69, H 7.21, N 14.30, found: C 68.74, H 7.23, N 
14.38. 
 
6-Methyl-N-(1-naphthyl)-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-326) – IR (cm-1): 3421, 3292 (N-H), 3018 (Ar-H), 2977, 2847 
(alkane), 1690, 1668 (C=O), 1521, 1448, 1413 (C=C), 1311 (C-N), 1059 (C-O), 841 
(OOP); Anal cacld for C19H21N3O2: C 70.83, H 6.71, N 13.32, found: C 70.90, H 6.76, N 
13.41. 
 
N-(2-Chlorophenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-327) - IR (cm-1): 3362, 3271 (N-H), 3058 (Ar-H), 2945, 2806 
(alkane), 1706, 1671 (C=O), 1586, 1480, 1422 (C=C), 1276 (C-N), 1172 (C-O), 757 
(OOP); Anal cacld for C15H18ClN3O2: C 63.58, H 6.32, N 13.73, found: C 63.64, H 6.36, 
N 13.79. 
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N-(4-Nitrophenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-328) - IR (cm-1): 3310, 3277 (N-H), 3082 (Ar-H), 2924, 2891 
(alkane), 1700, 1656 (C=O), 1545, 1473, 1429 (C=C), 1288 (C-N), 1055 (C-O), 811 
(OOP); Anal cacld for C15H18N4O4: C 62.29, H 6.20, N 16.14, found: C 62.36, H 6.26, N 
16.27. 
 
6-Methyl-N-(3-methylphenyl)-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-329) - IR (cm-1): 3369, 3296 (N-H), 3061 (Ar-H), 2916, 2817 
(alkane), 1685, 1666 (C=O), 1599, 1539, 1491 (C=C), 1317 (C-N), 1087 (C-O), 860 
(OOP); Mass (m/e): 302 (molecular ion peak), 258, 208, 181 (base peak), 153, 121, 105, 
84, 68; Anal cacld for C16H21N3O2: C 68.69, H 7.21, N 14.30, found: C 68.76, H 7.25, N 
14.37. 
 
6-Methyl-N-(3,4-dimethylphenyl)-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-330) - IR (cm-1): 3310, 3221 (N-H), 3057 (Ar-H), 2944, 2870 
(alkane), 1688, 1672 (C=O), 1543, 1485, 1411 (C=C), 1330 (C-N), 1140 (C-O), 795 
(OOP); Anal cacld for C17H23N3O2: C 69.16, H 7.40, N 13.91, found: C 69.20, H 7.46, N 
14.02. 
 
6-Methyl-N-(2-methylphenyl)-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-331) - IR (cm-1): 3330, 3274 (N-H), 3098 (Ar-H), 2905, 2864 
(alkane), 1704, 1680 (C=O), 1590, 1523, 1470 (C=C), 1329 (C-N), 1146 (C-O), 831 
(OOP); Anal cacld for C16H21N3O2: C 68.69, H 7.21, N 14.30, found: C 68.73, H 7.23, N 
14.41. 
 
6-Methyl-N-(2,4-dimethylphenyl)-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-332) - IR (cm-1): 3431, 3323 (N-H), 3107 (Ar-H), 2981, 2904 
(alkane), 1712, 1675 (C=O), 1521, 1473, 1440 (C=C), 1295 (C-N), 1127 (C-O), 740 
(OOP); Anal cacld for C17H23N3O2: C 69.16, H 7.40, N 13.91, found: C 69.22, H 7.44, N 
14.00. 
 
6-Methyl-N-(2,5-dimethylphenyl)-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-333) - IR (cm-1): 3300, 3211 (N-H), 3080 (Ar-H), 2966, 2811 
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(alkane), 1698, 1664 (C=O), 1498, 1453 (C=C), 1258 (C-N), 1071 (C-O), 817 (OOP); 
Anal cacld for C17H23N3O2: C 69.16, H 7.40, N 13.91, found: C 69.24, H 7.47, N 13.98. 
 
N-(3-Nitrophenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-334) - IR (cm-1): 3327, 3217 (N-H), 3045 (Ar-H), 2961, 2854 
(alkane), 1709, 1668 (C=O), 1540, 1479, 1420 (C=C), 1281 (C-N), 1156 (C-O), 719 
(OOP); 1H NMR (CDCl3 ) (δ ppm): 1.75 (3H, m), 1.98 (3H, s), 2.50 (2H, m), 3.14 (2H, 
m), 5.75 (1H, t), 6.79 (1H, dd, J=2.44, 8.56), 7.01 (1H, d, J=2.32), 7.18 (1H, d, J=8.72), 
7.38 (1H, d, J=8.92), 8.25 (1H, s), 8.51 (1H, s), 9.03 (1H, s); Anal cacld for C15H18N4O4: 
C 62.29, H 6.20, N 16.14, found: C 62.33, H 6.24, N 16.24. 
 
N-(2-Trifluorophenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-335) - IR (cm-1): 3429, 3310 (N-H), 3074 (Ar-H), 2945, 2875 
(alkane), 1688, 1563 (C=O), 1515, 1497, 1406 (C=C), 1276 (C-N), 1082 (C-O), 852 
(OOP); Anal cacld for C18H18F3N3O2: C 61.87, H 5.93, N 12.88, found: C 61.93, H 6.02, 
N 12.97. 
 
2,3-dihydro[1,3]thiazolo[3,2-a]benzimidazole (AKS-341) - IR (cm-1): 3007 (Ar-H), 
2981, 2943, 2743 (alkane), 1597, 1506, 1476, 1420 (C=C), 1325 (C-N), 784 (OOP); Anal 
cacld for C9H8N2S: C 61.34, H 4.58, N 15.90, found: C 61.41, H 4.56, N 16.03. 
 
3,4-dihydro-2H-[1,3]thiazino[3,2-a]benzimidazole (AKS-342) - IR (cm-1): 3088 (Ar-
H), 2926, 2855, 2817, 2756 (alkane), 1546, 1503, 1436 (C=C), 1315 (C-N), 801 (OOP); 
Anal cacld for C10H10N2S: C 63.13, H 5.30, N 14.72, found: C 63.17, H 5.36, N 14.83.  
 
2,3,4,5-tetrahydro[1,3]thiazepino[3,2-a]benzimidazole (AKS-343) - IR (cm-1): 3024 
(Ar-H), 2930, 2856, 2830 (alkane), 1543, 1478, 1428  (C=C), 1305 (C-N), 749 (OOP); 
Anal cacld for C11H12N2S: C 64.67, H 5.92, N 13.71, found: C 64.74, H 5.89, N 13.84. 
 
6-methoxy-2,3-dihydro[1,3]thiazolo[3,2-a]benzimidazole (AKS-344) - IR (cm-1): 3055 
(Ar-H), 2969, 2947, 2850 (alkane), 1604, 1583, 1531, 1494 (C=C), 1348 (C-N), 748 
(OOP); 1H NMR (CDCl3 d6) (δ ppm): 3.18 (2H, m), 3.83 (3H, s), 4.10 (2H, m), 6.79 (1H, 
dd, J=2.37, 8.73), 7.06 (1H, d, J=8.72), 7.11 (1H, d, J=2.36); Anal cacld for C10H10N2OS: 
C 58.23, H 4.89, N 13.58, found: C 58.18, H 4.93, N 13.69. 
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7-methoxy-3,4-dihydro-2H-[1,3]thiazino[3,2-a]benzimidazole (AKS-345) - IR (cm-1): 
3060 (Ar-H), 2944, 2908, 2859, 2811 (alkane), 1589, 1547, 1486, 1453 (C=C), 1330 (C-
N), 711 (OOP); 1H NMR (CDCl3 d6) (δ ppm): 2.45 (2H, m), 3.20 (2H, m), 3.84 (3H, s), 
4.14 (2H, m), 6.82 (1H, dd, J=2.26, 8.67), 7.09 (1H, d, J=8.68), 7.12 (1H, d, J=2.32); 
Anal cacld for C11H12N2OS: C 59.97, H 5.49, N 12.72, found: C 0.07, H 5.53, N 12.76. 
 
8-methoxy-2,3,4,5-tetrahydro[1,3]thiazepino[3,2-a]benzimidazole (AKS-346) - IR 
(cm-1): 3018 (Ar-H), 2928, 2843, 2769 (alkane), 1537, 1491, 1458 (C=C), 1309 (C-N), 
792 (OOP); Mass (m/e): 220 (molecular ion peak, base peak), 205, 192, 177, 149, 133, 
128, 86, 72; Anal cacld for C12H14N2OS: C 61.51, H 6.02, N 11.96, found: C 61.58, H 
5.98, N 12.07. 
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3.7.5.1   IR spectrum of AKS- 321 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.7.5.2   IR spectrum of AKS- 328 
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3.7.5.3   IR spectrum of AKS- 344 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.7.5.4   IR spectrum of AKS- 346 
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3.7.5.5  Mass spectrum of AKS- 322 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
3.7.5.6  Mass spectrum of AKS- 345 
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3.7.5.7  Mass spectrum of AKS- 330 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.7.5.8  Mass spectrum of AKS- 323 
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3.7.5.9  1H NMR spectrum of AKS- 345 
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3.7.5.10  1H NMR spectrum of AKS- 344 
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3.7.5.11  1H NMR spectrum of AKS- 334 
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4.1 Biological profile of 1,4-dihydropyridine 
 
Dihydropyridine (DHP) chemistry began in 1882 when Hantzch1,2 published the 
synthesis. In its simplest form of the synthesis involves heating an aldehyde 1,3-diketone 
and ammonia. The reaction almost certainly involves aldol condensation to form the 
benzylidene derivative as the first step. Conjugated addition of a second mole of 1,3-
diketone would then afford the 1,5-diketone. Reaction of the carbonyl group with 
ammonia will lead to the formation of the dihydropyridine ring. 
 
The DHP nucleus is common to numerous bioactive compounds which include various 
vasodilator, antihypertensive, bronchodilator, antiatherosclerotic, hepatoprotective, 
antitumor, antimutagenic, geroprotective, and antidiabetic agents3-8. 
  
DHPs have found commercial utility as calcium channel blockers, as exemplified by 
therapeutic agents such as Nifedipine9, Nitrendipine10 and Nimodipine11. Second-
generation calcium antagonists include DHP derivatives with improved bioavailability, 
tissue selectivity, and/or stability,such as the antihypertensive/antianginal drugs like 
Elgodipine12, Furnidipine13,14, Darodipine15, Pranidipine16, Lemildipine17, 
Dexniguldipine18, Lacidipine19, and Benidipine20. Number of DHP calcium agonists has 
been introduced as potential drug candidates for treatment of congestive heart failure21, 22. 
 
The key characteristic of calcium channel blockers is their inhibition of entry of calcium 
ions via a subset of channels, thereby leading to impairment of contraction. There are 
three main groups of calcium channel blockers, i.e. dihydropyridines, phenylalkylamines 
and benzothiazepines, typical examples of which are nifedipine, verapamil and diltiazem, 
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respectively23-26. Each has a specific receptor on the calcium channel and a different 
profile of pharmacological activity. Dihydropyridines have a less negative inotropic effect 
than phenylalkylamines and benzothiazepines but can sometimes cause reflex 
tachycardia. Dihydropyridines are able to reduce peripheral resistance, generally without 
clinically significant cardiodepression. 
 
Among DHPs with other types of bioactivity, Cerebrocrast27 has been recently introduced 
as a neuroprotectant and cognition enhancer lacking neuronal-specific calcium antagonist 
properties. In addition, a number of DHPs with platelet antiaggregatory activity have also 
been discovered28. These recent examples highlight the level of ongoing interest toward 
new DHP derivatives and have prompted us to explore this pharmacophoric scaffold to 
develope a fertile source of bioactive molecules. 
   
1,4- DHPs possess different pharmacological activities such as antitumor29, vasodilator30, 
coronary vasodilator and cardiopathic31, antimayocardiac ischemic, antiulcer32, 
antiallergic33, antiinflammatory34 and antiarrhythmic35, PAF antagonist36, Adenosine A3 
receptor antagonist37 and MDR reversal activity38,39. 
 
In particular, DHP-CA (calcium channel antagonist DHP) are extensively used for the 
treatment of hypertension,40 subarachnoid hemorrhage,41,42 myocardial infarction43-46 and 
stable47,48 and unstable angina49,50 even though recently their therapeutic efficacy in 
myocardial infarction and angina has been questioned51. This class of compounds is also 
under clinical evaluation for the treatment of heart failure52, ischemic brain damage53 
nephropathies, and atherosclerosis54. 
 
1,4-Dihydropyridines are now established as heterocycles having numerous applications 
and having widened scope for its pronounced drug activity like calcium channel 
antagonism and antihypertensive action. Many other cardiovascular activities are 
associated with such compounds and they can be presented in the structure as 2,6-
dimethyl-3,5-diacetyl or dicarboxylate or dicarbamoyl or many other homoaryl or 
heteroaryl carbon chain having C2 to C8 1,4-dihydropyridines substituted at 4-position. 
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Some representative Ca2+ andtagonists of Dihydropyridine class are as shown below: 
N
H
NO 2
COOCH 3H3COOC
CH3CH3
Nifedipine
N
H
H3COOC
CH3CH3
NO 2
O
O
N
CH3
Nicamcipine
Amlodipine
N
H
COOC 2H5H3COOC
CH3
Cl
O
NH2
 
 
A starting revelation is found recently in which the imidazolyl moiety is linked to the 
phenyl ring by means of a methylene bridge, the activity tends to decrease. Finally, the 
replacement of DHP itself by a pyridine ring gives an inactive compound 56. 
N
H
N
N
OO
CH3CH3
CH3
CH3
H
N
N
N
OO
CH3CH3
CH3
CH3
 
 
Cozzy and coworkers56 have synthesized a series of 4-phenyl-1,4-dihydropyridines 
bearing imidazol-1-yl or pyridine-3-yl moieties on the phenyl ring, with the aim of 
combining Ca2+ antagonism and thermboxane A2(TxA2) synthase inhibition in the same 
molecules. Some of the compounds showed significant combined activity in vitro, while 
other showed single activity. As far as Ca2+ antagonism is concerned, two points deserve 
comment. First, the SAR, in most cases, does not differ substantially from that reported 
for classic DHP-CA, even though the potency is lower than that found with the most 
potent drugs of this class as, for example, reference compound nifedipine. In fact, Ca2+ 
antagonism is dramatically reduced by (a) replacement of DHP by a pyridine ring, (b)    
substitution of DHP nitrogen N-1 by a methyl group, (c) para substitution on the phenyl 
ring, and (d) replacement of one ester function by a ketone or carboxy group. All these 
variations are also detrimental in classic DHP-CA.57  
 
Hernandez-Gallegos and coworkers58 have synthesized new 1,4-dihydropyridines and 
evaluated their relaxant ability (rat aorta), antihypertensive activity in spontaneously 
hypertensive rats and their microsomal oxidation rate (MOR) was determined. 
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N
H
R2 - OOC
H
COO-R1
CH3 CH3
 
R = 3-NO2, 4-F, 3,5-di-F, 3-Br-4-F.
R1 = R2= Me, Et, -CH2-CF3, -CH2CH2-OPh, -(CH2)2-N(CH3)-CH3-Ph  
Christiaans and Timmerman59 studied new molecules like CV-159 for possible variation 
at 3-position. 
N
H
CH3 CH3
CH3
NO2
O N
N
N
CH3
 
Carlos et al60 reported 1,4-DHPs derivatives with a 1,2-benzothiazol-3-one-1-sulphoxide 
group, linked through an alkylene bridge to the C3 carboxylate of the DHP ring, with both 
vasoconstricting and vasorelaxant properties were obtained. In blocking Ca2+ evoked 
contractions of K+ depolarized rabbit aortic strips. Many compounds were 10 times more 
potent than nifedipine. Their vascular versus cardiac selectivity was very pronounced. 
O
N
H
CH3 CH3
OH OH
OO
S
N
O
O
O
CH3
 
Schramm and coworker61 have proved that phenyl carbamoyl moiety in dihydorpyridine 
affords for cardiovascular selective activity. 
N
H
O O
O NNH
Cl
CH3 CH3
 
Similarly Kelvin Cooper (Pfitzer , USA) et al62 found that DHP can be highly selective as 
platlet activating factor (PAF) antagonist. They found potent compounds and prove that 
platlet aggregating activity (PAF) exhibits a wide spectrum of biological activities elicited 
either directly or via the release of other powerful mediator such as Thromboxane A2 or 
the Leukotrienes. In vitro PAF stimulates the movement and aggregation and the release 
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there from of tissue damaging enzymes and oxygen radicals. Accordingly compounds like 
UK-74505, antagonize the action of PAF and consequently also prevent mediator release 
by PAF, will have clinical utilities in the treatment of the variety of the allergic, 
inflammatory and hypersecretory conditions such as asthama, arthritis, rhinitis, bronchitis 
and utricaria63 in future.   
N
H
O O
N
CH3
Z
R1
R2
Y
X
N
H
CH3
COOC 2H5
O
NH
N N
N
CH3
 
Reddy and coworkers64 synthesized 4-aryl hetroaryl-2,6-dimethyl-3,5-bis-N-(2-methyl 
phenyl)carbamoyl-1,4-dihydropyridines through one-pot synthesis using appropriate 
aromatic aldehydes and liquid ammonia. Pharmacological screening of the new 1,4-
dihyropyridines were also carried out for CNS depresant (anticonvulsant and analgesic) 
and cardiovascular (inotropic and blood pressure) activities by standard methods. 
N
H
CH3 CH3
O O
NH NH
CH3 CH3
R
 
Neamati and coworkers44 reported that a 1,4-dihydorpyridine NCS-372643 came out with 
its anti-HIV activity, which has opened up the synthetic as well as pharmacological 
importance in antiviral area also. 
N
H
CH3 CH3
O O
NH NH
OH
OH
OH
OH
NO 2
 
Sonja66 and group have synthesized a new series of calcium channel agonists structurally 
related to Bay K8644, containing NO donor furoxans and the related furazans unable to 
release NO. The racemic mixtures were studied for their action on L-type Ca2+ channels 
expressed in cultured rat insulinoma RINm5F cells. All the products proved to be potent 
calcium channel agonists 
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Recent reports show that efonidipine, a dihydropyridine Ca2+ antagonist, has blocking 
action on T-type Ca channels, which may produce favorable actions on cardiovascular 
systems. However, the effects of other dihydropyridine Ca antagonists on T-type Ca 
channels have not been investigated yet. Therefore, Furukawa and group67 have examined 
the effects of dihydropyridine compounds clinically used for treatment of hypertension on 
a T-type Ca channel subtype, alpha1G, expressed in    Xenopus oocytes. Twelve DHPs 
(amlodipine, barnidipine, benidipine, cilnidipine, efonidipine, felodipine, manidipine, 
nicardipine, nifedipine, nilvadipine, nimodipine, nitrendipine) and mibefradil were tested. 
Cilnidipine, felodipine, nifedipine, nilvadipine, minodipine, and nitrendipine had little 
effect on the T-type channel. The blocks by drugs at 10 muM were less than 10% at a 
holding potential of -100 mV. The remaining 6 drugs had blocking action on the T-type 
channel comparable to that on the L-type channel. These results show that many 
dihydropyridine Ca2+ antagonists have blocking action on the alpha1G channel subtype. 
 
Labedipinedilol-A, a novel dihydropyridine-type calcium antagonist, has been shown to 
induce hypotension and vasorelaxation. Liou68 and co-workers have studied to investigate 
the effect of labedipinedilol-A on vascular function of rat aortic rings and cultured human 
umbilical vein endothelial cells (HUVECs).  
 
2-Heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters, 
which lack  the potential C3 symmetry of dihydropyridine calcium channel blockers, were  
evaluated for biological  activity. Biological assays using potassium-depolarized rabbit 
aorta and radioligand binding techniques showed that some of these compounds are 
potent mimics of dihydropyridine calcium channel blockers. The combination of a 
branched ester (e.g. isopropyl, sec-butyl) and an alkylthio group (e.g. SMe) was found to 
be optimal for biological activity69.  
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4.2 Current work   
 
 
In last few years, 1,4-dihydropyridine skeleton is extensively modified in our laboratory 
and very interesting results are obtained with these modification to various positions of 
1,4-dihydropyridine skeleton and can be discussed as below.  
 
3,5-dibenzoyl-1,4-dihydropyridines (BzDHPs) substituted at 4-phenyl ring were 
synthesized and compared for their cytotoxic activity and multidrug resistance reversing 
activity in in vitro assay systems. Among fifteen BzDHPs, 2-trifluoromethyl, 2-chloro 
and 3-chloro derivatives showed the highest cytotoxic activity70.  
N
H
OO
CH3 CH3
R
 
R = 2-CF3, 3-CF3, 4-CF3, 2-Cl, 3-Cl, 4-Cl, 2-NO2, 3-NO2, 3-OPh etc. 
 
3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydropyridine-2,6-dimethylpyridine, a BzDHP 
derivative as mdr inhibitor,  was investigated for cardiac effects in Langendorff-perfused 
rat heart and compared with nifedipine. It was found that this molecule represent a lead 
for development of potent DHP mdr chemosensitizers devoid of cardiac effect71.  
 
Dibenzoyl-DHPs, tested for their mdr reversing activity, were found to show one or two 
orders higher tumor-specific cytotoxic activity against human tumor cell lines than human 
normal cells72.  
 
Dihydropyridine derivatives with phenyl carbamoyl side chain on 3 and 5 positions were 
synthesized and evaluated for their anti-tubercular activity. The results of anti-tubercular 
activity for dicarbamoyl derivatives were studied for 2D QSAR. The study indicates the 
presence of bulkier group on 4-phenyl ring contributes for the activity. The electronic 
influence of substituents at carbamoyl phenyl ring is important for activity73.  
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To find out structural requirement of dicarbamoyl DHPs for anti tubercular activity, 
CoMFA and CoMSIA methods were applied on a set of 33 dicarbamoyl derivatives. The 
QSAR models reveal the importance of spatial properties and conformational flexibility 
of side chains for anti tubercular activity74.  
N
H
OO
NHNH
CH3 CH3
R2
R3
R4
R5
R
R1
R
R1
H
*
*
**
*
*
 
Dihydropyridines with N-phenyl substitution were synthesized and tested for tumor 
specific cytotoxicity and mdr reversal activity to find out the effects of N-phenyl 
substitution on activity. Asymmetric BzDHPs with different substitution on benzoyl 
aromatic ring were synthesized and evaluated for tumor specific cytotoxicity. In 
continuation, dihydropyridines with phenyl carbamoyl side chain on one arm and –CN, -
COOEt, -COOMe side chain on other arm were also synthesized and evaluated as mdr 
reversal dihydropyridines75.  
R
N
H
O
CH3 CH3
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H
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CH3 CH3
R1
R
N CH3CH3
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OO
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R1
R2
 
in continuation of skeleton modification, dihydropyridines with heterocyclic systems on 
side chain were synthesized and evaluated for anti tubercular activity. These derivatives 
showed moderate activity and it was found that aromatic heterocyclic systems on side 
chain do not enhance anti tubercular activity76.   
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In continuation of work on dihydropyridine skeleton modification, this chapter reports 
synthesis of symmetrical 1,4-DHPs with naphthyl ring at C3 and C5 positions of DHP; 
and asymmetrical derivatives with different substituted phenyl carbamoyl side chain. The 
reaction schemes for synthesis of compounds are given in Section 4.3. The synthesized 
compounds and their physical data along with Mp and Rf values are given in Section 4.5. 
The spectral data are discussed in Section 4.6. 
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4.3 Reaction Schemes  
 
4.3.1 Scheme 1 
 
 
 
 
 
 
 
 Scheme 1. Reagents and conditions: a = KOH/NaOH, toluene, 115° C. 
 
 
4.3.2 Scheme 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Reagents and conditions: b = MeOH, reflux. 
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 4.3.3 Scheme 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Reagents and conditions: c = IPA, piperidine, reflux  
 
4.3.4  Scheme 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4. Reagents and conditions: d = NH3, MeOH, stirring, 90° C 
 
 
H
N
O
O
OHC
R
O
R
N
H
O
c
O
R
N
H
O
d
H
NO
O R1
N
H
N
H
O R
N
H
O
R1
  
131
4.3.5  Scheme 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5. Reagents and conditions: e = NH3, MeOH, stirring, 90° C 
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Reaction Mechanism  
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4.4 Experimental  
 
 
4.4.1  Substituted acetoacetanilide 
Substituted aniline (0.1M) and ethyl aceto acetate was refluxed at 110° C in 40 ml of 
toluene and catalytic amount of KOH/NaOH. The completion of reaction was monitored 
with TLC. After completion of reaction, toluene was distilled out. The residue was cooled 
at room temperature and was treated with ether. The solid was filtrated and dried. 
(Physical data is given in Table 4.5.1) 
4.4.2 2,6-Dimethyl-N,N’-di-(1-naphthyl)-4-(substitutedphenyl)-1,4-
dihydropyridine-3,5-dicarboxamide 
N-1-Naphthyl-3-oxobutanamide (0.02M) and aldehyde (0.01M) were dissolved in 20 ml 
of methanol. The rection mixture was stirred and refluxed. Ammonia (1.5 ml) was added 
dropwise and the reaction mixture was stirred with reflux to complete the reaction. (7-12 
hours). The reaction mixture was allowed to cool and solid separated was filtered and 
washed with methanol. The crude product was crystallized from dimethylformamide. 
(Physical data is given in Table 4.5.2) 
4.4.3  2-(Substitutedbenzylidene)-N-1-naphthyl-3-oxobutanamide 
Substituted acetoacetanilide (0.01M) and aromatic aldehyde (0.01M) were taken into 30 
ml of isopropyl alcohol. The reaction mixture was stirred for 30 minutes and then, 
catalytic amount of piperidine was added. The reaction was stirred until the completion of 
reaction observed by TLC. The reaction mixture was allowed to cool. The solid separated 
was filtered, washed with isopropyl alcohol and crystallized from methanol.  
4.4.4 N-(Substitutedphenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-
(substitutedphenyl)-3,5-carbamoyl-1,4-dihydropyridine  
2-(Substitutedbenzylidene)-N-1-naphthyl-3-oxobutanamide (0.01M) and substituted 
acetoacetanilide (0.01M) were dissolved in 25 ml of methanol. The reaction mixture was 
stirred and refluxed at 90° C. Ammonia (2 ml) was added drop wise and the reaction was 
stirred and refluxed until the completion of reaction (8-12 hours). The reaction mixture 
was allowed to cool and solid separated was filtered and washed with methanol. The 
crude product was crystallized from dimethylformamide. (Physical data is given in Table 
4.5.3 & 4.5.4) 
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4.5 Physical data 
 
 
4.5.1 Physical data of N-(substituted phenyl)-3-oxobutanamide [compounds 1a-f] 
 
 
 
 
 
 
 
 
 
Compound  Code  R1 MF MW Yield Rf 
1a AKS-401 4-Cl C10H10ClNO2 211.64 58 0.64 
1b AKS-402 4-F C10H10FNO2 195.19 52 0.69 
1c AKS-403 3-Cl,4-F C10H9ClFNO2 229.64 45 *0.51 
1e AKS-404 4-CH3 C11H13NO2 191.22 53 0.52 
1f AKS-405 2,3-benzo C14H13NO2 227.25 57 0.47 
 
 
 
 
 
 
 
H
N
O O
R1
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4.5.2 Physical data of 2,6-Dimethyl-N,N’-di-(1-naphthyl)-4-(substitutedphenyl)-1,4-dihydropyridine-3,5-
dicarboxamide [compounds 2a-e]  
 
N
H
CH3 CH3
NH
OO
NH
R
 
 
 
Compound  Code  R MF MW MP Yield Rf 
2a AKS-411 1-naphthyl  C39H31N3O2 573.68 234-36 38 0.45 
2b AKS-412 4-NO2-Ph  C35H28ClN3O2 558.06 240-41 42 0.53 
2c AKS-413 4-OCH3-Ph  C36H31N3O3 553.65 233-36 40 0.42 
2d AKS-414 4-OH-Ph C35H29N3O3 539.65 202-04 40 0.62 
2e AKS-415 4-Cl-Ph C35H28N4O4 568.62 258-61 32 0.55 
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4.5.3 Physical data of N-(Substitutedphenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(substitutedphenyl)-3,5-
carbamoyl-1,4-dihydropyridine [compounds 4a-p] 
 
N
H
CH3 CH3
NH
OO
NH
R
R1
 
 
 
 
Compound  Code  R R1 MF MW MP Yield  Rf 
4a AKS-431 Ph 4-Cl C31H26ClN3O2 508.01 211-13 42 0.47 
4b AKS-432 4-Cl-Ph 4-Cl C31H25Cl2N3O2 542.45 230-31 45 0.51 
4c AKS-433 4-NO2-Ph 4-Cl C31H25ClN4O4 553.00 207-10 38 0.39 
4d AKS-434 4-OCH3-Ph 4-Cl C32H28ClN3O3 538.03 252-55 40 0.43 
4e AKS-435 Ph 4-F C31H26FN3O2 491.55 197-99 42 0.55 
4f AKS-436 4-Cl-Ph 4-F C31H25ClFN3O2 526.00 204-07 47 0.58 
4g AKS-437 4-NO2-Ph 4-F C31H25FN4O4 536.55 233-34 36 0.62 
4h AKS-438 4-OCH3-Ph 4-F C32H28FN3O3 521.58 184-85 42 0.60 
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4i AKS-439 Ph 3-Cl,4-F C31H25ClFN3O2 526.00 244-45 46 0.46 
4j AKS-440 4-Cl-Ph 3-Cl,4-F C31H24Cl2FN3O2 560.44 267-69 33 0.50 
4k AKS-441 4-NO2-Ph 3-Cl,4-F C31H24ClFN4O4 570.99 253-56 30 0.43 
4l AKS-442 4-OCH3-Ph 3-Cl,4-F C35H27ClFN3O3 556.02 220-22 38 0.56 
4m AKS-443 Ph 4-CH3 C32H29N3O2 487.59 192-93 44 0.61 
4n AKS-444 4-Cl-Ph 4-CH3 C32H28ClN3O2 522.03 199-00 40 0.59 
4o AKS-445 4-NO2-Ph 4-CH3 C32H28N4O4 532.58 213-14 45 0.52 
4p AKS-446 4-OCH3-Ph 4-CH3 C33H31N3O3 517.61 204-05 42 0.47 
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4.5.4 Physical data of methyl 5-(naphthalen-1-ylcarbamoyl)-1,4-dihydro-2,6-dimethyl-4-
(substitutedphenyl) pyridine-3-carboxylate [compounds 5a-e] 
 
 
N
H
CH3 CH3
O
OO
NH
CH3
R
 
 
 
Compound  Code  R MF MW MP Yield Rf 
5a AKS-451 Ph C26H24N2O3 412.67 188-89 42 0.45 
5b AKS-452 4-Cl-Ph C26H23ClN2O3 446.92 208-10 38 0.36 
5c AKS-453 4-OCH3-Ph C27H26N2O4 443.50 165-67 35 0.52 
5d AKS-454 4-NO2-Ph C26H23N3O5 457.47 192-93 40 0.33 
5e AKS-455 4-CH3-Ph C27H26N2O3 426.50 176-79 38 0.47 
 
 
TLC solvent system:  Compound 1a-f (EA:Hexane )  2:8, *1:9 
   Compound 2a-e (EA:Hexane ) 4:6   
   Compound 4a-p (EA:Hexane ) 3:7 
   Compound 5a-e (EA:Hexane) 4:6 
MPs were taken in open capillary and are not corrected 
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4.6 Spectral discussion  
 
 
4.6.1  Mass spectral study 
 
Molecular ion peak was observed in agreement with molecular weight of compound in 
mass spectra of synthesized dihydropyridine compounds. Systematic fragmentation 
pattern was observed in mass spectral analysis. Characteristic peaks for specific 
fragments were identified in each mass spectrum. Following diagram shows characteristic 
fragments which gave peak at particular m/e values in mass spectrum. Cleavage of bonds 
adjacent to carbonyl double bond gave fragments at specific m/e values. In case of 
compound AKS-446, molecular ion peak was observed at 518 m/e and base peak was 
obtained at 269 due to cleavage of two C-N bond adjacent to both carbonyl groups. 
Compound AKS-451 and AKS-453 gave molecular ion peak at 413 and 444 m/e 
respectively. Following fragmentation pattern was observed in all spectra.     
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(Mass spectrums of AKS-412, AKS-446, AKS-451, and AKS-453 are given on Page no. 
150 & 151) 
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4.6.2  IR spectral study  
 
In IR spectrums, characteristic frequencies were observed for functional group present in 
the molecule.  Functional groups present in the molecules like –NH-, Ar-H, -Me, C=O, 
Ar-C=C, C-N, C-O and OOP vibrations were observed in IR spectrum. Secondary amide 
(N-H) vibrations gave peaks between 3302-3470 cm-1. Characteristic peaks were 
observed for aromatic ring vibrations (Ar-H, C=C, OOP). In case of dicarbamoyl DHP, 
two amide carbonyl groups gave two peaks between 1654-1698 cm-1, while DHPs with 
ester group on side chain gave carbonyl frequency at 1705-1715 cm-1. Methyl groups also 
gave characteristic peaks between 2900-3100 cm-1.  C-N vibrations were observed 
between 1250-1320 cm-1.  
(IR spectrums of AKS-431, AKS-436, AKS-441, and AKS-446 are given on Page no. 
146 & 147) 
 
4.6.3 1H NMR spectral study 
 
Number of protons and their chemical shifts were found to support the structure of the 
synthesized compounds. In spectrum of compound AKS-411, methyl proton at 2 & 6 
position gave singlet for six protons at 2.32 δ ppm. C4-proton was observed at 5.66 δ 
ppm. A triplet was observed for four protons at 6 & 7 position of both naphthyl rings at 
7.42, while proton at 3rd positions of both naphthyl rings gave triplet for two protons at 
7.32. Doublets were obtained at 7.50, 7.57, 7.68 and 8.21 δ ppm for two protons each 
with 7.16, 8.44, 8.04 and 8.56 J value respectively. Two carabmoyl –NH- protons gave 
singlet 2H at 9.17 δ ppm.    
 
In case of AKS-413, 6H of two methyl group of DHP gave singlet at 2.83 while methoxy 
protons gave singlet in downfield at 3.78 δ ppm. C4 proton singlet was obtained at 5.00 δ 
ppm. Aromatic protons were obtained 6.97-7.83 δ ppm. A triplet was obtained at 7.26 δ 
ppm for two protons with J value of 7.00. a double doublet with J value of 2.96 and 9.28 
was observed at 7.69 δ ppm. Doublets were obtained at 6.97, 7.16, 7.65 and 7.80 with 
8.76, 8.48, 8.72 and 8.16 J value respectively. Two –NH- protons gave singlet at 10.06 δ 
ppm.  
 (1H NMR spectrum of AKS-411 and AKS-413 are given on Page no. 148 & 149) 
  
141
 
4.6.4 Elemental analysis  
Elemental analysis of synthesized compounds was in agreement with calculated values of 
carbon, hydrogen and nitrogen. The spectral and elemental analysis data of individual 
compound is given below.  
 
Spectral data of synthesized compounds (AKS 411-415, AKS 431-
446 & AKS-451-455) 
 
2,6-Dimethyl-N,N’-di-(1-naphthyl)-4-(1-naphthyl)-1,4-dihydropyridine-3,5-
dicarboxamide (AKS-411) – IR (cm-1): 3457, 3318 (-NH-), 3145 (Ar-H), 3078, 2946 (-
Me), 1689, 1676 (C=O), 1633, 1568 (C=C), 1287 (C-N), 1143 (C-O), 834, 766 (OOP); 
1H NMR (DMSO d6) (δ ppm): 2.32 (6H, s), 5.66 (1H, s), 7.32 (2H, t, J=7.60, 7.44), 7.42 
(4H, t, J=7.68, 7.18), 7.50 (2H, d, J=7.16), 7.57 (2H, d, J=8.44), 7.68 (2H, d, 8.04), 7.77 
(5H, m), 7.97 (2H, d), 8.21 (2H, d, J=8.56), 9.17 (2H, s); Anal cacld for C20H18ClN3OS: 
C 62.57, H 4.73, N 10.95, found: C 62.61, H 4.72, N 10.97. 
 
2,6-Dimethyl-N,N’-di-(1-naphthyl)-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxamide (AKS-412) - IR (cm-1): 3456, 3384 (-NH-), 3109 (Ar-H), 3057, 2921 (-
Me), 1697, 1663 (C=O), 1607, 1552 (C=C), 1308 (C-N), 1181 (C-O), 814 (OOP);  Mass 
(m/e): 566 (molecular ion peak), 424, 397, 382, 367, 312, 281, 255 (base peak), 225, 209, 
182, 169, 143, 115, 89, 70; Anal cacld for C20H18ClN3OS: C 62.57, H 4.73, N 10.95, 
found: C 62.61, H 4.72, N 10.97. 
 
2,6-Dimethyl-N,N’-di-(1-naphthyl)-4-(4-methoxyphenyl)-1,4-dihydropyridine-3,5-
dicarboxamide (AKS-413) - IR (cm-1): 3474, 3361(-NH-), 3124 (Ar-H), 3027, 2952 (-
Me), 1677, 1653 (C=O), 1602, 1582 (C=C), 1260 (C-N), 1164 (C-O), 786 (OOP); 1H 
NMR (DMSO d6) (δ ppm): 2.83 (6H, s), 3.78 (3H, s), 5.00 (1H, s), 6.97 (2H, d, J=8.76), 
7.16 (2H, d, J=8.48), 7.26 (2H, t, J=7.00), 7.42 (4H, m), 7.65 (2H, d, J=8.72), 7.69 (2H, 
dd, J=2.96, 9.28), 7.80 (2H, d, J=8.16), 7.83 (3H, d), 10.06 (2H, s); Anal cacld for 
C20H18ClN3OS: C 62.57, H 4.73, N 10.95, found: C 62.61, H 4.72, N 10.97. 
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2,6-Dimethyl-N,N’-di-(1-naphthyl)-4-(4-hydroxyphenyl)-1,4-dihydropyridine-3,5-
dicarboxamide (AKS-414) - IR (cm-1): 3386 (-OH-), 3341 (-NH-), 3107 (Ar-H), 3033, 
2928 (-Me), 1670, 1654 (C=O), 1600, 1555 (C=C), 1258 (C-N), 1113 (C-O), 814, 725 
(OOP); Anal cacld for C20H18ClN3OS: C 62.57, H 4.73, N 10.95, found: C 62.61, H 4.72, 
N 10.97. 
 
2,6-Dimethyl-N,N’-di-(1-naphthyl)-4-(4-chlorophenyl)-1,4-dihydropyridine-3,5-
dicarboxamide (AKS-415) – IR (cm-1): 3450, 3368 (-NH-), 3103 (Ar-H), 3055, 2933 (-
Me), 1696, 1658 (C=O), 1613, 1577 (C=C), 1310 (C-N), 1086 (C-O), 804(OOP); Anal 
cacld for C20H18ClN3OS: C 62.57, H 4.73, N 10.95, found: C 62.61, H 4.72, N 10.97. 
 
N-(4-Chlorophenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-phenyl-3,5-carbamoyl-1,4-
dihydropyridine (AKS-431) – IR (cm-1): 3423, 3313 (-NH-), 3093 (Ar-H), 2925, 2844 (-
Me), 1662, 1653 (C=O), 1604, 1533 (C=C), 1290 (C-N), 1114 (C-O), 833, 742 (OOP); 
Anal cacld for C31H26ClN3O2: C 73.29, H 5.16, N 8.27, found: C 73.35, H 5.19, N 8.32. 
 
N-(4-Chlorophenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(4-chlorophenyl)-3,5-
carbamoyl-1,4-dihydropyridine (AKS-432) - IR (cm-1): 3410, 3372 (-NH-), 3088 (Ar-
H), 3015, 2946 (-Me), 1690, 1668 (C=O), 1617, 1562(C=C), 1247 (C-N), 1077 (C-O), 
796 (OOP); Anal cacld for C31H25Cl2N3O2: C 68.64, H 4.65, N 7.75, found: C 68.68, H 
4.66, N 7.81. 
 
N-(4-Chlorophenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(4-nitrophenyl)-3,5-carbamoyl-
1,4-dihydropyridine (AKS-433) - IR (cm-1): 3376, 3327 (-NH-), 3110 (Ar-H), 3005, 
2955 (-Me), 1672, 1656 (C=O), 1616, 1546 (C=C), 1332 (C-N), 1121 (C-O), 812 (OOP); 
Anal cacld for C31H25ClN4O4: C 67.73, H 4.56, N 10.13, found: C 67.75, H 4.60, N 
10.21. 
 
N-(4-Chlorophenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(4-methoxyphenyl)-3,5-
carbamoyl-1,4-dihydropyridine (AKS-434) – IR (cm-1): 3354, 3286 (-NH-), 3117 (Ar-
H), 3050, 2944 (-Me), 1698, 1657 (C=O), 1630, 1525 (C=C), 1290 (C-N), 1167 (C-O), 
817, 763 (OOP); Anal cacld for C32H28ClN3O3: C 71.43, H 5.25, N 7.81, found: C 71.48, 
H 5.27, N 7.88. 
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N-(4-Fluorophenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-phenyl-3,5-carbamoyl-1,4-
dihydropyridine (AKS-435) - IR (cm-1): 3433, 3347 (-NH-), 3104 (Ar-H), 3022, 2952 (-
Me), 1679, 1665 (C=O), 1613, 1580 (C=C), 1272 (C-N), 1086 (C-O), 830, 747 (OOP); 
Anal cacld for C31H26FN3O2: C 75.75, H 5.33, N 8.55, found: C 75.79, H 5.35, N 8.61. 
 
N-(4-Fluorophenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(4-chlorophenyl)-3,5-
carbamoyl-1,4-dihydropyridine (AKS-436) – IR (cm-1): 3410, 3372 (-NH-), 3088 (Ar-
H), 3015, 2946 (-Me), 1690, 1668 (C=O), 1617, 1562(C=C), 1247 (C-N), 1077 (C-O), 
796 (OOP); Anal cacld for C31H25ClFN3O2: C 70.79, H 4.79, N 7.99, found: C 70.75, H 
4.79, N 8.06. 
 
N-(4-Fluorophenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(4-nitrophenyl)-3,5-carbamoyl-
1,4-dihydropyridine (AKS-437) - IR (cm-1): 3431, 3251 (-NH-),  2921, 2853 (-Me), 
1681, 1631 (C=O), 1592, 1516 (C=C), 1221 (C-N), 1083 (C-O), 747 (OOP); Anal cacld 
for C31H25FN4O4: C 69.39, H 4.70, N 10.44, found: C 69.44, H 4.73, N 10.51. 
 
N-(4-Fluorophenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(4-methoxyphenyl)-3,5-
carbamoyl-1,4-dihydropyridine (AKS-438) - IR (cm-1): 3462, 3316 (-NH-), 3118(Ar-
H), 3066, 2925 (-Me), 1697, 1670 (C=O), 1630, 1561 (C=C), 1282 (C-N), 1141 (C-O), 
801 (OOP); Anal cacld for C32H28FN3O3: C 73.69, H 5.41, N 8.06, found: C 73.74, H 
5.47, N 8.13. 
 
N-(3-Chloro-4-fluorophenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-phenyl-3,5-carbamoyl-
1,4-dihydropyridine (AKS-439) - IR (cm-1): 3417, 3310 (-NH-), 3144 (Ar-H), 3077, 
2945 (-Me), 1688, 1671 (C=O), 1637, 1519 (C=C), 1283(C-N), 1157 (C-O), 755 (OOP); 
Anal cacld for C31H25ClFN3O2: C 70.79, H 4.79, N 7.99, found: C 70.54, H 4.82, N 8.05. 
 
N-(3-Chloro-4-fluorophenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(4-chlorophenyl)-3,5-
carbamoyl-1,4-dihydropyridine (AKS-440) - IR (cm-1): 3403, 3341 (-NH-), 3111 (Ar-
H), 3017, 2904 (-Me), 1690, 1662 (C=O), 1608, 1547 (C=C), 1288 (C-N), 1122 (C-O), 
740 (OOP); Anal cacld for C31H24Cl2FN3O2: C 69.82, H 4.76, N 6.78, found: C 69.87, H 
4.79, N 6.86. 
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N-(3-Chloro-4-fluorophenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(4-nitrophenyl)-3,5-
carbamoyl-1,4-dihydropyridine (AKS-441) – IR (cm-1): 3427, 3244 (-NH-), 3111 (Ar-
H), 2926, 2854 (-Me), 1707, 1660 (C=O), 1591, 1518 (C=C), 1295 (C-N), 1186 (C-O), 
856, 741 (OOP); Anal cacld for C31H24ClFN4O4: C 65.21, H 4.24, N 9.81, found: C C 
65.26, H 4.26, N 9.88. 
 
N-(3-Chloro-4-fluorophenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(4-methoxyphenyl)-3,5-
carbamoyl-1,4-dihydropyridine (AKS-442) - IR (cm-1): 3375, 3263 (-NH-), 3120 (Ar-
H), 3053, 2947 (-Me), 1681, 1658 (C=O), 1630, 1547 (C=C), 1250 (C-N), 1137 (C-O), 
811 (OOP); Anal cacld for C35H27ClFN3O3: C 71.65, H 5.25, N 6.82, found: C 71.67, H 
5.28, N 6.89. 
 
N-(4-Methylphenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-phenyl-3,5-carbamoyl-1,4-
dihydropyridine (AKS-443) - IR (cm-1): 3444, 3361 (-NH-), 3107 (Ar-H), 3047, 2991 (-
Me), 1677, 1655 (C=O), 1622, 1542 (C=C), 1255 (C-N), 1078 (C-O), 744 (OOP); Anal 
cacld for C32H29N3O2: C 78.17, H 5.89, N 7.44, found: C 78.22, H 5.94, N 7.52. 
 
N-(4-Methylphenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(4-chlorophenyl)-3,5-
carbamoyl-1,4-dihydropyridine (AKS-444) - IR (cm-1): 3486, 3314 (-NH-), 3140 (Ar-
H), 3071, 2913 (-Me), 1695, 1664 (C=O), 1610, 1554 (C=C), 1302 (C-N), 1188 (C-O), 
798 (OOP); Anal cacld for C32H28ClN3O2: C 74.75, H 5.50, N 7.12, found: C 74.79, H 
5.54, N 7.19. 
 
N-(4-Methylphenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(4-nitrophenyl)-3,5-carbamoyl-
1,4-dihydropyridine (AKS-445) - IR (cm-1): 3417, 3330 (-NH-), 3119 (Ar-H), 3037, 
2944 (-Me), 1688, 1653 (C=O), 1612, 1554 (C=C), 1286 (C-N), 1187 (C-O), 815 (OOP); 
Anal cacld for C32H28N4O4: C 73.76, H 5.43, N 8.78, found: C 73.82, H 5.46, N 8.86. 
 
N-(4-Methylphenyl)-2,6-dimethyl-N’-(1-naphthyl)-4-(4-methoxyphenyl)-3,5-
carbamoyl-1,4-dihydropyridine (AKS-446) – IR (cm-1): 3409, 3282 (-NH-), 3022 (Ar-
H), 2920 (-Me), 1676, 1652 (C=O), 1598, 1490 (C=C), 1292 (C-N), 1128 (C-O), 875, 752 
(OOP); Mass (m/e): 518 (molecular ion peak), 411, 382, 375, 367, 347, 269 (base peak), 
210, 183, 143, 116, 89, 63; Anal cacld for C33H31N3O3: C 76.70 H 5.92, N 7.16, found: C 
76.77 H 5.95, N 7.27. 
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Methyl-5-(naphthalen-1-ylcarbamoyl)-1,4-dihydro-2,6-dimethyl-4-phenylpyridine-3-
carboxylate (AKS-451) – IR (cm-1): 3512 (-NH-), 3027 (Ar-H), 2918 (-Me), 1708, 1658 
(C=O), 1590, 1497 (C=C), 1272 (C-N), 1120 (C-O), 752 (OOP); Mass (m/e): 413 
(molecular ion peak), 386, 270, 244, 217, 182, 169, 143, 115, 89, 44 (base peak); Anal 
cacld for C26H24N2O3: C 75.71 H 5.86, N 6.79, found: C 75.78 H 5.90, N 6.87. 
 
Methyl-5-(naphthalen-1-ylcarbamoyl)-1,4-dihydro-4-(4-chlorophenyl)-2,6-
dimethylpyridine-3-carboxylate (AKS-452) – IR (cm-1): 3378(-NH-), 3102 (Ar-H), 
2956 (-Me), 1714, 1656 (C=O), 1522, 1441 (C=C), 1303 (C-N), 1121 (C-O), 875 (OOP); 
Anal cacld for C26H23N2O3: C 69.87 H 5.19, N 7.93, found: C 69.92 H 5.23, N 7.99. 
 
Methyl-5-(naphthalen-1-ylcarbamoyl)-1,4-dihydro-4-(4-methoxyphenyl)-2,6-
dimethylpyridine-3-carboxylate (AKS-453) – IR (cm-1): 3411, 3280 (-NH-), 3029 (Ar-
H), 2956 (-Me), 1716, 1651 (C=O), 1598, 1490 (C=C), 1259 (C-N), 1175 (C-O), 851, 748 
(OOP); Mass (m/e): 444 (molecular ion peak), 309 (base peak), 280, 275, 252, 236, 223, 
188, 169, 121, 108, 89, 71; Anal cacld for C27H26N2O4: C 73.28 H 5.92, N 6.33, found: C 
73.34 H 5.91, N 6.39. 
 
Methyl-5-(naphthalen-1-ylcarbamoyl)-1,4-dihydro-4-(4-nitrophenyl)-2,6-
dimethylpyridine-3-carboxylate (AKS-454) – IR (cm-1): 3396 (-NH-), 3048 (Ar-H), 
2920, 2876 (-Me), 1712, 1659 (C=O), 1522, 1423 (C=C), 1262 (C-N), 1177 (C-O), 874, 
750 (OOP); Anal cacld for C26H23N3O5: C 68.26 H 5.07, N 9.19, found: C 68.29 H 5.10, 
N 9.25. 
 
Methyl-5-(naphthalen-1-ylcarbamoyl)-1,4-dihydro-4-(4-methylphenyl)-2,6-
dimethylpyridine-3-carboxylate (AKS-455) – IR (cm-1): 3345 (-NH-), 3018 (Ar-H), 
2988, 2855 (-Me), 1705, 1656 (C=O), 1555, 1476 (C=C), 1252 (C-N), 1125 (C-O), 806 
(OOP); Anal cacld for C27H26N2O3: C 76.03 H 6.14, N 6.57, found: C 76.11 H 6.11, N 
6.60. 
  
146
 
 
4.6.5.1  IR spectrum of AKS-431 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.6.5.2 IR spectrum of AKS-436 
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4.6.5.3 IR spectrum of AKS-441 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.6.5.4 IR spectrum of AKS-446 
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4.6.5.5 1H NMR spectrum of AKS- 411 
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4.6.5.6 1H NMR spectrum of AKS- 413 
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4.6.5.7 Mass spectrum of AKS- 412 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.6.5.8 Mass spectrum of AKS- 446 
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4.6.5.9 Mass spectrum of AKS-451   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.6.5.10 Mass spectrum of AKS-453   
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Azoles and azines are well known for their diversed biological activities. It is also known 
that fusion of the heterocyclic nuclei enhances the pharmacological activities more than 
its parent nucleus. The importance of the indole nucleus is well established in 
pharmaceutical chemistry as it’s corresponding derivatives are used as antipyretic, 
anticonvulsant, antianalgesic and antidepresant agents1-3. 
 
5.1 Pharmacological profile 
 
 
The antiviral activity of as-triazines4 and clinical efficacy of methisazone5 were well 
documented. The action of isatin-3-thiosemicarbazone is known to have antiviral activity 
against certain poxviruses6,7. The antiviral spectrum of 1-methylisatin-3-
thiosemicarbazone, which reportedly extends to adenoviruses, may be rather broader but 
is still limited to several groups of DNA viruses8-9. It was therefore an unexpected finding 
that these compounds are also active against certain rhinoviruses. J.M.Z.Gladych10 and 
co-workers have studied isatin thiosemicarbazone analogues among which two 
compounds were found to have activity against all rhinovirus strains used so far. 
Human rhinovirus (HRV) is a primary cause of mild upper respiratory infection in 
humans. Although rhinovirus infection, as the “common cold” is known to spread easily 
throughout human populations, only higher primates are susceptible11,12; thus, the virus 
possesses a narrow host range. This narrow host range is reflected in tissue culture in that 
the HRV replicates only in cells of primate origin. 
In vitro testing of the 5H-triazino[5,6-b]indoles show a broad spectrum antiviral activity 
against both DNA and RNA viruses. A notable feature of the series is the wide spread 
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action against several strains of rhinovirus which is most consistently shown by 
compounds containing hydroxyalkylamino substituents at C3.   
N
O
NNHCSNH2
R
Isatin-3-thiosemicarbozones
R = CH3  Methisazone or 
(1-methylisatin-3-thiosemicarbazone) 
N
N
N
N
R2
R3
R1
    5H-as-triazino[5,6-b]indoles                                
R1 = H,Cl, NO2, Me, Pr, NO, OMe    R2 = H, Me, C6H5(CH2)2, C6H5CH2  
R3 =  OH(CH2)2NH, OH(CH2)3NH, NH2, Me2N, Morphonyl, Me2CH(CH2)2NH, 
Me(CH2)11NH, CH3(CH2)17NH, OHCH2CH(OH)CH2NH, OH(CH2)4NH, 
MeO(CH2)3NH, OH(CH2)2NH(CH2)2NH, Me2N(CH2)3NH, OH(CH2)6NH etc.
 
Isatin-3-thiosemicarbazone exhibits antiviral activity, mainly against poxviruse13,14. A 
group of 3-substituted triazinoindoles, which are structurally related to isatin 
thiosemicarbazone, inhibit the growth of several rhinoviruses15,16. Ehud Katz et 
al17suggested SK&F 21681 (3,10-dimethyl-10-H-s-triazolo[4',3':2,3]-astriazino-[5,6-
b]indole) as an inhibitor of the growth of herpes simplex viruses types 1 and 2 at a 
concentration of 60µg/ml without causing any morphological alterations in BSC1 cells. 
The DNA synthesis rate of BSC1 affected by 16% between 0.5 to 7 hrs and this inhibition 
increased upto 33% between 2 to 22 h.p.i.   
 
 
The growth of HSV-1 and HSV-2 in BSC1 cells was followed in the presence of different 
concentrations of SK&F 21681. It was shown that the highest rate of inhibition occurred 
at the concentration of 60µg/ml (the upper limit of solubility of this compound in aqueous 
solution); decreasing the concentration resulted in a parallel loss in the efficiency of the 
inhibition (Fig. 3). Concentrations of SK&F 21681 lower than 10µg/ml were not active. 
The results also suggest that the susceptibility of the growth of HSV-2 to this compound 
N
N
N
N
N
N
CH3
CH3 SK&F 21681 
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is higher than that of HSV-1 (Fig. 3). When formation of plaques of HSV in the presence 
of SK&F 21681 (60 p.g/ml) was studied, a remarkable inhibition was observed. 
 
Scott Baginski and co-researchers18 have reported the discovery of a small molecule 
inhibitor of pestivirus replication. The compound, designated VP32947, inhibits the 
replication of bovine viral diarrhea virus (BVDV) in cell culture at a 50% inhibitory 
concentration of approximately 20nM. VP32947 inhibits both cytopathic and 
noncytopathic pestiviruses, including isolates of BVDV-1, BVDV-2, border disease virus 
and classical swine fever virus. However, the compound shows no activity against viruses 
from unrelated virus groups. 
 
Bovine viral diarrhea virus (BVDV), the prototypic representative of the pestivirus genus, 
family Flaviviridae, is ubiquitous and causes a range of clinical manifestations, including 
abortion, teratogenesis, respiratory problems, chronic wasting disease, immune system 
dysfunction, and predisposition to secondary viral and bacterial infections19. Certain 
BVDV strains can cause acute fatal disease with mortality rates of 17–32%20-22. BVDV is 
also able to establish persistent infections in fetuses23,24. When born, these persistently 
infected animals remain viremic throughout life and serve as continuous sources for virus 
spread in herds. Persistently infected animals may also succumb to fatal mucosal disease 
on superinfectionwith closely related BVDV strains. Vaccines are used in some countries 
in an attempt to control pestivirus disease with varying degrees of success25. 
 
Time of drug addition studies indicated that VP32947 acts after virus adsorption and 
penetration and before virus assembly and release. Analysis of viral macromolecular 
synthesis showed VP32947 had no effect on viral protein synthesis or polyprotein 
processing. The investigation of the effect of VP32947 on viral RNA synthesis indicated 
when virus-infected cells, treated with actinomycin D(to inhibit cellular RNA synthesis) 
with or without  VP32947 in the cell culture medium. There was a clear inhibition of 
incorporation of 3H-uridine into viral RNA found in the drug treated culture. Although 
the drug-free culture showed the time-dependent incorporation of 3H-uridine into viral 
RNA. When this experiment was performed in the absence of actidomycin D, no change 
of 3H-uridine uptake in the presence of drug was observed for cellular RNA synthesis, 
indicating that VP32947 had no obvious effect on uridine uptake by the cells or on 
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cellular RNA synthesis. These results suggest that VP32947 exerted its antiviral effect at 
the level of viral RNA synthesis. 
   
Oonagh Kinsman and co-workers26 have described GR99060 and GR99062 as 
representatives of a series of 1,2,4-triazino[5,6-b]indole compounds. This series 
possessed broad-spectrum antifungal activity in vitro. The MIC ranges of the two 
compounds were as follows: 0.25 to 4 µg/ml for Candida albicans, 0.25 to 16 µg/ml for 
Candida sp., 1 to 8 µg/ml for Asperigllus spp., and 0.25 to 16 µg/ml for Cryptococcus 
neoformans. GR99062 was metabolized to corresponding N-oxide analogue GR107867 in 
vitro by a mouse liver microsomal preparation, while GR99060 was stable. GR99060 was 
efficacious in a murine model of systemic candidiasis by oral or parenteral 
administration, although no clear dose-response was achieved; suggesting that other 
factors adversely affected the compound’s in vivo activity. 
 
N
N N
N
N
N
CH3
CH3
N
N N
N
CH3
CH3 N
N CH3
N
N N
N
CH3
CH3 N
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GR99060 showed a therapeutic effect in mice with systemic C. albicans infections when 
it was administered by both the oral and subcutaneous routes. Since the levels of the drug 
in blood after subcutaneous dosing were low, the compound may be released slowly over 
a longer period of time. In the efficacy test, the dose-response was variable by both 
routes. Toxicity in infected animals may account for the reduced activity at high doses, 
VP32947
N
H
N
N
N S
(CH2)2
(n-C3H7)2N
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since a lower survival rate was noted in mice that received 100 mg/kg than in those that 
received lower doses. Variations in bioavailability and possible further metabolism may 
also account for the lack of good dose-responses. Similarly, in the subacute infection 
model, the oral route of administration was more effective than the subcutaneous route in 
reducing kidney counts when a dose of 100 mg/kg was used. 
 
Tomas Vijkovsky et al27 have patented compounds of formula I and II for treating c-MET 
related disorders or in another preferred embodiment, the cancer selected from the group 
consisting breast cancer, lung cancer, prostate cancer, pancreatic cancer, glioma, liver 
cancer, gastric cancer, throat cancer, melanoma, renal cancer, leucamia, myeloma and 
sarcoma. The investion deals with a family of novel tetracyclic compounds which 
exhibits c-MET modulationg activity and have ameliorating effect against disorders 
related to abnormal c-MET activity.  
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R4
R5
R6
R7
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N
N
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R3
R2
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R6
R7
(R10)q
Formula -1 Formula -2
R1=substituted aryl or heteroaryl 
group
R2 & R3=H, halogen, OH, OR, N(R)2, 
-CN, -COR, COOR, CON(R)2, CF3, lower 
alkyl, cycloalkyl, heterocycle, alkenyl 
and alkynyl or R2 & R3 togather form 
cycloalkyl or heterocyle
R4, R5, R6 and R7= H, halogen, OR, 
N(R)2, -CN, -COR, COOR, CON(R)2, 
NO2, S(O)nR (where n=0,1,2), CF3,lower 
alkyl, cycloalkyl, heterocycle, alkenyl, 
alkynyl or  aryl
p=0,1,2,3,4 or 5
R10=OH,OR, COR, COOR, CON(R)2, N(R)2, CN, 
NO2, SO2R, SO2N(R)2, CF3, lower alkyl, 
cycloalkyl, heterocycle, alkenyl or aryl
q=1,2,3,4 or 5 G = C or N 
R2 & R3=H, halogen, OH, OR, N(R)2, -CN, -COR, 
COOR, CON(R)2, CF3, lower alkyl, cycloalkyl, 
heterocycle, alkenyl and alkynyl or R2 & R3 
togather form cycloalkyl or heterocyle
R4, R5, R6 and R7= H, halogen, OR, N(R)2, -CN, 
-COR, COOR, CON(R)2, NO2, S(O)nR (where 
n=0,1,2), CF3,lower alkyl, cycloalkyl, 
heterocycle, alkenyl, alkynyl or  aryl
p=0,1,2,3,4 or 5
 
 
Joseph Kgokong et al28 have synthesized the unsubstituted and the 6-trifluoromethyl-
1,2,4-triazino[5,6b]indole analogues and evaluated for antimalarial activity in vitro 
against the chloroquine sensitive and chloroquine-resistant strains of P. falciparum. The 
results have revealed that the CF3 group tends to lead to an increased in vitro antimalarial 
  
160
activity of the 1,2,4-triazino[ 5,6b]indole albeit to a smaller degree in some compounds. 
Analogues without the trifluoromethyl group, which were evaluated simultaneously, were 
all devoid of activity even at concentrations as high as 400 µM. The increased activity 
resulting from the presence of this group could be ascribed to the increased lipophilicity 
of the compound, as this group is known to be more hydrophobic than even the fluorine 
atom.29 In this series, the size of the substituent on the thiol group have no significant 
effect on in vitro antimalarial activity. Replacement of a thiol group by a hydrazino group 
in the trifluoromethyl substituted derivatives leads to compounds with half the potency of 
those with alkyl groups on the thiol group. On the other hand, the activity of the 6-
trifluoromethyl-5H-1,2,4-triazolo[1’,5’,2,3]-1,2,4-triazino[5,6b]indole series  was almost 
identical to those of the 6-trifluoromethyl-1,2,4-triazino[5,6b]indole-3-alkylthiols, with 
the exception of compound  containing the 6-CF3  and the 3-CH3 groups. The later 
exhibited a four fold improvement in activity against the chloroquine-sensitive strains. 
However, introduction of a second CF3 particularly at position 3 tends to lead to 
compounds with diminished antimalarial activity. Further consideration of the structure–
activity relationship of compounds in the series without the 6-CF3  indicates that  
compound with 3 –CH3 substitution was the most active against the chloroquine-sensitive 
strains followed by unsubstituted skeleton. The former exhibited activity against the 
chloroquine-sensitive strains in the same molar range as chloroquine and mefloquine 
under identical experimental conditions, while later was the most active 
N
H
N
N
NF3C R1
6-(trifluoromethyl)-5H-[1,2,4]
triazino[5,6-b]indole
R1 is =S, -SCH3, -SC2H5, NHNH2,
N
H
N
N
N
R
N
N
R1
5H-[1,2,4]triazolo[1',5',2,3][1,2,4]-triazino-[5,6-b]indole
R=H, CF3
R1=H, -CH3, CF3, C6H4Cl  
against the chloroquine-resistant strains of P. falciparum. Both –CF3 and –C6H4Cl groups 
at position 3 without CF3 at position 6 lead to relatively inactive compounds. The fact that 
the P. falciparum lactate dehydrogenase (PfLDH)activity can be distinguishable from the 
host LDH30 by using the 3-acetyl pyridine adenine dinucleotide analogue of nicotinamide 
adenine dinucleotide (APAD) has afforded an opportunity for the development of an 
enzymatic method for the evaluation of antimalarial compounds.31 The compounds 
selected for screening against the chloroquine-resistant strain of P. falciparum have 
shown identical but much higher in vitro activity than against the chloroquine-sensitive 
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strain, with the exception of compound having no substitution, which has a IC50 value of 
48.0 µM, which was very close to that of chloroquine (IC50 of 277.5 µM) against this 
strain. The 3-CF3 substitution did not lead to any improvement on the in vitro antimalarial 
activity than it did when attached at position 6. The 3,6-bis(trifluoromethyl)-5H- 1,2,4-
triazolo-[10,50,2,3]-1,2,4-triazino-[5,6b]indole has a much lower activity against both the 
chloroquine- sensitive and chloroquine-resistant strains of P.falciparum than the other 6-
CF3 substituted derivatives. As a result of a direct relationship between the level of drug 
accumulation in the parasite food vacuole and antimalarial drug potency, but no simple 
relationship between accumulation and either pKa or lipophilicity,32-34 it could be inferred 
that the bulkiness of the molecule conferred by the second CF3 group will affect the 
relative membrane permeability of the molecule, leading to reduced drug accumulation 
within the parasite food vacuole. 
 
Monge A. et al35 have studied the regulation of the PGI2/TXA2 system with 
antihypertensive effects by synthesizing a series of 4-hydrazino-5H-pyridazino[4,5-
b]indole and 4-hydrazinopyridazino[4,5-a]indole derivatives (Scheme-1), structurally 
related to hydralazine36 (1-hydrazinophthalazine) and dihydralazine(1,4-
dihydrazinophthalazine), peripheral vasodilators used in the treatment of  hypertension. 
The demonstration of selective inhibitory actions of the compounds was determined in 
concordance with the Gorman mode37, namely, the inhibition of the second wave of 
platelet aggregation induced by adenosine 5'-diphosphate (ADP), inhibition of 
aggregation induced by arachidonic acid (AA), and prostaglandin H, (PGH2) and 
prostaglandin H2(PGH2) production with AA as aggregating agent with concomitant 
inhibition of TXA2 production. 
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Compounds 3,5, and 10-12 were studied as potential inhibitors of the blood platelet 
aggregation induced by ADP and/or AA, PGH2, and adrenaline.  Compounds 3c and 
5a.HCl were found to be the most potent inhibitors in all of these experiments. These 
compounds were inhibitors of the in vitro platelet aggregation induced by ADP, AA, and 
PGH, and compound 5a.HCl also inhibited the aggregation induced by adrenaline. 
Compounds 3c and 5a-HCl were subsequently studied with ASA as reference as potential 
inhibitors of thromboxane synthetase in the in vitro blood platelet aggregation induced by 
AA and in the ex vivo blood platelet aggregation induced by ADP and AA. In both types 
of experiments, 3c and 5a.HCl showed an inhibitory effect on the synthesis of TXB2 and 
a stimulation of the synthesis of prostaglandin E2(PGE2). Both effects are more 
significant with 5a-HCl. To a 100 µM concentration, this compound as compared with 
ASA showed no significant inhibitory effect on the PGI2 release from rat aortic tissue. 
The antihypertensive effect of the compounds was measured in spontaneously 
hypertensive rats (SHR), after intraperitoneal, oral, and intravenous administration to 
SHR for compounds 3-8, 12 and hydralazine.  The introduction of the hydrazino group in 
the position 4 of the 5H-pyridazino[4,5-b]indole system considerably increased the 
antihypertensive activity and toxicity. However, compounds 6a and 6b were less active as 
compared with compound 5. Considering the results together following decreasing order 
of activity may be stated for compounds 5: hydralazine >/=  5a = 5d >/= 5 (R’ = H)>/=5b 
>> 5c. The results for 5a, 5b, 5d, and hydralazine for a short time after iv administration 
revealed that decreasing order of activity seems to be 5d > hydralazine = 5a > 5b. 
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After this, the same group have extended their study with a series of 5H-triazino[5,6-
b]indole. Only one compound 3-hydrazino-5H-[1,2,4]triazino [5,6-b] indole 
hydrochloride was found to be most potent as antihypertensive agent with slighly 
affecting the cardiac rhythm but did not present any antiaggregative effect. 
N
H
N N
N
NH
NH2
3-hydrazino-5H-[1,2,4]triazino[5,6-b]indole  
Morsy J.M. and Abd el-Monem W.R.38 have synthesized 3-(5,6-Diphenyl-1,2,4-triazin-3-
yl)-5-substituted-1,2,4-triazino[5,6-b]indole derivatives showed pronounced effect on the 
Cellobiase produced by Thermomyces lanuginosus and Chaetomium thermophilum. 
N
N N
N
N
N
N
R
3-(5,6-diphenyl-1,2,4-triazine-3-yl)-5-s
ubstituted-1,2,4-triazino[5,6-b]indoles
 
Ethyl 1,2,3-triazino[5,4-b]indole-4-carboxylate N3-oxide (13) and 2-chloroethyl 1,2,3-
triazino-[5,4-b]indole-4-carboxylate N3-oxide (14) have shown potent platelet 
antiaggregating and hypotensive activity, and their precursors 2-ethoxy-carbonylmethyl-
1-methylindole-3-carboxylic acid (15) and 2-(2-chloroethoxy carbonylmethyl)-1-
methylindole-3-carboxylic acid (16) were tested in four strains of Salmonella 
typhimurium (TA98, TA100, TA97 and TA102) using the standard plate incorporation 
technique. 15 &  16 were not mutagenic whereas 13 was mutagenic to all the strains and 
14 was mutagenic to TA97, TA98 and TA10039. 
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In  continuation with this, Garcia  et al40 have  studied quantitative structure-mutagenic 
activity relationship  of 3-(4’-benzylidenamino)-5H-1,2,30triazin[5,4-b]indole-4-one 
derivatives. The title compounds were assayed with the Ames test using the Salmonella 
typhimurium strains TA97, TA98, TA100 and TA102. The adaptive least-squares method 
(ALS method) was used to carry out a quantitative structure-activity relationship (QSAR) 
analysis. Three equations, based on 10 congeners, were found for strains TA97, TA98 
and TA100. The results suggest that lipophilicity of the substituent decreases the 
mutagenicity of the series. 
N
H
N N
N
O
NH2
3-(4'-benzylidenamino)-5H-[1,2,3]
triazino[5,4-b]indol-4-one
 
N
H
N N
N N
NX
R
6H-5-aryl-9-halo-1,2,4-triazolo             
[3’ , 4’ :3,4]-1,2,4-triazino[5,6-b]-indoles  
 
Holla B.S. et al41 synthesized a series of 6H-5-aryl-9-halo-1,2,4-triazolo [3’ , 4’ :3,4]-
1,2,4-triazino[5,6-b]-indoles  and 5H-1-aryl-5-halo-1,2,4- triazolo [4’ ,3’ :2,3]-1,2,4-
triazino [5,6-b]-indoles. The titled compounds assayed against B. subtilis, E.coli, P. 
aeruginosa and S.aureus. 
 
 
5.2 Synthetic Methodology and Chemistry 
 
 
Joshi et al42 reported that the reaction of 3-hydrazino[1,2,4]triazino[5,6-b]indole (17) with 
nitrous acid (sodium nitrite/PPA) gave 10H-tetrazolo[5’,1’:3,4][1,2,4]triazino[5,6-
b]indole(18), where as reaction of (17) with nitrous acid gave azide(19)43,44, the structure 
of the azide was confirmed by its analytical and spectral data. The azide (19) was cyclized 
to tetrazolo compound (18b) on treatment with acetic anhydride, while cyclization with 
ethyl cyanoacetate in presence of sodium ethoxide afforded 5-amino-4-carboxy[1,2,3]-
triazolyl-[1,2,4]-triazino-[5,6-b]indole (20)45. On the other hand, treatment of (17) with 
sodium nitrite/concentrated hydrochloric acid gave the corresponding tetrazolo compound 
18a. 
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F.F.Abdel-Latif et al46 have studied reactivity of hydrazino compound (21) toward 
different condensing cyclization reagents47(Scheme-3) , found that when (21) treated with 
acetic anhydride affords the fused triazolo compound (22) namely 10-acetyl-1-methyl-
10H-[1,2,4]triazolo[3’,4’:3,4[-1,2,4]triazino[5,6-b]indole. Refluxing (21) with carbon 
disulphide produced 1,2-dihydro-10H-[1,2,4]triazolo[3’,4’:3,4][1,2,4]triazino[5,6-
b]indol-1-thione (23a). In the same manner, refluxing (21) with ethyl chloro formate 
produced 1,2-dihydro-10H-[1,2,4] triazolo[3’,4’:3,4][1,2,4]triazino[5,6-b]indol-1-one 
(23b). On the other hand refluxing (21) with 1-napthaldehyde in absolute ethanol 
produced 1-naphthylidine-(5H-[1,2,4]-triazino[5,6-b]indol-3-yl)hydrazone (24a), where 
as  upon heating in glacial acetic acid gave corresponding triazolo compound, namely 10-
acetyl-1-(1-naphthyl)-10H-[1,2,4]triazolo[3’,4’:3,4] triazino[1,2,4] [5,6-b]indole (25a). 
Treatment of (21) with benzaldehyde or p-nitrobenzaldehyde in ethanol and/or in glacial 
acetic acid similarly afforded both benzylidene((5H-[1,2,4]-triazino[5,6-b]indol-3-
yl)hydrazone(24b) and 10-acetyl-1-(p-nitrophenyl)-10H-[1,2,4]triazolo[3’,4’:3,4 
]triazino[1,2,4] [5,6-b]indole (25b) respectively. Cyclization of (21) with ethyl 
acetoacetate yielded        the pyrazolino compound 3-(5’-hydroxy-3’-methyl-1H-pyrazol-
1-yl)-5H-[1,2,4]triazino[5,6-b]indole (26a). Similarly, refluxing (21) with acetyl acetone 
produced 3(3’,5’-dimethyl-1H-pyrazolo-1-yl)-5H-[1,2,4]triazino[5,6-b]indole (26b). 
Condensation of (21) with malanonitrile resulted 3-(3’,5’-diamino-1H-pyrazol-1-yl)-5H-
[1,2,4]triazino[5,6-b]indole (27a), while treatment of (21) with ethyl cyanoacetate gave 3-
(3’-amino-5’-hydroxy-1H-pyrazol-1-yl)-5H-[1,2,4]triazino[5,6-b]indole (27b). 
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The reaction of (21) with α-dicarbonyl compounds was assumed to involve one or both 
carbonyl groups in the condensation. Thus, heating of (21) and diacetyl in ethanol gave 
only the corresponding mono hydrazone namely 2-(5H-[1,2,4]triazino[5,6-b]indol-3-yl)-
hydrazono-3-oxobutane (28). However in the presence of excess of (21) the 
corresponding 2,3-bis(5H-[1,2,4]triazino[5,6-b]indol-3-yl)hydrazonobutane (29) was 
formed.. The same result was also obtained if the monohydrazone (28) was heated with 
excess of hydrazine(21). All the resulting compounds were well characterized by IR and 
NMR spectral data and elemental analysis. 
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Joseph Kgokong et al48 have synthesized a series of  unsubstituted and 6-trifluoromethyl-
1,2,4- triazino[5,6b]indole and 5H-1,2,4-triazolo[1’,5’,2,3]-1,2,4-triazino[5,6b]indole 
derivatives and their chemical structures confirmed by 1H NMR and 13C NMR, 
elemental, IR and mass spectrophotometric analyses. The synthetic stretegy was to 
condense Isatin or the 6-trifluoromethyl isatin with thiocarbazide in K2CO3 solution to 
form 1,2,4-triazino-[5,6b]indole-3-thione (30) or 6-trifluoromethyl-1,2,4-triazino-
[5,6b]indole-3-thione (31) as show in scheme below. Each of one of these products was 
alkylated with each of methyl chloride, ethylchloride and chlorocyclopropylmethane to 
form 3-methylthio- (32), 3-methylthio-6-trifluoromethyl- (33), 3-ethylthio- (34), 3-
ethylthio-6-trifluoromethyl-(35) and 3-cyclopropylmethylthio-(36) and 3-
cyclopropylmethylthio-6-trifluoromethyl-(37) 1,2,4-triazino-[5,6b]indole derivatives 
following a known procedure. Refluxing a mixture of 30 or 31 with hydrazine hydrate in 
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HCl resulted in the formation of 3-hydrazo-1,2,4-triazino-[5,6-b]indole (38) or 3-hydrazo-
6-trifluoromethyl-1,2,4-triazino-[5,6b]indole (39), which on reaction with sodium nitrite 
resulted in the formation of 3-azido derivatives. In the presence of HCl, formic, acetic, 
trifluoroacetic or chlorobenzoic acid, the hydrazo and azido derivatives cyclize to form 
fused tetrazole compounds, 5H-1,2,4-triazolo-[1’,5’,2,3]-1,2,4-triazino-[5,6-b]indole 
derivatives (40 and 41), 3-methyl- (42 and 43), 3-trifluoromethyl- (44) and 3,6-
bis(trifluoromethyl)-(45) and 3-(2-chlorophenyl)- (46 and 47) 5H-1,2,4-triazolo-
[1’,5’,,2,3]-1,2,4-triazino-[5,6-b]indole derivatives.  
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Tomas Vijkovsky et al49 have described general procedure for synthesis of 3-(4-
hydroxybenzyl-10H-[1,2,4]triazolo[4',3':2,3][1,2,4]triazino[5,6-b]indole derivatives. 
 
Monge et al50 have reported a series of 5H-1,2,4-triazino[5,6-b]indole derivatives of type 
50 and 51 as per shown in scheme below. The 1,2,4-triazino[5,6-b]indoles (49 & 50) were 
obtained by cyclization of isatin(48) with semicarbazide or thiosemicarbazide in the 
presence of potassium carbonate. When a mixture of 50 and hydrazine hydrate was 
boiled, 90% of 51a was obtained. The compound was characterized as the free base and 
its monohydrochloride by elemental analysis and spectroscopic data (IR &1H-NMR). 
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Several other hydrazones, not reported earlier (51d, 51e, and 51f), were prepared by 
standard methods and also characterized. Upon boiling, solutions of 50 with piperidine 
and morpholine, compound 51b and 51c were obtained in good yields 80 and 83% 
respectively. 
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The synthetic approach suggested that p-hydroxyphenyl acetic acid methyl ester was 
condensed with neat hydrazine-hydrate to afford corresponding hydrazide. The hydrazide 
was treated with cyanogen bromide in the presence of potassium hydrogen carbonate to 
yield appropriate 1,3,4-oxadiazole, which on treatment with hydrazine hydrate would 
converted into 1,2-diamino-1,3,4-triazole derrivative. Condensation of later with 
substituted isatins afforded the 3-(4-hydroxybenzyl-10H-
[1,2,4]triazolo[4',3':2,3][1,2,4]triazino[5,6-b]indole derivatives. 
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5.3 Current work  
 
 
Earlier 1-substituted phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4]triazino[5,6-b]indole 
derivatives were synthesized in our lab and tested for their antibacterial, anti tubercular 
and antiviral activity. Some promising results were obtained and few molecules showed 
potent activity. In continuation of work, linearly fused triazolo-triazino-indloe derivatives 
are synthesized to find out effect of linear and angular fused derivatives on their 
biological profile.   
 
Current chapter deals with the synthesis of compounds containing triazolo-triazino-indole 
fused system. Synthetic methodology is illustrated in reaction Schemes 1-4. First step is 
the reaction between isatin and thiosemicarbazide. The reaction is carried out in water 
using potassium carbonate as base. After completion of reaction, acidification of the 
reaction mixture yielded triazino-indole-3-thione in 78% yield.  
 
Triazino-indole-3-thione, thus obtained, was reacted with hydrazine hydrate by refluxing 
for four hours to give hydrazino derivative. It was crystallized from dimethylformamide 
and the yield of hydrazino compound was 60%. The hydrazino compound and various 
aldehydes were refluxed in methanol to yield corresponding benzylidine derivative in 
very good yield (70-80%). The benzylidine derivative was cyclized using bromine and 
acetic acid to form title compound i.e. triazolo-triazino-indole derivatives. The reaction 
schemes are given in Section 5.4 and physical data are given in Section 5.6. The spectral 
characterizations are discussed in Section 5.6.  
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5.4 Reaction schemes  
 
 
5.4.1 Scheme 1 
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Scheme 1. Reagents and conditions: a = i) K2CO3, H2O, reflux, 24 hrs. ii) gl. AcOH. 
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5.4.2 Scheme 2 
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Scheme 2. Reagents and conditions: b = reflux, 4 hrs. 
 
 
5.4.3 Scheme 3  
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Scheme 3. Reagents and conditions: c = EtOH, gl. AcOH, reflux. 
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5.4.4  Scheme 4 
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Scheme 4. Reagents and conditions: d = Br2, AcOH, stirring.   
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Reaction Mechanism  
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5.5 Experimental  
 
 
 
5.5.1 Synthesis of 2,5-dihydro-3H-[1,2,4]triazino[5,6-b]indole-3-thione (3): Isatin 
(0.1mole), thiosemicarbazidde (0.11mole), potassium carbonate(0.15mole) and 
distilled water (500ml) were stirred and refluxed for 24 hrs. The mixture was 
filtered after cooling and acidified with acetic acid. The solid was filtered off, 
washed with water and dried. Recrystallized from dimethylformamide. Yield 
78%, m.p. >300°C. 
 
5.5.2 Synthesis of 3-hydrazino-5H-[1,2,4]triazino[5,6-b]indole (4): 2,5-dihydro-3H-
[1,2,4]triazino[5,6-b]indole-3-thione (0.01mole) was refluxed with 99% 
Hydrazine hydrate (15ml) for 4 hrs. Crystals, separated on cooling, were filtered 
washed with ethanol to afford 1.4gms (71%) Yield. Recrystallized from 
dimethylformamide. Yield 60% m.p. 275-278°C.  
 
5.5.3 Synthesis of 2-(substitutedbenzylidene)-1-(5H-[1,2,4]triazino[5,6-b]indol-3-
yl)hydrazine (6a-r): A mixture of substituted benzaldehyde (0.01mole) and  3-
hydrazino-5H-[1,2,4]triazino[5,6-b]indole (0.01mole) with catalytic amount of 
glacial acetic acid were refluxed  in ethanol. On cooling, it gives crystals of 
corresponding 2-(substitutedbenzylidene)-1-(5H-[1,2,4]triazino[5,6-b]indol-3-
yl)hydrazine in good yield (70-80%), which were purified by recrystallization 
from dimethylsulfoxide.  
 
5.5.4 3-substituted phenyl-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole 
(7a-r): Bromine (0.12mole) in 10 ml of glacial acetic acid was added dropwise to 
the solution of 2-(substitutedbenzylidene)-1-(5H-[1,2,4]triazino[5,6-b]indol-3-
yl)hydrazine (6a-r) (0.01mole) in glacial acetic acid. The reaction mixture was 
then stirred at ambient temperature for 4-6 hours. Solid was filtered and it was 
washed with petroleum ether and recrystallized from dimethylsulfoxide.  (Physical 
data is given in Table 5.6.1) 
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5.6 Physical data 
  
  
5.5.1 Physical data of 3-(substituted phenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole 
[compound 7a-r]   
 
N
H N
N
N
N
N
R
 
Compound Code R MF MW Yield MP Rf 
7a AKS – 501 Ph C16H10N6 286.29 63 223-25 0.69 
7b AKS – 502 4-SCH3-Ph C17H12N6S 332.38 54 289-90 0.45 
7c AKS – 503 2-Cl-Ph C16H9ClN6 320.74 59 261 0.53 
7d AKS – 504 4-OCH3-Ph C17H12N6O 316.32 55 238-40 0.58 
7e AKS – 505 3,4- OCH3-Ph C18H14N6O2 346.34 52 251-52 0.66 
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7f AKS – 506 4-OH-Ph C16H10N6O 302.29 53 272-74 0.48* 
7g AKS – 507 4-F-Ph C16H9FN6 304.28 56 247 0.55 
7h AKS – 508 3-NO2-Ph C16H9N7O2 331.29 48 >300 0.49 
7i AKS – 509 3-OH-Ph C16H10N6O 302.29 45 265-66 0.52* 
7j AKS – 510 4-Cl-Ph C16H9ClN6 320.74 54 253-55 0.59 
7k AKS – 511 2,5-OCH3-Ph C18H14N6O2 346.34 56 243-44 0.64 
7l AKS – 512 2-OH-Ph C16H10N6O 302.29 48 269-70 0.41 
7m AKS – 513 4-CH3-Ph C17H12N6 300.32 59 221-22 0.57 
7n AKS – 514 9-anthryl C24H14N6 386.41 50 188-90 0.68 
7o AKS – 515 4-OH-3-OCH3-Ph C17H12N6O2 332.32 54 233-35 0.44* 
7p AKS – 516 2-NO2-Ph C16H9N7O2 331.29 43 284-87 0.51 
7q AKS – 517 m-phenoxy-Ph C22H14N6O 378.39 52 231-32 0.60 
7r AKS – 518 Furfuryl C14H8N6O 276.25 56 211-12 0.68 
 
Solvent system for TLC:  EA:Hexane – 4:6      MPs were taken in open capillary and are uncorrected  
     *EA:Hexane – 3:7  
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5.7 Spectral discussion  
 
 
5.7.1  Mass spectral study 
 
In mass spectra of synthesized compounds, molecular ion peaks obtained were in 
agreement with molecular weight of respective compounds. Base peak in each spectrum 
was observed same because of specific fragment. Intense peak obtained at 157 m/e in 
each mass spectrum, and was identified as base peak. AKS-507 gave molecular ion peak 
at 304 and base peak at 157. M+2 peak was observed at 323 with 1/3 intensity of 
molecular ion peak for AKS-510 because of presence of chlorine atom. Similarly, 
molecular ion peaks were observed at 386 and 378 for AKS-514 and AKS-517. In case of 
AKS-517, cleavage of phenoxy group (Ar-O bond) gave peaks at 301 and 285. Base peak 
obtained in each spectrum can be assigned to the fragment generated because of cleavage 
of two C-N bond of triazine ring.  
(Mass spectrum of AKS-507, AKS-510, AKS-514 and AKS-517 are given on Page no. 
188 & 189) 
 
5.7.2   IR spectral study  
In IR spectrums, characteristic frequencies were observed for functional group present in 
the molecule. There is absence of carbonyl, hydroxyl and other functional groups in basic 
skeleton. Cyclic –NH- functionality, aromatic ring and –C=N- groups are present in basic 
moiety. –NH- group was observed at 3380-3450 cm-1. Characteristic peaks were observed 
for aromatic ring.  (Ar-H, 3010-3140 cm-1), (-C=C-, 1580-1640 cm-1) and (OOP bending, 
680-780 cm-1). C=N vibrations gave peak at 1615-1670 cm-1. C-N vibrations were 
observed at 1210-1270 cm-1. These are the characteristic frequencies observed in each 
spectrum, while other frequencies were obtained for the functional group present on the 
3-phenyl ring. Presence of methyl, methoxy, thiomethyl, hydroxy etc. groups was 
identified with their characteristic frequencies and is mentioned in the spectral data of 
individual compound.  
(IR spectrum of AKS-513, AKS-511, AKS-504 and AKS-505 are given on Page no. 183 
& 184) 
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 5.7.3 1H NMR spectral study 
 
In NMR spectra of the compounds, number of protons and their chemical shifts were 
found to support the structure of the synthesized compounds. Aromatic protons were 
obtained between 6.8-8.2 δ ppm. N-H proton in each spectrum, gave signal in downfield 
between 12-13 δ ppm.  
 
In NMR spectrum of AKS-504, singlet was observed for three protons of methoxy group 
on 3-phenyl ring at 4.20 δ ppm. A doublet was obtained for two protons beacuse of 
coupling with ortho protons (J=8.57). Two protons showed ortho as well as meta 
coupling, and each give triplet with J values 7.19&1.87 and 8.14&2.16 respectvely. 
Antoher doublet was observed for one proton with ortho coupling J value (J=8.79). 
remaining there aromatic protons could not be reoslved and obtained as multiplet. –NH- 
proton gave signal in downfiled at 13.05 δ ppm.  
 
In case of compound AKS-505, two singlets were observed due to two methoxy group 
protons at 3.90 and 4.07 δ ppm. Three protons of 3-phenyl ring gave two doublets and a 
singlet. Two protons on adjacent carbon atoms gave two doublets due to orhto coupling 
(J= 7.11, 8.31). Two protons of benzenoid part of indole, gave two triplet, while another 
two proton observed as doublet for each. –NH- proton signal was observed in downfield 
as in earlier spectrum (12.21 δ ppm).  
 
In case of compound AKS-501, nine aromatic protons were obtained between 7.46-8.48 δ 
ppm and –NH- proton gave singal at 13.10 δ ppm. The splitting of signals and their J 
values are given in spectral data of compounds.  
 
(1H NMR spectrum of AKS-505, AKS-501 and AKS-504 are given on Page no. 185, 
186 & 187)  
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5.7.4  Elemental analysis   
Percentage values of carbon, hydrogen and nitrogen found in elemental analysis were in 
agreement with calculated values of elements. The spectral and elemental analysis data 
are given below for individual compound.   
 
Spectral data of synthesized compounds (AKS 501-518) 
 
3-Phenyl-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-501) – IR (cm-
1): 3378 (N-H), 3106 (Ar-H), 1628 (C=N), 1607, 1581, 1472 (C=C), 1217 (C-N), 881, 
749 (OOP); 1H NMR (DMSO d6) (δ ppm): 7.46 (1H, t, J=8.27), 7.59 (1H, d, J=7.63), 7.70 
(3H, m), 7.84 (1H, t, J=8.05), 8.31 (1H, d, J=8.52), 8.48 (2H, d, J=7.83), 13.10 (1H, s); 
Anal cacld for C16H10N6: C 67.12, H 3.52, N 29.35, found: C 67.18, H 3.53, N 29.42.  
 
3-(4-Methylthiophenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-
502) - IR (cm-1): 3441 (N-H), 3086 (Ar-H), 2978 (-CH3), 2577 (S-H), 1644 (C=N), 1586, 
1540, 1417 (C=C), 1212 (C-N), 831 (OOP); Anal cacld for C17H12N6S: C 61.43, H 3.34, 
N 25.28, found: C 61.47, H 3.35, N 25.33.  
 
3-(2-Chlorophenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-503) 
- 3354 (N-H), 3123 (Ar-H), 1618 (C=N), 1596, 1552, 1431 (C=C), 1256 (C-N), 831, 718 
(OOP); Anal cacld for C16H9ClN6: C 59.92, H 2.83, N 26.20, found: C 59.90, H 2.85, N 
26.26.  
 
3-(4-Methoxyphenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-
504) - IR (cm-1): 3419 (N-H), 3118 (Ar-H), 3008, 2925 (-CH3), 1620 (C=N), 1528, 1475 
(C=C), 1299 (C-N), 1073 (C-O), 771 (OOP); 1H NMR (DMSO d6) (δ ppm): 4.20 (3H, s), 
7.24 (2H, d, J=8.57), 7.47 (1H, t, J=7.19, 1.87), 7.60 (1H, d, J=8.79), 7.84 (1H, t, J=8.14, 
2.16), 9.39 (3H, m), 13.05 (1H, s);  Anal cacld for C17H12N6O: C 64.55, H 3.82, N 26.57, 
found: C 64.50, H 3.81, N 26.63.  
 
3-(3,4-dimethoxyphenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole 
(AKS-505) - IR (cm-1): 3419 (N-H), 3129 (Ar-H), 2924, 2832 (-CH3), 1637 (C=N), 1594, 
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1561, 1460 (C=C), 1256 (C-N), 1159 (C-O), 754 (OOP); 1H NMR (DMSO d6) (δ ppm): 
3.90 (3H, s), 4.07 (3H, s), 7.22 (1H, d, J=7.92), 7.34 (1H, t, J=8.53), 7.42 (1H, d, J=7.58), 
7.71 (1H, t, J=8.16), 7.92 (1H, s), 8.06 (1H, d, 7.11), 8.25 (1H, d, J=8.31), 12.21 (1H, s); 
Anal cacld for C18H14N6O2: C 62.42, H 4.07, N 24.27, found: C 62.43, H 4.05, N 24.30. 
 
3-(4-Hydroxyphenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-
506) – 3517 (-OH-), 3346 (N-H), 3078 (Ar-H), 1624 (C=N), 1577, 1551, 1486 (C=C), 
1226 (C-N), 806 (OOP); Anal cacld for C16H10N6O: C 63.57, H 3.33, N 27.80, found: C 
63.59, H 3.32, N 27.84.  
 
3-(4-Fluorophenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-507) 
- 3456 (N-H), 3120 (Ar-H), 1609 (C=N), 1581, 1542, 1479 (C=C), 1263 (C-N), 796 
(OOP); Mass (m/e): 304 (molecular ion peak), 285, 209, 189, 179, 157 (base peak), 143, 
127, 77; Anal cacld for C16H9FN6: C 63.16, H 2.98, N 27.62, found: C 63.19, H 3.00, N 
27.67.  
 
3-(3-Nitrophenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-508) - 
3443 (N-H), 3115 (Ar-H), 1678 (C=N), 1633, 1561, 1422 (C=C), 1344 (C-NO2), 1272 
(C-N), 817, 773 (OOP); Anal cacld for C16H9N7O2: C 58.01, H 2.74, N 29.60, found: C 
58.03, H 2.75, N 29.68.  
 
3-(3-Hydroxyphenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-
509) - 3502 (-OH-), 3318 (N-H), 3155 (Ar-H), 1617 (C=N), 1602, 1567, 1457 (C=C), 
1211 (C-N), 881, 732 (OOP); Anal cacld for C16H10N6O: C 63.57, H 3.33, N 27.80, 
found: C 63.60, H 3.36, N 27.90.  
 
3-(4-Chlorophenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-510) 
- 3418 (N-H), 3111 (Ar-H), 1681 (C=N), 1555, 1521, 1464 (C=C), 1207 (C-N), 745 
(OOP); Mass (m/e): 323 (M+2), 321 (molecular ion peak), 286, 243, 163, 157(base peak), 
128, 72; Anal cacld for C16H9ClN6: C 59.92, H 2.83, N 26.20, found: C 59.90, H 2.84, N 
26.24.  
 
3-(2,5-dimethoxyphenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole 
(AKS-511) – IR (cm-1): 3404 (N-H), 3130 (Ar-H), 2923, 2854 (-CH3), 1603 (C=N), 
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1515, 1480 (C=C), 1261 (C-N), 1190 (C-O),  774 (OOP); Anal cacld for C18H14N6O2: C 
62.42, H 4.07, N 24.27, found: C 62.45, H 4.08, N 24.31.  
 
3-(2-Hydroxyphenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-
512) - 3562 (-OH-), 3337 (N-H), 3130 (Ar-H), 1658 (C=N), 1621, 1554, 1467 (C=C), 
1273 (C-N), 894, 714 (OOP); Anal cacld for C16H10N6O: C 63.57, H 3.33, N 27.80, 
found: C 63.59, H 3.33, N 27.82.  
 
3-(4-Methylphenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-
513) - IR (cm-1): 3404 (N-H), 3136 (Ar-H), 3025, 2923 (-CH3), 1650 (C=N), 1600, 1542, 
1476 (C=C), 1268 (C-N), 837, 737 (OOP); Anal cacld for C17H12N6: C 67.99, H 4.03, N 
27.98, found: C 68.03, H 4.01, N 28.05.  
 
3-(9-Anthryl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-514) - 
3448 (N-H), 3122 (Ar-H), 1666 (C=N), 1628, 1593, 1447 (C=C), 1217 (C-N), 853, 786 
(OOP); Mass (m/e): 386 (molecular ion peak), 282, 231, 217, 185, 157 (base peak), 115, 
86; Anal cacld for C24H14N6: C 74.60, H 3.65, N 21.75, found: C 74.63, H 3.66, N 21.80.  
 
3-(3-Methoxy-4-Hydroxyphenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-
b]indole (AKS-515) – 3588 (-OH-), 3418 (N-H), 3108 (Ar-H), 3011, 2956 (-CH3), 1652 
(C=N), 1607, 1588, 1461 (C=C), 1260 (C-N), 888, 764 (OOP); Anal cacld for 
C17H12N6O2: C 61.44, H 3.64, N 25.29, found: C 61.47, H 3.66, N 25.34.  
 
3-(2-Nitrophenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-516) - 
3403 (N-H), 3016 (Ar-H), 1658 (C=N), 1617, 1563, 1420 (C=C), 1348 (C-NO2), 1223 
(C-N), 740 (OOP); Anal cacld for C16H9N7O2: C 58.01, H 2.74, N 29.60, found: C 58.04, 
H 2.73, N 29.67.  
 
3-(3-Phenoxyphenyl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-
517) - 3347 (N-H), 3119 (Ar-H), 1641 (C=N), 1602, 1578, 1433 (C=C), 1210 (C-N), 833, 
762 (OOP); Mass (m/e): 378 (molecular ion peak), 301, 285, 189, 157(base peak), 143, 
127, 77; Anal cacld for C22H14N6O: C 69.83, H 3.73, N 22.21, found: C 69.85, H 3.75, N 
22.27.  
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3-(2-Furfuryl)-10H-[1,2,4]triazolo[4,3-b][1,2,4] triazino [5,6-b]indole (AKS-518) -  
3399 (N-H), 3023 (Ar-H), 1655 (C=N), 1621, 1577, 1463 (C=C), 1296(C-O), 1267 (C-
N), 810 (OOP); Anal cacld for C14H8N6O: C 60.87, H 2.92, N 30.42, found: C 60.90, H 
2.94, N 30.49.  
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5.7.5.1  IR spectrum of AKS-513 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.7.5.2  IR spectrum of AKS-511 
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5.7.5.3  IR spectrum of AKS-504 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.7.5.4  IR spectrum of AKS-505 
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5.7.5.5  1H NMR spectrum of AKS-505 
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5.7.5.6  1H NMR spectrum of AKS-501 
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5.7.5.7  1H NMR spectrum of AKS-504 
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5.7.5.8  Mass spectrum of AKS-507 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.7.5.9 Mass spectrum of AKS-510 
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5.7.5.10 Mass spectrum of AKS-514 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.7.5.11 Mass spectrum of AKS-517 
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In earlier Chapters (1,2 & 3), synthetic and biological profile of dihydropyrimidinone 
derivatives has been reviewed in brief. A large number of references is sited for 
modification of Biginelli multi component reaction by means of catalyst, microwave 
assisted synthesis and solid phase synthesis. It has been of great interest to develop 
convenient methods for synthesis of modified dihydropyrimidinone derivatives. Three 
building blocks of Biginelli reaction (1) 1,3-diketone (2) aldehyde and (3) urea (thiourea) 
has been widely modified to develop libraries of DHPM derivatives. The biological 
importance of DHPM skeleton has encouraged developing better synthetic methods for 
synthesis of modified derivatives for potent biological profiles.  
 
6.1 Efforts from our laboratory 
 
1,4-dihydropyridine skeleton has been extensively modified at 3 and 5 position in our lab 
where –COCH3 group at 3rd and 5th position replaced with –CO-(substituted)Ph and –CO-
NH-(substituted)Ph. This modifications to 1,4-DHPs showed potent anti tubercular 
activity and 1,4-DHP skeleton can be developed for potent anti tubercular structure class.  
The results obtained were studied for 2D-QSAR and 3D-QSAR study to find structural 
requirements for 1,4-DHP skeleton.    
 
Dihydropyrimidinones (DHPMs, aza analogs of 1,4-DHPs) is also very interesting 
bioactive skeleton. From results obtained in 1,4-DHP modification, we started 
modifications to DHPM skeleton. Priti, Dinesh and Chintan synthesized DHPMs with –
CO-NH-(substituted)Ph moiety at 5th position. These molecules were screened for their 
anti tubercular activity and showed moderate activity profile.  
 
 
 
Chapter 6 
3D-QSAR study of DHPM derivatives 
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In continuation of work, earlier chapters of thesis deal with the modifications to DHPM 
skeleton as below.  
 
1. (N-Ph with –CO-NH-(substituted)Ph at 5th position)  
 
 
 
  
 
 
 
 
 
 
 
 
 
2. (Alkyl chain at 4th position with –CO-NH-(substituted)Ph at 5th position) 
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3. (Fused system with –CO-NH-(substituted)Ph at 5th position)  
 
 
 
 
 
 
 
 
 
 
 
 
To find out the structural requirements, the results obtained with earlier modification 
were studied for 3D QSAR.  The molecules were synthesized as per Scheme 1 and 2.  
 
 
 
 
 
 
 
 
 
Scheme 1. Reagents and conditions: a) NaOH/KOH, toluene, 110º C, 10-15 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Reagents and conditions: b) HCl, methanol, reflux, 5-10 hours.  
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Table 1. Physical data with anti tubercular activity. (Training set)   
 
 
 
 
 
 
 
 
 
 
 
Compound R R1 R2 R3 R4 % Inhibition 
3a 4-OCH3 CH3 H H CH3 2 
3b 3-OPh CH3 H H CH3 27 
3c 3-OPh CH3 CH3 H H 65 
3d 2-NO2 Cl H H H 11 
3e 4-NO2 CH3 H H CH3 4 
3f 4-Cl H H H H 6 
3g 4-OH F H H H 18 
3h 4-NO2 Cl H H Cl 18 
3i 4-OH CH3 H CH3 H 12 
3j 4-OH H NO2 H H 2 
3k 3-Cl H Cl F H 48 
3l 4-NO2 F H H H 4 
3m 4-NO2 H CH3 CH3 H 13 
3n 4-NO2 CH3 H CH3 H 12 
3o 3-NO2 Cl H H H 26 
3p 3-NO2 H Cl F H 29 
3q 3-NO2 F H H H 24 
3r 3-Cl H H F H 38 
3s 4-NO2 H H OCH3 H 21 
3t 3-NO2 H H Cl H 29 
3u 3-NO2 H H CH3 H 28 
3v 3-NO2 H H F H 30 
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Table 2. Physical data with ant tubercular activity (Test set)  
 
 
 
 
 
 
Compound R R1 R2 R3 R4 % Inhibition 
4a 3-NO2 CH3 H H H 6 
4b 4-Cl Cl H H H 26 
4c 4-NO2 H H Cl H 9 
4d 3-OPh H CH3 CH3 H 32 
4e 4-NO2 H H H H 25 
4f 3-NO2 H CH3 CH3 H 63 
4g 4-NO2 H Cl F H 22 
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6.2 QSAR study  
 
 
6.2.1 Computational Details: The 3D-QSAR techniques of CoMFA and CoMSIA were 
carried out with Sybyl 7.1 (Tripos Inc., USA) running on a Pentium IV computer under 
the Linux Red Hat Enterprise 2.3.1 OS 
 
6.2.2 Ligand preparation: A novel set of N-phenyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-
tetrahydro-pyrimidine-5-carboxamide analogs with substituuions on the 4-phenyl and N-
phenyl rings were synthesized and screened for anti-tubercular activity (Table 1) was 
used for the 3D-QSAR study.  The dataset was divided into a training set (23 molecules) 
and a test set (7 molecules) on the basis of chemical and biological diversity using the 
Tanimoto similarity coefficient. 
For the QSAR study, the activity values were transformed as follows 
Log activity = -log c + logit (where c is molar concentration = concentration (µg/mL) * 
0.001 / (molecular weight); logit = log [% inhibition / (100 - % inhibition)] 
 
The molecules were built using the builder module in Sybyl 7.1.  The crystal 
structure of methyl-4-(3-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-
5-carboxylate was used as a template (Figure 1) to built the molecules in the dataset.  The 
template structure of N-phenyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydro-pyrimidine-
5-carboxamide had the pyrimidine ring in the boat conformation with the 4-phenyl ring in 
the axial orientation with C4 atom of the pyrimidine having S-configuration.  The ligand 
geometries were optimized by energy minimization using the Powel gradient method with 
the MMFF94 charges and forcefield, till a gradient of 0.005 kcal/mol/Å was reached 
while maintaining the template structure rigid. 
 
6.2.3 Molecular Alignment: The molecules of the dataset were aligned by two 
techniques.  First by the atom-fit technique, using atoms common with the crystal 
structure of methyl-4-(3-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-
5-carboxylate; this is  depicted in Figure 2a.  In the second approach, the molecules were 
aligned by the field-fit technique where the steric and electrostatic fields of the most 
active molecule in the series were extracted and used for the alignment of the fields of the 
other molecules (Figure 2b). 
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6.2.4 CoMFA and CoMSIA studies: CoMFA (Comparative Molecular Field Analysis) 
and CoMSIA (Comparative Molecular Similarity Indices Analysis)studies were carried 
out with the default settings for the 3D cubic lattice, the grid spacing, the probe atom, and 
the energy cutoff. 
 
For CoMSIA, five physicochemical properties (steric, electrostatic, hydrophobic, 
and hydrogen-bond donor and acceptor) were explored, and the attenuation factor was set 
to the default value of 0.3.  The CoMFA and CoMSIA descriptors were used as 
independent variables and the log activities as the dependent variable in a partial least 
squares (PLS) regression analysis to derive the 3D-QSAR models.  The models were 
internally evaluated by leave-one-out (LOO) cross-validation.  The optimal number of 
components was determined by the SAMPLS method which was subsequently used to 
derive the final QSAR models.  In addition to the q2, the conventional correlation 
coefficient r2, and standard errors (SE) were also computed.  The robustness of the 
models was gauged by cross validation using leave-group-out (LGO) of 10 groups and 
bootstrapping carried out with 100 runs.  The CoMFA and CoMSIA models were also 
validated for their predictivity on an external dataset of 7 molecules.   
 
All the molecules have N-phenyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydro-
pyrimidine-5-carboxamideas the common substructure.  The substitutions are at the ortho, 
meta and para positions of the 4-phenyl and the 5-N-phenyl rings. 
 
The CoMFA and CoMSIA studies were conducted on a training set of 23 
molecules which as mentioned earlier were aligned by the atom-fit and field-fit 
techniques.  The molecules predicted by the initial CoMFA models with residuals greater 
than 0.80 were reintroduced into the dataset with alternate conformations, and the QSAR 
models regenerated.  The correlation coefficients (r2) of the 3D-QSAR CoMFA and 
CoMSIA models for the atom-fit technique are excellent with acceptable cross-validated 
coefficients (q2) and suitably reliable predicted r2. 
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6.2.5 Graphical Analysis 
 
The CoMFA and CoMSIA contour maps were generated using scalar products of 
coefficients and standard deviation (STDEV*COEFF) set at 80% and 20% for favored 
and disfavored levels, respectively.  The CoMFA and CoMSIA contours are depicted in 
Figure 3 and 4 respectively.  CoMFA exhibits equal steric and electrostatic contribution 
to the activity while electrostatic and hydrophobicity contributions are seen to be 
dominated in CoMSIA. 
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The 3D-QSAR contours are explained with the help of Figure 4.  The CoMFA 
steric fields favor (green contours, Figure 3a) the substitution of bulky groups at the meta 
position of the both 5-N-phenyl and the 4-phenyl moieties, while disfavored steric fields 
(yellow contours) are seen at the para position of the 4-phenyl group, which is also 
supported by the CoMSIA steric contours (Figure 4a).  In addition, disfavored steric 
CoMSIA contours are also seen at the meta′-position of the 5-N-phenyl residue.  
 
The CoMFA electrostatic contours depict that electropositive groups (blue 
contour, Figure 3b) are favored at meta position of the 5-N-phenyl group and the ortho′ 
meta, para positions of the 4-phenyl group.  However, electronegative groups (red 
contour) at the meta′-position of the 4-phenyl moiety are likely to increase the activity.  
The CoMSIA electrostatic contours (Figure 4b) also favor electropositive groups at the 
para and ortho′ positions of the 4-phenyl and in addition, electronegative groups at the 
para position of 5-N-phenyl group.  The hydrophobic contours of CoMSIA indicate 
desired and undesired hydrophobic regions around the two phenyl rings.  The 
hydrophobic groups (white contours, Figure 4c) would cause  
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Figure 2a and 2b 
 
 
 
 
Figure 3a and 3b  
 
 
Figure 4a, 4b and 4c 
 
Figure 4d and 4e 
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the activity to decrease when placed at on the meta′ position of 5-N-phenyl ring or the 
meta′, para positions of the 4-phenyl; small hydrophobic groups (yellow fields) are 
accepted at the meta position of the 5-N-phenyl ring. 
 
The H-bond donor fields are absent in the CoMSIA model.  The disfavored fields 
of the H-bond acceptor are seen as red contours in Figure 4d, are found in the vicinity of 
the 5-carboxamide, the ortho, and meta position of the 5-N-phenyl ring, while the favored 
magenta contours are found to encapsulate the para and meta′ positions of the 4-phenyl 
ring. 
 
Table 3.  New molecules with improved predicted activity  
H
N
HN NH
O
O
R1
R2
 
 
Sr. 
No. Molecule R1 R2 
Predicted 
Activity 
(CoMFA)* 
Predicted 
Activity 
(CoMSIA)*
1 N001 H 
NO2 
5.36 4.65 
2 N002 –OCONHCH3 
N
O
N(CH3)2
 
5.57 4.63 
3 N003 –COCH3 
N
O
N(CH3)2
 
5.36 4.55 
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4 N004 –CN 
N
O
N(CH3)2
 
5.61 4.47 
5 N005 –NHSO2CH3 
N
O
N(CH3)2
 
5.52 4.35 
6 N006 –CF3 
N
O
N(CH3)2
 
5.61 4.37 
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Summary 
  
The work presented in the Thesis entitled “Study of some bioactive synthetic 
heterocycles” can be summarized as below. 
 
Chapter 1 covers the synthesis of novel dihydropyrimidine derivatives via three 
component Biginelli reaction between acetoacetanilides, aromatic aldehydes and 
substituted phenyl urea. Synthesized molecules have phenyl carbamoyl moiety at 5th 
position and phenyl ring on Nitrogen atom of DHPM skeleton. Acetoacetanilides were 
prepared from substituted aniline and ethylacetoacetate using NaOH/KOH as catalyst and 
toluene as solvent. Substituted phenyl ureas were prepared by reacting hydrochloride salt 
of amines and urea in water. Components of the reaction, thus prepared, were reacted in 
methanol using catalytic con. HCl. The spectral data is presented to support the structure 
of synthesized molecules. Twenty dihydropyrimidine derivatives are synthesized and 
characterized.  
 
In chapter 2, bicyclic systems are synthesized from Biginelli dihydropyrimidine 
derivatives. DHPM skeleton is very important scaffold to synthesize variety of bicyclic 
systems. Acetoacetanilides, synthesized as mentioned in chapter 1, were reacted with 
thiourea and aldehydes. The DHPMs, thus synthesized, were reacted with dibromo 
alkanes to obtain fused bicyclic systems. The thiazolo-pyrimidine and pyrimido-thiazine 
systems thus synthesized were studied by NMR, Mass and IR spectroscopy. Total 
eighteen derivatives are synthesized with phenyl carbamoyl moiety at side chain.  
 
Chapter 3 includes application of microwave in the synthesis of dihydropyrimidone 
molecules. Acetoacetanilides, butyraldehyde and urea were reacted to yield derivatives 
with propyl chain at 4th position of DHPM skeleton to find out effects of replacement of 
phenyl ring with alkyl chain in classical DHPM skeleton with –CONH-Ph side chain. 
Very low yield was obtained by conventional method (5-10%). The reaction was carried 
out under microwave irradiation and that lead to increase in the yield of reaction product 
(30-35%). Benzimidazole-2-thiol was reacted with dihalo alkanes in DMF under 
microwave and yield bicyclic systems in 65-70%. Spectral data for synthesized 
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compounds are in support of their structures. Fifteen dihydropyrimidine and six fused 
bicyclic system from benimidazole-2-thiols are synthesized and characterized.        
 
In chapter 4, synthesis of different 1,4-DHP derivatives, one of most important 
biologically active scaffold, is reported. A large number of drugs are marketed containing 
this basic skeleton. These skeleton derivatives are mostly known as calcium channel 
blockers since long time. Earlier findings from our lab reported these derivatives to 
possess mdr reversal, anti tubercular and other activity. In continuation of earlier work 
done, symmetrical and unsymmetrical dihydropyridines are synthesized with naphthyl 
ring in side chain. Twenty-six DHPs are synthesized and characterized.  
 
Chapter 5 covers a brief literature survey on fused system containing indole system, their 
synthesis and biological profile. This chapter deals with the synthesis of triazolo-triazine-
indole systems starting from isatin and thiosemicarbazide. The subsequent reaction with 
hydrazine hydrate and aldehydes; and cyclization using bromine/acetic acid yielded title 
compounds. Synthesis of eighteen compounds and their spectral data are reported.  
 
In the last chapter, efforts made in our lab to modify DHPM skeleton and anti tubercular 
activity data obtained for them are studied for QSAR to find out structural requirement 
and to throw light on further modifications to this skeleton. CoMFA and CoMSIA 
methods are applied and new molecules are designed and predicted to exhibit better 
activity.    
 
Total 103 compounds are synthesized and characterized in entire work. Synthesized 
compounds are under anti tubercular and anti viral screening and their results are awaited.  
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